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Introduction and Outline of the Thesis
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HISTORy
An explosive, common-source outbreak of pneumonia caused by a previously 
unrecognized bacterium affected primarily persons attending an American Legion 
convention in Philadelphia in July, 1976. Thirty-four of 221 cases were fatal. Despite 
intensive laboratory investigation, the cause of the outbreak was undetected for 
months. An epidemiologic investigation determined that the disease most likely was 
airborne and focused primarily at one convention hotel, which subsequently had to 
be closed because of adverse publicity [1]. About 6 months later, two investigators 
at the United States Centers for Disease Control and Prevention, Joseph McDade 
and Charles Shepard, announced that they had discovered the etiologic agent, a 
fastidious Gram-negative bacillus [2]. Because of the historical association with the 
American Legion convention, this disease was called Legionnaires’ disease (LD) and 
the etiologic agent Legionella pneumophila. L. pneumophila belongs to the family 
Legionellaceae. Use of an antibody test for the disease soon learned that several prior 
unsolved outbreaks of pneumonia had been LD, including outbreaks in the 1950s 
and 1960s. In addition, members of the genus had been isolated some 25 years earlier 
from sporadic cases of pneumonia [3]. An unsolved outbreak of a nonpneumonic 
febrile illness was also found to have resulted from exposure to Legionella bacteria; 
this illness was called Pontiac fever, after Pontiac, Michigan, where this had occurred 
[4]. As with LD, prior epidemics of Pontiac fever had occurred as early as 1949 
without solved etiology.
There are three important lessons from the Philadelphia outbreak. First and fore-
most was the dismissal of the idea that infectious diseases and their causes are a 
thing of the past or even that all infectious diseases are known. Second, LD occurs 
as a consequence of altering the environment for human benefit. Cases of LD have 
been traced to a wide variety of man-made water sources, including cooling towers, 
whirlpools and spas, fountains, ice machines and vegetable misters. A third lesson 
is how difficult it can be to break out of traditional patterns of thought when con-
fronted with the unknown. In Philadelphia, initially, viral and toxic etiologies were 
sought, because of the clinical resemblance of the pneumonia to severe influenza. 
When bacteria that had the morphology of Gram-negative bacilli were subsequently 
demonstrated with electron microscopy in lung tissues of fatal LD cases, the signifi-
cance of the observation was obscured by the consideration that they were merely 
secondary invaders [3].
MICROBIOLOgy
The family Legionellaceae consists of the single genus Legionella. Legionella are 
Gram-negative coccobacilli that measure 0.3 µm to 0.9 µm in width and 2 to 20 µm 
in length. In tissue and clinical specimens, the organisms are coccobacillary, mea-
suring 1 to 2 µm. Elongated filamentous forms may be seen after growth on some 
culture media. Soluble iron and l-cysteine are required for optimal growth and for 
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the initial isolation of the bacterium from both clinical and environmental sources. 
Iron, l-cysteine, α-ketoglutarate, and charcoal-containing yeast extract agar buffered 
with an organic buffer (BCYEα agar) is the preferred growth medium for clinical 
isolation. To support bacterial growth, the pH of the agar is critical and should be 
adjusted to pH 6.9 by adding N-2-acetamino-2-aminoethansulfonic acid (ACES) [5]. 
Proteins rather than carbohydrates are used as an energy source. Legionnellae are 
obligate aerobes, and grow at temperatures ranging from 20° to 42°C. Clinically im-
portant Legionella species grow best at 35°C in humidified air on BCYEα medium, 
usually in 2 to 5 days after inoculation of plates. An incubation of up to 10 days may 
very rarely be required for the isolation of unusual Legionella species.
The number of recognized species and serogroups of the genus Legionella continues 
to increase. There are currently 50 species (http://www.dsmz.de/bactnom/bactname.
htm) comprising about 70 distinct serogroups. L. pneumophila comprises at least 
16 different serogroups; seven other species comprise two different serogroups, with 
the remaining species comprising only one serogroup each [6]. Some legionellae can-
not grow on routine Legionella-specific media and have been called Legionella-like 
amoebal pathogens (LLAPs). These organisms have been isolated and maintained by 
cocultivating the bacteria with their protozoan hosts. One LLAP strain was isolated 
from the sputum of a pneumonia patient by enrichment in amoebae and is considered 
a rare human pathogen [7]. Additional LLAP strains may be human pathogens, but 
proving this is difficult because they cannot be detected by conventional techniques 
used for legionellae.
Legionella spp. are ubiquitous. They are found in natural aquatic environments 
(streams, rivers, ponds, lakes and thermal pools) in moist soil and in mud. They have 
even been found in the canopy of the rain forest. The organisms are able to survive 
in moist environments for long periods of time and can withstand temperatures of 
0–68°C and a pH range of 5.0–8.5 They can survive chlorination and thus enter 
water supply systems and proliferate in thermal habitats, including air-conditioning 
cooling towers, hot water systems, shower heads, taps, whirlpool spas and respira-
tory ventilators. The organisms are found in biofilms on the surfaces of these systems, 
where they are far less susceptible to the effects of biocides and chlorine.
Most cases of legionellosis can be traced to man-made aquatic environments where 
the water temperature is higher than ambient temperature. The growth of Legionella 
spp. is aided by co-existing micro-organisms, which provide nutrients, and free-living 
amebae, in which the Legionella spp. can reside and multiply. The presence of the 
bacteria in an aquatic environment and warm water temperature are two factors that 
can increase the risk of LD. The third component is the presence of nutritional fac-
tors that allow the bacteria to amplify. Legionellae survive in aquatic and moist soil 
environments as intracellular parasites of free-living protozoa [8]. Thermally altered 
aquatic environments can shift the balance between protozoa and bacteria, resulting 
in rapid multiplication of legionellae. However, multiple strains may colonize water-
distribution systems, but only a few specific species and types will cause disease in 
patients exposed to the water.
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LD is a major concern of public health professionals and individuals involved with 
the construction or maintenance of water systems, such as air-conditioning systems, 
circulating water systems and cooling towers. Legionellosis is generally considered 
a preventable illness because controlling or eliminating the bacterium in certain 
reservoirs will (in theory) prevent disease. This concept of preventable illness has 
resulted in a number of guidelines and control strategies aimed at reducing the risk of 
legionellosis in building water systems. The factors that lead to outbreaks or cases of 
LD are not completely understood, but certain events are considered prerequisites for 
infection. These include the presence of virulent bacteria in an aquatic environment, 
amplification of the bacterium to an unknown infectious dose, and transmission of 
the bacteria via aerosol to a human host that is susceptible to infection.
L. pneumophila serogroup 1 caused the 1976 Philadelphia outbreak and is the 
cause of approximately 90% of all cases of LD from which a bacterial strain was 
isolated [9,10,11]. However, although L. pneumophila serogroup 1 accounts for the 
majority of American and European Legionella isolates, in Australia and New Zea-
land, L. pneumophila serogroup 1 accounts for only approximately 50% of cases of 
community-acquired legionellosis, while L. longbeachae accounts for approximately 
30% of cases [10]. L. pneumophila serogroup 1 can be further divided into multiple 
subtypes using a variety of serologic, other phenotypic, and genetic methods. One 
particular subtype of L. pneumophila serogroup 1 causes 67% to 90% of cases of 
LD, and 85% of cases due to L. pneumophila serogroup 1; this subtype is distin-
guished by its reactivity with a particular monoclonal antibody, and it is variously 
termed the Pontiac, the Joly monoclonal type 2 (MAb2), or the Dresden monoclonal 
type 3/1 (MAb 3/1) subtype [12]. Because of the diversity within L. pneumophila 
serogroup 1, clinical and environment isolates must be matched by molecular tech-
niques to adequately identify environmental sources of disease. These include ribo-
typing, amplified fragment length polymorphism (AFLP) analysis, pulsed-field gel 
electrophoresis (PFGE), restriction fragment length polymorphism (RFLP) analysis, 
restriction endonuclease analysis (REA), multi locus sequence typing (MLST) and 
arbitrarily primed PCR [13]. One of these methods, a single-endonuclease, amplified 
fragment length polymorphism analysis method by which the patterns are resolved 
by standard agarose electrophoresis, was adopted as an international standard and 
is now widely used by members of the European Working Group for Legionella 
Infections (EWGLI) [14,15].
CLINICAL SPECTRUM
Legionellosis classically presents as two distinct clinical entities, LD, a pneumonia 
with severe multisystem disease [2], and Pontiac fever, a self-limited flu-like illness 
[4]. In addition, many persons who are infected with legionellae, as proven by se-
roconversion, will remain asymptomatic [16]. LD is transmitted from the environ-
ment to man by inhalation of an infectious aerosol [17]. In an unknown fraction of 
cases, microaspiration of contaminated water into the lungs could be the mode of 
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nosocomial transmission [18]. Multiple examples of exclusive aerosol transmission 
of LD exist, especially in epidemics where a cooling tower, water spa, water fountain, 
or water mister are the source of disease [19].
Cases may be sporadic or occur as part of an outbreak. Sporadic cases are reported 
throughout the year, but most cases of epidemic infection occur in the summer and 
autumn, presumably because warmer weather encourages proliferation of the bac-
teria in water. In moderate climates many cases are travel-associated. The disease 
tends to occur in the middle-aged and elderly, especially in people who have impaired 
respiratory and cardiac function, who are heavy smokers or who are immunocom-
promised [20,21].
The incubation time of LD is between 2 and 10 days. Among patients of the 
Bovenkarspel outbreak the reported incubation period was 2 to 19 days (median 
7 days). In 22 cases (16%) the time before onset of illness exceeded 10 days [16]. 
A prodromal illness may occur, lasting for hours to several days, with symptoms of 
headache, myalgia, asthenia, and anorexia. It is not possible to clinically distinguish 
patients with LD from patients with pneumococcal pneumonia. Several prospective 
studies have shown that the two diseases have nearly identical clinical and radiologi-
cal findings, and that nonspecific laboratory test results cannot differentiate between 
the two diseases [19,22,23,24]. Nonspecific features of LD include fever, nonpro-
ductive cough, myalgias, rigors, dyspnea and diarrhea [25]. Neurological symptoms 
range from headache and lethargy to encephalopathy. Change in mental status is the 
most common neurologic abnormality [26]. Suspicion should be raised in cases of 
pneumonia and the presence of headache, confusion, hyponatremia, elevated cre-
atine kinase [27]. Also, the diagnosis becomes more likely if an acute consolidating 
pneumonia fails to respond to several days of β-lactam antimicrobial therapy, or if 
the pneumonia is severe enough to require intensive care unit hospitalization. Epide-
miologic clues might include use of a hot tub or recreational spa; recent pneumonia 
of a co-worker, relative, or fellow traveler; and recent plumbing work done at home 
or work. The nonspecific presentation of LD makes clinical diagnosis very difficult 
and mandates empiric therapy for this disease in most patients with community-
acquired pneumonia (CAP) of uncertain etiology. The key to diagnosis is performing 
appropriate microbiologic testing.
In addition to L. pneumophila, 20 Legionella species have been documented as hu-
man pathogens on the basis of their isolation from clinical material. Pneumonia due 
to non-pneumophila Legionella species resembles, both clinically and radiographi-
cally, that due to L. pneumophila [28]. Like L. pneumophila, other Legionella spe-
cies are inhabitants of natural and man-made aqueous environments. The majority 
of confirmed infections involving non-pneumophila Legionella species has occurred 
in immunosuppressed patients [28].
LD is considered a very rare cause of pneumonia in children; most children with LD 
are immunosuppressed [29]. All cases of LD in neonates were hospital-acquired, and 
most patients had potential risk-factors including prematurity, bronchopulmonar 
dysplasia, and corticosteroid use.
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Mortality rates are highly variable, ranging from less than 1% to as high as 80%, 
depending on the underlying health of the patient, the promptness of specific therapy, 
and whether the disease is sporadic, nosocomial, or part of a large outbreak [30]. 
Fatality rates of nosocomial disease have declined by more than 50% in the United 
States over the past 20 years; a similar but less dramatic decrease in death rates of 
community-acquired cases has also been observed. The declines in mortality rates 
appear to result from better and faster disease recognition, especially through use of 
the urinary antigen test, and more widespread use of empiric therapy for pneumonia 
that includes drugs active against L. pneumophila.
DIAgNOSIS
Although diagnostic methods have improved since L. pneumophila was first de-
scribed in 1976, no currently available test is able to diagnose all Legionella spp. in 
a timely fashion with a high degree of sensitivity and specificity. Most of the data 
are applicable to L. pneumophila, since sensitivity and specificity estimates for non-
pneumophila species are not known.
Culture
Isolation of Legionella spp., which has a specificity of 100%, is considered the gold 
standard for diagnosis of LD. Culture diagnosis requires special media, adequate 
processing of specimens, and technical expertise. Several days are required to obtain 
a positive result, with most Legionella spp. colonies being detected within 7 days. 
Species other than L. pneumophila may grow at a slower rate and may therefore be 
detectable only after 10 days of incubation [19,31]. The standard medium used to 
culture Legionella is BCYE agar supplemented with α-ketoglutarate, with or without 
antimicrobial agents. The antibiotics most commonly added are polymyxin to control 
Gram-negative growth, anisomycin against yeasts, and cefamandole or vancomycin 
against Gram-positive bacteria. Vancomycin should be chosen if culture is aimed at 
species other than L. pneumophila, because cefamandole inhibits some Legionella 
spp. that do not produce beta-lactamases [32].
Legionellae can be isolated from a variety of sample types, although lower respira-
tory tract secretions (e.g., sputum and bronchoscopy samples) are the samples of 
choice. Culture yield depends on the severity of illness, with the lowest yield (15% 
to 25%) in mild pneumonia and the highest yield (>90%) for severe pneumonia 
causing respiratory failure [33]. A major limitation of sputum culture is that fewer 
than one-half of patients with LD produce sputum [33,34,35,36]. Some patients with 
LD produce sputum that has relatively little purulence; these samples may be rejected 
by laboratories that discard sputum samples containing few polymorphonuclear 
leukocytes. However, Ingram and Plouffe demonstrated that up to 84% of L. pneu-
mophila-positive samples would have been discarded by using established sputum 
purulence screens and they recommend acceptance of all specimens submitted for 
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Legionella culture [37]. Estimated sensitivities of sputum culture range from <10% 
to 80% and vary according to different comparison standards and by individual 
laboratories [19,31,33]. In practice, the better results are likely to be achieved only 
by laboratories with a special interest in Legionella infection.
Serology
The indirect immunofluorescence assay (IFA) was used to detect antibodies in patients 
from the Philadelphia outbreak and was instrumental in determining the cause of the 
illnesses. Since then, a number of serologic test methodologies has been developed to 
detect antibodies to Legionella spp. [38]. Of the various antibody detection methods 
that are available, IFA and enzyme-linked immunosorbent assays (ELISA) are the 
most commonly used. Nowadays, ELISA assays are preferred by many laboratories 
over IFA testing because they are less subjective, thought to be more accurate than 
IFA testing and have the potential for automated performance [39,40,41]. The re-
ported sensitivities of serological assays vary substantially, from 41% to 94% [31]. 
Seroconversion may take several weeks, which is a major limitation of serological 
testing. Approximately 25%-40% of patients with LD seroconvert within the first 
week after the onset of symptoms [42]. In most cases, a 4-fold increase in antibody 
titer is detected within 3-4 weeks, but in some cases, this may take more than 10 
weeks [43]. Acute-phase reciprocal IFA antibody titers of ≥ 256 in the presence of 
pneumonia were once considered sufficient for a presumptive diagnosis, but this 
has been shown to be unreliable, especially given the high prevalence of Legion-
ella antibody positivity in persons without clinical evidence of legionellosis [44]. 
The specificity of seroconversion using L. pneumophila serogroup 1 antigen in IFA 
has been reported to be approximately 99% [38,45]. A disadvantage of serological 
testing is the inability to accurately detect all Legionella species and serogroups. 
Although seroconversion to L. pneumophila serogroup 1 is generally regarded as be-
ing highly diagnostic, the sensitivity and specificity of seroconversion to other species 
and serogroups has not been rigorously confirmed [33].
Detection of Legionella antigen in urine
The detection of Legionella antigenuria has been used already, shortly after the 
first outbreak in Philadelphia [42]. Legionella antigenuria can be detected as early 
as 1 day after onset of symptoms and persists for days to weeks. In one instance, 
excretion of antigen was documented to occur for more than 300 days [46]. The 
antigen detected is a component of the lipopolysaccharide portion of the Legionella 
cell wall and is heat stable [47,48]. The urinary antigen tests combine reasonable 
sensitivity and high specificity with rapid results. It has revolutionized the laboratory 
diagnosis of LD, making it the most common laboratory test for diagnosis [11,49]. 
Commercial kits that use both radioimmunoassay (RIA) and enzyme immunoassay 
(EIA) methodologies have been available for several years and have similar perfor-
mance characteristics [19]. Agglutination assays have also been introduced, but they 
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have not demonstrated acceptable sensitivity and specificity [50]. In addition, im-
munochromatographic assays have been developed that have similar sensitivity and 
specificity to EIA assays [51,52]. The majority are most sensitive for the detection of 
the Pontiac (MAb2) monoclonal antibody type of L. pneumophila serogroup 1 (up 
to 90%), less sensitive for other monoclonal antibody types of L. pneumophila sero-
group 1 (∼60%), and poorly sensitive (∼5%) for other L. pneumophila serogroups 
and other Legionella species [53,54]. Because the majority (about 90%) of cases 
of community-acquired LD are caused by the Pontiac subtype of L. pneumophila 
serogroup 1, the average sensitivity of this test is in the range of 70% to 80%. An 
important feature of these assays is their high specificity (>99%), which is a require-
ment when testing a relatively rare disease.
Detection of Legionella nucleic acid
The first assay designed to detect the DNA of L. pneumophila was a radiolabeled 
ribosomal probe specific for all strains of Legionella spp. (Gen-Probe, San Diego, Ca-
lif.). Researchers reported varying sensitivity and specificity for this assay [55,56,57]. 
The use of the probe at one hospital resulted in 13 false-positive cases [58] and the 
assay was removed from the market soon after this pseudo-outbreak.
PCR enables specific amplification of minute amounts of Legionella DNA and 
can provides results within a short time frame. It also has the potential to detect 
infections caused by any Legionella species and serogroup. Real-time PCR has added 
benefits to routine diagnosis, as it minimizes manual time for the PCR and makes the 
use of post-PCR analysis superflues. Diagnostic PCR assays have principally targeted 
specific regions within 16S rRNA genes [59,60-65], the 23S-5S spacer region [66], 
5S rDNA [67], or the macrophage inhibitor potentiator (mip) gene [63,69-74]. Thus 
far, encouraging results obtained mostly from in vitro evaluations and small patient 
series have been reported. When testing samples from the lower respiratory tract, 
PCR has repeatedly been shown to have a sensitivity equal to or greater than culture 
[59,75,76,77]. Indeed, PCR is considered the test of choice for patients who produce 
sputum by some authors [33]. However, a number of false-positive results have been 
reported, both with commercially available tests and with in house tests [19]. Legio-
nella DNA can be detected in urine, serum, and leukocyte samples obtained from 
patients with LD with sensitivities of 10%-86% [68,78,79]. The application of PCR 
to nonrespiratory samples seems particularly attractive, because this will circumvent 
the problem of patients who do not produce sputum. Legionella PCR is only avail-
able in a limited number of laboratories that use a variety of in-house or commercial 
assays [19,31,80]. These assays promise increased sensitivity and specificity, although 
further validation is required.
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TREATMENT
LD is regarded by many as a plague with a high mortality. It must be remembered 
that the original cases were patients with severe disease who did not receive appropi-
ate antibiotics. In this milennium, mortality has decreased with the increased index 
of suspicion by physicians, early empirical treatment with antibiotics that cover Le-
gionella spp. and the advent of rapid laboratory tests. Delay in starting appropriate 
therapy has been associated with increased mortality [81]. Benin et al. reported data 
from a large-scale study by the Centers for Disease Control and Prevention showing 
a decrease in the case-fatality rate for community-acquired Legionella pneumonia 
from 26% to 10% for the period 1980-1998 [9]. This finding is in accordance with 
recent studies of patients with outbreak-related LD who received rapid diagnoses 
by means of urine antigen testing; these studies have reported case-fatality rates of 
0%-5.5% [82,83,84].
The choice of empiric antibiotic therapy for CAP is based on the intention of pro-
viding optimal therapy, the epidemiological features of various microorganisms in the 
Netherlands, and an inference of the most likely pathogen [85,86,87]. In the Dutch 
Working Party on Antibiotic Policy (SWAB) and Dutch Thoracic Society (NVALT) 
guideline, the choice of antibiotic is based primarily on the severity of illness [85,86]. 
Rapid tests for detection of L. pneumophila antigen have a prominent place in both 
guidelines. Empirical antibiotic therapy should target primarily S. pneumoniae be-
cause of its high incidence. In both seriously ill patients and those suspected of having 
LD, antibiotic therapy should also target L. pneumophila. Empirical therapy should 
be replaced with pathogen-directed therapy when a causative agent is identified.
The intracellular location of the pathogen is relevant for the efficacy of the antimi-
crobial agent. Antimicrobial agents that achieve intracellular concentrations higher 
than the minimal inhibitory concentration (MIC) are more effective than antibiotics 
with poor intracellular penetration [88]. Thus, macrolides, quinolones, tetracyclines, 
and rifampicin are most likely to be efficacious. A number of small uncontrolled, or 
underpowered prospective controlled studies of the treatment of LD exist. Prospec-
tive, adequate-size clinical trials of antimicrobial therapy for LD have not yet been 
performed. Three observational studies have evaluated the efficacy of macrolides 
(erythromycin, clarithromycin and azithromycin) versus levofloxacin [82,89,90]. 
Time to defervescence was shorter in patients on levofloxacin therapy in two studies. 
Length of hospital stay was significantly shorter for patients treated with levofloxa-
cin in three studies. The overall mortality was 4.5% for the macrolide group and 
1.1% for the levofloxacin group but this difference was not statistically significant. 
Because these studies are not randomized, the possible superiority of levofloxacin 
therapy over therapy with the older macrolides should be interpreted with caution. It 
is possible that concomitant early recognition of Legionella spp. and a trend toward 
levofloxacin treatment in the past few years coincided to achieve less morbidity and 
fewer fatalities and that levofloxacin is not a better treatment than macrolides.
In the absence of adequate-size human studies, decisions about potential antimi-
crobial efficacy for LD are mostly made on the basis of experimental animal and cell 
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culture studies. The ability of a drug to inhibit or kill intracellular L. pneumophila 
usually correlates well with its clinical effectiveness for LD. Similarly, therapy studies 
using a guinea pig model of LD correlate quite well with drug effectiveness for the 
treatment of the disease in humans. In vitro data suggest that newer macrolides 
(azithromycin and clarithromycin) and many fluoroquinolone agents show the best 
activity against Legionella species. Additionally, these agents have fewer side effects 
than erythromycin [88,91]. Newer macrolides and levofloxacin are licensed by the 
Food and Drug Administration for the treatment of LD and are considered preferable 
to erythromycin. There is debate as to whether rifampin provides additional benefit 
to patients with LD [90]. Newer macrolides (especially azithromycin) have been 
shown to have some additional beneficial effect. However, the lack of an intravenous 
formulation limits the use of newer macrolides in severely ill patients.
OUTLINE OF THE THESIS
This thesis focuses on the evaluation and use of current and novel diagnostic tests for 
Legionella infection, with a particular emphasis on (molecular) tests that provide a 
diagnosis in a time frame that can affect initial infection management.
Chapter 1 provides a concise description of the history, microbiology, clinical spec-
trum, diagnosis and therapy of LD, and describes the outline of the thesis.
Part I. Serology. Of the various antibody detection methods that are available to 
detect LD, indirect immunofluorescent assays (IFA) and enzyme-linked immunosor-
bent assays (ELISA) are the most commonly used methodologies. The availability of 
commercial ELISA and IFA kits has resulted in the increasing use of these products, 
despite the fact that few studies determining their sensitivity and specificity are avail-
able. In chapter 2 we describe the evaluation of commercial ELISA and IFA assays for 
the detection of antibodies against L. pneumophila in a well described population of 
patients with and without LD. Chapter 3 describes a case of probable LD in which 
the diagnosis was complicated by the presence of cross-reacting antibodies to C. 
burnetii.
Part II. Urinary antigen detection. Detection of soluble Legionella antigen in urine 
specimens is a rapid method that can provide an early diagnosis of Legionella infec-
tion. In the Netherlands, cases diagnosed by culture and serology have declined, 
while cases diagnosed by urinary antigen have increased dramatically. The most fre-
quently used method for detecting antigenuria is the immunochromatographic (ICT) 
membrane assay (Binax NOW). In chapter 4, 5 and 6, the evaluation of four new 
ICT assays for their ability to detect L. pneumophila serogroup 1 antigen in urine is 
described. In chapter 7, an evaluation of the Binax NOW Streptococcus pneumoniae 
urinary ICT assay is described.
Part III. Polymerase Chain Reaction (PCR). PCR represents one of the few diag-
nostic tests with the potential to detect infections caused by all of the known species 
of Legionella. PCR could be a useful test for patients who produce sputum. The 
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role of PCR for testing samples other than respiratory sample types is less clear. In 
chapter 8, we describe two patients with LD diagnosed by PCR on serum samples. 
In these patients quantification of L. pneumophila DNA using real-time PCR during 
the course of illness was carried out. The aim of chapter 9.1 was to assess the perfor-
mance of PCR as a rapid diagnostic method and to compare the results of different 
PCR assays of serum samples from patients with LD. In chapter 9.2 we investigated 
the relationship between PCR test sensitivity and the severity of disease using serum 
specimens from patients with outbreak-related LD. Chapter 10 describes the case of 
a patient who developed a community-acquired pneumonia due to L. longbeachae, 
identified by 16S rRNA based PCR assay and sequence based typing.
Part IV. Detection of Legionella spp. in potable water. Chapter 11 describes the oc-
curence and identity of Legionella spp. in Dutch tap water installations using culture, 
real-time PCR and sequence analysis.
Part V. The role of Legionella spp. in the aetiology of respiratory tract infections 
and in exacerbations of chronic obstructive pulmonary disease. Acute respiratory 
infections (ARI) are a major cause of morbidity and mortality worldwide. Studies 
found serological evidence of infection with Legionella spp. in patients with ARI. 
The aim of chapter 12 was to assess the frequency of Legionella spp. in nose and 
throat samples of patients presenting with ARI in general practice using real-time 
PCR. Chapter 13. The term “atypical” pathogen commonly refers to M. pneumo-
niae, C. pneumoniae and L. pneumophila. Serological studies suggest that these 
pathogens may play a role in acute exacerbations of chronic obstructive pulmonary 
disease (AECOPD). We investigated the presence of these atypical pathogens in 
sputum samples in patients with stable COPD and those with AECOPD using real-
time PCR. Chapter 14. For many respiratory pathogens, especially viruses, PCR has 
been shown to be more sensitive than conventional microbiological methods, and 
it could help to increase the number of microbiological diagnosis for patients with 
community-acquired pneumonia (CAP). We conducted a study on oropharyngeal 
swabs obtained from a group of hospitalised CAP patients to evaluate if the use of 
real-time PCR for detection of respiratory viruses and Legionella spp. would increase 
the diagnostic yield.
Part VI. The use of PCR for the diagnosis of LD in routine clinical practice. Since 
most rapid tests only detect infections due to L. pneumophila serogroup 1, an accu-
rate PCR test might enhance the ability to diagnose these infections. However, the use 
of PCR has not found widespread application and a limited number of laboratories 
test for Legionella by PCR at this time. Limited studies suggest that PCR may add to 
the diagnostic repertoire, but PCR may lack the sensitivity and specificity to provide 
additional information to the clinician. In chapter 15 we evaluated the use of PCR 
for the diagnosis of LD to assess the practical value of this technique for routine use 
in the clinical microbiology laboratory.
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ABSTRACT
We evaluated the abilities of the Vircell immunoglobulin G (IgG) and IgM indirect 
immunofluorescence assay (IFA) for Legionella pneumophila serogroup 1, the IgM 
and IgG enzyme-linked immunosorbent assay (ELISA) for Legionella pneumophila 
serogroup 1, and the IgM-plus-IgG ELISA for Legionella pneumophila serogroups 1 
to 6 to diagnose Legionnaires’ disease (LD) in a sample of patients with and without 
LD. Also, we determined the agreements, sensitivities, and specificities of the differ-
ent Vircell assays in comparison to a validated ELISA (Serion classic ELISA). Clinical 
sensitivity and specificity were 74.6% and 96.6%, respectively, for the IgM IFA, 
65.1% and 88.0% for the IgG IFA, 92.3% and 100% for the IgM ELISA, 43.3% and 
96.6% for the IgG ELISA, and 90.8% and 100% for the IgM-plus-IgG ELISA. Com-
pared to Serion classic ELISA, agreement, sensitivity, and specificity were 79.4%, 
66.2%, and 88.9%, respectively, for the IgM IFA, 75.0%, 59.3%, and 83.8% for the 
IgG IFA, 89.5%, 97.3%, and 83.3%, respectively, for the Vircell IgM ELISA, 81.9%, 
55.2%, and 96.3%, respectively, for the Vircell IgG ELISA, and 93.5%, 96.0%, and 
91.5%, respectively, for the Vircell IgM and IgG combined ELISA. The value of a 
positive diagnostic result obtained by the Vircell IgM IFA, the Vircell IgG IFA, and 
the Vircell IgG ELISA might not be acceptable for a diagnostic assay. Both the high 
specificities and sensitivities of the Vircell IgM ELISA and the IgM-plus-IgG ELISA 
and the high correlation with the Serion classic ELISA indicate that they are useful 
in the diagnosis of LD.
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INTRODUCTION
The genus Legionella of the family Legionellaceae includes more than 45 species of 
fastidious gram-negative bacilli, 20 of which have been reported to infect humans. 
Bacteria of the family Legionellaceae are ubiquitous in both natural and man-made 
aqueous environments, and inhalation or aspiration of contaminated water can cause 
Legionnaires’ disease (LD), a severe pneumonia. Legionellae can also cause subclini-
cal infection and extrapulmonary inflammation [1]. Legionella pneumophila causes 
91% of all reported cases of LD, with serogroup 1 being the most predominant 
serogroup, causing approximately 80% of all culture-confirmed cases [2].
Of the various antibody detection methods that are available to detect Legionella 
infection, indirect immunofluorescent assays (IFA) and enzyme-linked immunosor-
bent assays (ELISA) are the most commonly used methodologies [3-5]. A 4-fold or 
greater increase in antibody titer is considered diagnostic. An ELISA assay is gen-
erally preferred over IFA testing because it is less subjective, thought to be more 
sensitive than IFA testing and has the potential for automated performance [3,6,7]. 
The availability of commercial ELISA and IFA kits has resulted in the increasing use 
of these products, despite the fact that few studies determining their sensitivity and 
specificity are available.
The aim of our study was to evaluate commercial ELISA and IFA assays (VIR-
CELL, S.L., Santa Fe, Granada, Spain) for the detection of antibodies against L. 
pneumophila.
MATERIAL AND METHODS
Clinical samples
Serum samples were collected between 1999 and 2004 and stored at –20°C until 
processing was performed. We included 129 serum samples of 65 patients with 
proven LD (cases). A proven case of LD was defined as a patient who suffered from 
symptoms of pneumonia, had radiological signs of infiltration, and who showed 
laboratory evidence of infection with L. pneumophila. Laboratory evidence in-
cluded: (i) one or more of the following criteria: isolation of L. pneumophila from a 
respiratory sample; a positive urinary antigen test (Binax NOW Legionella Urinary 
Antigen Test, Binax Inc.); a positive PCR result on respiratory tract samples using a 
16S rRNA assay [8] and (ii) a single high titer in IgM and/ or IgG or seroconversion 
to positive IgM and/or IgG antibodies to L. pneumophila in paired acute-phase and 
convalescent-phase sera using a commercial enzyme-linked immunosorbent assay 
(L. pneumophila seroserogroup 1 to 7 antibodies, Serion ELISA; Institut Virion\Se-
rion GmbH, Würzburg, Germany). The Serion ELISA has more or less been validated 
in extensive studies [3,9]. Age and sex distribution of cases were as follows: 46 were 
male and 19 were female, with ages between 32 and 79 years (mean age 54.5). 
All included patients with LD had evidence for LD in at least two laboratory tests, 
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most often a positive urinary antigen test in combination with serology. None of 
the patients were diagnosed based on serodiagnosis only. The laboratory results of 
patients with proven LD were as follows (number positive/number tested): serology 
65/65 (100%), culture on respiratory tract samples 14/28 (50%), PCR on respiratory 
tract samples 24/24 (100%), urinary antigen test 52/58 (90%).
In addition, serum samples of patients with respiratory tract infections other than 
Legionella were tested in a similar manner to serve as controls, and to test specific-
ity. These samples were obtained from 29 patients with respiratory tract infections 
and who had a fourfold rise or more in (complement-fixating) antibodies against 
influenza A virus, adenovirus, Chlamydia psittaci or Mycoplasma pneumoniae (50 
samples). Age and sex distribution of controls were as follows: 15 were male and 14 
were female, with ages between 2 and 84 years (mean age 43.5).
Legionella pneumophila IFA IgM and Igg
(VIRCELL, S.L., Santa Fe, Granada, Spain). Samples were tested for L. pneumophila 
serogroup 1 IgM and IgG antibodies by an IFA procedure according to the manufac-
turer’s instructions [10]. IgG titers ≥ 1:64 or IgM titers ≥ 1:96, as well as seroconver-
sion (four fold rise in titer) were considered positive.
VIRCELL Legionella pneumophila serogroup 1-6 ELISA IgM, Igg and combined 
IgM plus Igg
(VIRCELL, S.L., Santa Fe, Granada, Spain). The kits include a microplate coated 
with lipopolysaccharide from Legionella pneumophila either from serogroup 1 (IgM, 
IgG) or serogroups 1-6 (IgM plus IgG combined). For IgM testing, IgG and rheuma-
toid factor was removed by treatment with sorbent directly into the well. Samples 
were tested, and the results were interpreted in accordance with the package inserts 
provided with the assays.
SERION classic ELISA L. pneumophila serogroup 1 to 7 assay
(SERION immunodiagnostica, Würzburg, Germany). Samples were tested for IgG 
and IgM antibodies against Legionella pneumophila serogroup 1-7. Samples were 
tested, and the results were interpreted in accordance with the package inserts pro-
vided with the two assays.
Statistical analysis
Clinical sensitivity and specificity of the assays were determined using a two-by-two 
contingency table. Also, the agreement, sensitivity and specificity of the VIRCELL 
assays was determined by comparing the results with those obtained with SERION 
classic ELISA. Equivocal results were not included in the calculations.
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RESULTS
Clinical sensitivity and specificity were 74.6% and 96.6%, respectively, for the IgM 
IFA and 65.1% and 88.0% for the IgG IFA (Table 1). If the results of both the 
IgM IFA and IgG IFA of each separate assay were combined, clinical sensitivity and 
specificity would be 87.5% and 84.0%, respectively. Clinical sensitivity and specific-
ity were 92.3% and 100%, respectively, for the IgM ELISA, 43.3% and 96.6% for 
the IgG ELISA, and 90.8% and 100% for the IgM-plus-IgG ELISA (Table 1). If the 
results of both the IgM ELISA and IgG ELISA of each separate assay were combined, 
clinical sensitivity and specificity would be 91.1% and 96.6%, respectively.
Table 1. Clinical sensitivity and specificity obtained using VIRCELL IFA and VIRCELL ELISA for the 
detection of Legionella pneumophila specific IgM and IgG antibodies in patients with and without 
Legionnaires’ disease. Samples were tested for L. pneumophila serogroup 1 antibodies in IFA IgM, IFA IgG, 
ELISA IgM, ELISA IgG and L. pneumophila serogroup 1-6 in IgM and IgG combined ELISA.
No. (%) of samples/total no. tested
IFA IgM IFA IgG ELISA IgM ELISA IgG ELISA IgM plus IgG
Sensitivity 47/63 (74.6%) 41/63 (65.1%) 60/65 (92.3%) 26/60 (43.3%) 59/65 (90.8%)
Specificity 27/28 (96.6%) 22/25 (88.0%) 29/29 (100%) 28/29 (96.6%) 27/27 (100%)
A calculated agreement, sensitivity, and specificity of 79.4%, 66.2% and 88.9%, 
respectively, was found for IFA IgM compared to SERION IgM and 75.0%, 59.3% 
and 83.8%, respectively, for IFA IgG compared to SERION IgG (Table 2). Of the 179 
samples tested, 24 (9 in IFA IgM and 15 in IFA IgG) were equivocal results that were 
not included in the calculations.
Table 2. Results of samples tested with VIRCELL Legionella IFA compared to SERION classic ELISA for 
the detection of L. pneumophila IgM and IgG specific antibodies. Samples were tested for L. pneumophila 
serogroup 1 antibodies in IFA IgM, IFA IgG, ELISA IgM, ELISA IgG and L. pneumophila serogroup 1-6 in 
IgM and IgG combined ELISA.
Vircell IFA results
Serion ELISA result 
(IgM/IgG)
IFA IgM IFA IgG IFA IgM IFA IgG IFA IgM IFA IgG
Positive Negative Equivocal
Positive 47 35 24 24 5 2
Negative 11 17 88 88 2 5
Equivocal 2 4 0 3 0 1
A calculated agreement, sensitivity, and specificity of 89.5%, 97.3%, and 83.3%, 
respectively, was found for VIRCELL IgM compared to SERION IgM and 81.9%, 
55.2%, and 96.3%, respectively, was found for VIRCELL IgG compared to SERION 
IgG (Table 3). A calculated agreement, sensitivity, and specificity of 93.5%, 96.0%, 
and 91.5%, respectively, was found for VIRCELL IgG plus IgM combined ELISA 
compared to SERION IgM. Of the 179 samples tested, 31 (8 in ELISA IgM, 13 in 
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ELISA IgG and 10 in IgG plus IgM combined ELISA) were equivocal results that 
were not included in the calculations.
Table 3. Results of samples tested with VIRCELL Legionella ELISA compared to SERION classic ELISA for 
the detection of L. pneumophila IgM and IgG specific antibodies. Samples were tested for L. pneumophila 
serogroup 1 antibodies in IFA IgM, IFA IgG, ELISA IgM, ELISA IgG and L. pneumophila serogroup 1-6 in 
IgM and IgG combined ELISA
VIRCELL ELISA results
Serion ELISA 
result (IgM/IgG)
IgM IgG IgM+IgG IgM IgG IgM+IgG IgM IgG IgM+IgG
Positive Negative Equivocal
Positive 73 32 72  2  26  3 1 3 1
Negative 16  4  8 80 104 86 5 2 7
Equivocal  2  4  2  0   4  0 0 0 0
DISCUSSION
Several methods of antibody detection against L. pneumophila have been developed, 
such as IFA, microagglutination test, indirect hemagglutination test, and ELISA 
[3,6,11-15]. Historically, the IFA was the first assay used to detect antibodies against 
Legionella pneumophila. Nowadays, commercially available ELISA kits are exten-
sively used for the diagnosis of LD because they are at least as sensitive as IFA, 
can have an objectively determined end point, and allow automation. The reported 
sensitivities of serological assays vary substantially, from 41% to 94% [3,6,13]. This 
variation may be due to differences in the study population, the design of the study, 
differences in the antigen preparation or in the valence (mono- or polyvalent) of 
the antigen used, cross-reacting antibodies, and differences in the ability to detect 
IgM or IgG. In this study, we evaluated the ability of commercial IFA and ELISA to 
diagnose LD in a well-described population of patients with and without LD. Also, 
we determined the agreements, sensitivities, and specificities of the different Vircell 
assays in comparison to a validated ELISA [3,9].
The clinical sensitivity of the Vircell ELISA to diagnose LD was significantly higher 
for the detection of IgM and IgM-plus-IgG antibodies in comparison to that of the 
IFA for IgM detection (92.3%, 90.8%, and 74.6% for the Vircell IgM ELISA, the 
IgM-plus-IgG ELISA, and the IgM IFA, respectively; P < 0.01). The clinical sensitiv-
ity of the Vircell ELISA for the detection of IgG-specific antibodies was significantly 
lower than that of the IFA for IgG detection (43.3% and 65.1% for the Vircell IgG 
ELISA and the IgG IFA, respectively; P = 0.02).
The correlation between Serion and Vircell varied between the assays evaluated. 
The correlation was highest between the Serion classic ELISA and the Vircell ELISA 
for the detection of IgM and IgG combined and lowest for the IgG IFA. Although 
equivocal results were not included in the calculations, a considerable percentage of 
samples gave equivocal results in both the Vircell IFA and ELISA. For example, in 
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the IgM IFA, 6.5% (5/76) of samples positive in the Serion ELISA tested equivocal. 
Similar percentages can be seen for both the Vircell ELISA and IFA.
A drawback in the current evaluation is that we evaluated a relatively small group 
of patients with respiratory tract infections other than LD. This could influence the 
specificity. Also, the majority of LD-positive patients were infected with L. pneu-
mophila serogroup 1, making it difficult to conclude anything for L. pneumophila 
infections caused by other serogroups.
Usually both IgM and IgG can be detected in samples of patients during the course 
of their illness, but in a significant proportion of patients, no IgG is detectable [6]. 
Studies have shown that many patients produce primarily IgM antibodies and that 
these are useful for the early diagnosis of Legionnaires’ disease [1,10]. However, 
IgM may be present later in some confirmed cases, limiting the usefulness of the 
assay for early diagnosis in all patients. In a study by Rojas et al., serum antibody 
detection (Vircell) and urine antigen detection techniques (Binax Now) were com-
pared in samples from 116 patients epidemiologically characterized as belonging to 
a legionellosis outbreak [10]. ELISA for IgM, ELISA for IgG plus IgM, antigenuria 
detection, and IFA for IgM were able to diagnose 72.3%, 60.5%, 53.3%, and 51.4% 
of patients, respectively. Antigenuria was detected in 53.8% of first samples, ELISA 
detected IgM in 29.7%, ELISA detected IgG plus IgM in 7.9%, and IFA detected IgM 
in 3.9%. For the patient series as a whole, serological techniques displayed greater 
sensitivities than antigen detection; 35 patients would have been scored as negative 
if serological testing had not been carried out.
For an illness of low prevalence, such as LD, the specificity of a test is an important 
parameter. Our results suggest that the predictive value of a positive diagnostic result 
obtained by the Vircell IgM IFA, the Vircell IgG IFA, and the Vircell IgG ELISA might 
not be acceptable for a diagnostic assay. The positive and negative predictive values 
obtained by the Vircell IgM ELISA and the IgM-plus-IgG ELISA approach 100%, 
assuming that the prevalence of LD is 4% of patients with pneumonia. Both the 
high sensitivities and specificities of these two assays and their high correlation with 
the Serion classic ELISA indicate that considerable confidence can be placed in the 
validity of the diagnosis when specimens from a patient give serodiagnostic results. 
The Vircell IgG ELISA shows moderate sensitivity, but high specificity, and could be 
included together with IgM or IgM-plus-IgG for optimal clincal decision making.
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ABSTRACT
Legionella pneumophila and Coxiella burnetii are both intracellular Gram-negative 
bacteria potentially responsible for similar clinical syndromes. We present a case 
of probable Legionnaires’ disease in which the diagnosis was complicated by the 
presence of cross-reacting antibodies to Coxiella burnetii. It is important that the 
existence of this cross-reaction is recognized, as misdiagnosis of either condition may 
lead to incorrect and ineffective treatment.
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INTRODUCTION
Legionnaires’ disease (LD) is a pneumonia caused by Legionella spp., rod-shaped 
gram-negative bacilli ubiquitous in (man-made) aquatic reservoirs. Legionella spp. 
are responsible for 1 to 5% of cases of community-acquired pneumonia (CAP) requir-
ing hospital admission [1,2]. The vast majority of such cases are due to Legionella 
(L.) pneumophila, with a substantial minority due to other species, most commonly 
L. micdadei, L. bozemanii, L. dumoffii, and L. longbeachae [2]. Legionella infec-
tion can present as a severe pneumonia and high mortality, but it can also present 
as a self-limiting flu-like illness. Coxiella (C.) burnetii is the causative agent of Q 
fever, a worldwide zoonosis. Animals shed C. burnetii in milk, faeces, urine, and 
especially in birth by-products and infection in humans results from the inhalation 
of contaminated aerosols. Although the clinical signs of acute infection vary, acute Q 
fever usually presents as an influenza-like illness with varying degrees of pneumonia 
and hepatitis and a case-fatality rate of 1-2% [3].
We present a case of probable LD in which the diagnosis was complicated by the 
presence of cross-reacting antibodies to C. burnetii.
CASE REPORT
A 60-year-old caucasian woman was admitted to the hospital complaining of pleuritic 
chest pain, chills and fever accompanied by fatigue and malaise. Two weeks prior 
to admission, the patient suffered from tonsillitis and was treated with feneticillin 
prescribed by her general practitioner. Examination of her chest revealed decreased 
breath sounds and crackles in the left posterior lung base, and a chest radiograph 
showed a consolidation of the left lung base. Laboratory studies revealed a WBC 
count of 8200/µL (54% neutrophils, 36% lymphocytes, 4% monocytes, and 2% 
eosinophils), hematocrit of 35%, an erythrocyte sedimentation rate of 51 mm/h 
and a C-reactive protein value (CRP) of 144 mg/l. Results of liver function tests 
were within the normal range. Small spectrum antibiotic therapy with intravenous 
amoxicillin (1000 mg per 6 hours) was started. The patient seemed to respond after 
initiating antibiotic therapy; her condition became better and CRP-values dropped to 
75 mg/l on day 3 after hospital admission. She was discharged home four days after 
admission. Three sets of blood cultures were taken at admission but no organisms 
were cultured. Bacterial cultures for bacteria and fungi of sputum remained negative. 
Sputum culture on Legionella-specific media was not performed. An immunochro-
matographic membrane test (Binax NOW; Binax, USA) to detect L. pneumophila se-
rogroup 1 soluble antigens in urine had been performed, but the result was negative. 
Four days after hopital admission, results of ELISA for L. pneumophila seroroup 
1-7 (Virion/Serion, Würzburg, Germany) demonstrated negative levels of IgM (74 U/
ml) and IgG (< 10 U/ml) antibodies (reference ranges IgM/IgG: negative < 120/50, 
equivocal 120-140/50-70, positive > 140/70). Two weeks later, tests revealed marked 
levels of complement fixating (CF; Virion/Serion, Würzburg, Germany) antibodies to 
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C. burnetii (titer of < 1 : 10 in the acute phase serum, and ≥ 1 : 160 in the convalescent 
serum sample). CF tibodies to influenza A and B viruses, adenovirus, coronavirus, 
Mycoplasma pneumoniae, respiratory syncytial virus and Chlamydophila psittaci 
were negative. Because the patient had always lived in an urban setting, without con-
tact with animals except for a domestic dog, the diagnosis Q fever was thought to be 
very unlikely. The clinical microbiologist noticed the increased IgM level of 74 U/ml 
and suspected a serological cross-reaction between L. pneumophila and C. burnetii. 
Serology for L. pneumophila was repeated. Three weeks after hospital admission, 
results of ELISA for L. pneumophila demonstrated increased levels of IgM (93 U/
ml) and after four weeks, levels of IgM increased further above the cut-off value 
(204 U/ml). IgG levels remained negative (<10 U/ml) at both three and four weeks. 
In addition, samples were tested for L. pneumophila serogroup 1 (VIRCELL, S.L., 
Santa Fe, Granada, Spain [4]) and C. burnetii IgM and IgG antibodies by an indirect 
immunofluorescent assay (in-house assay). Using acute and convalescent serum, IgG 
titers were 1:16 and 1:64 respectively, and IgM titers 1:128 and 1:256 respectively 
for L. pneumophila. IgG antibodies against C. burnetii were absent in the acute 
serum and 1:64 in the convalescent serum, IgM titers were 1:64 in both the acute and 
convalescent serum sample.
DISCUSSION
The background frequency of elevated anti-L. pneumophila titers in the normal pop-
ulation in The Netherlands has been found to be very low. In a study using 480 blood 
samples from a serum bank established in a nation-wide population based survey, 
the prevalance of measured IgM levels between 50 and 94 U/ml was only 2.7% [5]. 
Seropositivity for IgG is much more common, with 5.4% seropositivity (>70 U/ml) 
and another 4.4% with borderline increased IgG titer (50-70 U/ml). Cross-reactive 
antibodies with L. pneumophila are occasionally found in patients with respiratory 
tract infections (Bordetella pertussis, Haemophilus influenzae, Chlamydophila pneu-
moniae) and infections other than respiratory tract, including Pseudomonas spp., 
Bacteroides spp., Campylobacter spp., Salmonella typhi and Neisseria meningitidis 
[6,7]. Serological cross-reactions between Legionella spp. and Coxiella spp. have 
been reported previously [6,8,9]. One report described a patient with Q fever pneu-
monia and cross-reacting antibodies to L. pneumophila sg 4, demonstrated by a 
cross absorption study [8]. Musso et al. found that 34.5% of Q fever patients had a 
significant titer of antibodies against L. micdadei at levels significantly higher than 
those found in the healthy population, using microimmunofluorescence assay [6]. 
Cross-reactions involved IgG antibodies and were demonstrated by a cross-adsorption 
study and protein immunoblotting. Western blot analysis performed indicated that 
cross-reactions were probably due to both protein and lipopolysaccharide antigens. 
It should be remembered, however, that these cross-reactions are the exceptions and 
that the specificity of most commercial used ELISAs is high [4,5].
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Serological cross-reactions between L. pneumophila and C. burnetii are in fact 
not surprising given the phylogenetic similarity between the two species. Both these 
bacteria are in the gamma subdivision of the proteobacteria, distantly placed from 
Rickettsiae which belong in the alpha subdivision. Sequencing of the C. burnetii 
16S rRNA and genome has identified substantial homology with L. pneumophila 
[10,11,12]. These organisms have similar intracellular lifestyles and may utilize com-
mon genes to infect their host. In addition, the C. burnetii antigen has also been 
reported to express on its surface epitopes of the so-called common bacterial antigen 
and eukaryotic chaperoning protein [13,14], which has extensive homology with 
proteins from other prokaryotes, such as L. pneumophila [15].
The presence of cross-reacting antibodies in patients with CAP emphasizes the 
need for cautious interpretation of antibody titers to members of the family Coxiella 
and Legionella. L. pneumophila and C. burnetii are both gram-negative bacteria po-
tentially responsible for similar clinical syndromes. Although the clinical condition 
of the patient described was benign and probably self-limiting, both Q fever and LD 
are able to cause severe illness with high mortality. A misdiagnosis of either condition 
may lead to incorrect and ineffective treatment. Tetracycline is the standard treat-
ment for Q fever and is less effective for LD [16]; erythromycin and quinolones are 
standard treatment for LD and is probably ineffective for Q fever [17]. In addition, 
failure to recognize cases of LD will hamper the detection of potential clusters or 
outbreaks of LD.
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ABSTRACT
We evaluated two new immunochromatographic assays for their abilities to detect 
Legionella pneumophila serogroup 1 antigen in urine. The results were compared 
with those obtained by the Binax NOW urinary antigen test. The sensitivities and 
specificities were estimated to be 71.2% and 96.6%, respectively, for the Rapid U 
test; 31.5% and 98.9%, respectively, for the SD Bioline test; and 91.8% and 100%, 
respectively, for the Binax NOW test.
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INTRODUCTION
Legionnaires’ disease (LD) is a pneumonia responsible for 1 to 5% of cases of com-
munity-acquired pneumonia (CAP) requiring hospital admission [1,2]. However, this 
percentage is found to be lower in some European countries [3]. Since antigen detec-
tion in urine has proved to be a sensitive and rapid method for the detection of L. 
pneumophila serogroup 1, this technique has become one of the most-used tools for 
the diagnosis of LD [3]. An immunochromatographic (ICT) assay (the Binax NOW 
legionella urinary antigen test) that has a sensitivity and a specificity similar to those 
of enzyme immunoassays (EIAs) has been developed [4]. ICT assays have important 
advantages over conventional EIAs: the tests are simple to perform, they do not 
require special laboratory equipment, and results can be obtained within 15 min.
The aim of our study was to evaluate two newly developed ICT urine antigen tests, 
the Rapid U Legionella antigen test (Rapid U test; Diamondial, Sees, France) and the 
SD Bioline Legionella urinary antigen test (SD Bioline test; Standard Diagnostics, 
Inc., Kyonggi-do, Korea), for the detection of L. pneumophila serogroup 1 in urine. 
Neither test is yet commercially available.
MATERIAL AND METHODS
We evaluated the abilities of the new antigen tests to diagnose LD in a well-described 
sample of patients with and without LD using frozen urine samples. Urine samples 
were collected between 1997 and 2005 and were stored at –70°C until processing 
was performed. We included 73 urine samples from 73 patients with LD (cases). A 
case of LD was defined as a patient with pneumonia who had radiological signs of 
infiltration and who showed laboratory evidence of infection with L. pneumophila. 
One or more of the following criteria constituted laboratory evidence of infection 
with L. pneumophila: isolation of L. pneumophila from a lower respiratory tract 
(LRT) sample, a positive PCR result with an LRT sample by a 16S rRNA-based 
assay [5], or seroconversion to positivity for immunoglobulin M (IgM) and/or IgG 
antibodies to L. pneumophila in paired acute-phase and convalescent-phase sera by a 
commercial enzyme-linked immunosorbent assay (ELISA; Serion ELISA; Institut Vi-
rion/Serion GmbH, Würzburg, Germany). Urine from all patients with LD-positive 
samples tested negative for pneumococcal antigen (PAG; Binax NOW; Binax, Port-
land, Maine). The laboratory results for these patients were as follows (number of 
patients positive/number of patients tested): serology, 53/60 (88%); isolation, 7/17 
(41%); and PCR, 37/38 (97%).
Urine samples from 89 patients with respiratory tract infections other than Legion-
ella infections were tested in a similar manner to test the specificity of the assays. The 
laboratory test results for these patients were as follows: Streptococcus pneumoniae 
(total, 50 patients; cultured from blood [blood], PAG detected in urine [PAG], and 
cultured from sputum [sputum], 8 patients; blood and PAG, 23 patients; blood, 
11 patients; sputum and PAG, 2 patients; sputum, 4 patients; PAG, 2 patients), 
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Haemophilus influenzae (total, 10 patients; blood, 3 patients; sputum, 7 patients), 
Moraxella catarrhalis (sputum, 3 patients), Staphylococcus aureus (total, 4 patients; 
blood and sputum, 2 patients; sputum, 2 patients), Escherichia coli (total, 2 patients; 
blood and sputum, 1 patient; sputum, 1 patient), Acinetobacter baumannii (blood 
and sputum, 1 patient), Streptococcus pyogenes (blood and sputum, 2 patients), 
Klebsiella pneumoniae (sputum, 1 patient), Mycobacterium tuberculosis (sputum, 
3 patients), and Pneumocystis jirovecii (Giemsa and silver stain positive, 1 patient). 
Twelve patients who had a fourfold rise or more in (complement-fixating) antibodies 
against influenza A virus (n = 3), adenovirus (n = 1), Chlamydia psittaci (n = 3), 
Mycoplasma pneumoniae (n = 4), and parainfluenza virus (n = 1) were included.
Urine samples were investigated for the presence of L. pneumophila antigens by 
using the Rapid U test and the SD Bioline test. Both tests are qualitative ICT tests. 
We compared the sensitivities and specificities of these assays to those of a widely 
used ICT assay, the Binax NOW urinary antigen test (Binax NOW; Binax). All three 
tests were performed simultaneously, and the results were calculated according to the 
manufacturers’ instructions. However, to ensure maximum sensitivity for the urinary 
antigen tests [6], all samples were reexamined after 60 min. Fisher’s exact test was 
used to compare categorical data. A result with a P value of <0.05 was considered 
statistically significant.
RESULTS
The results obtained are shown in Table 1. The sensitivities and specificities were 
71.2% (52/73) and 96.6% (3/89), respectively, for the Rapid U Legionella antigen 
test; 31.5% (23/73) and 98.9% (1/89), respectively, for the SD Bioline Legionella 
urinary antigen test; and 91.8% (67/73) and 100% (0/89), respectively, for the Binax 
NOW urinary antigen test. The sensitivity of the SD Bioline test decreased to 27.4% 
(20/73) (P = 0.71) if the tests were reexamined after 55 min. The sensitivities of the 
Table 1: Results of ICT tests after 5 min (SD Bioline Legionella urinary antigen test) or 15 min (Rapid U 
Legionella antigen test, Binax NOW) and 1 hour of incubation. LD: Legionnaires’ disease, RTI: respiratory 
tract infection).
No. of patients with a positive test result/total number of patients (%)
5-15 min 1 hour
LD (cases)
Rapid U Legionella 52/73 (71.2) 59/73 (80.8)
SD Bioline 23/73 (31.5) 20/73 (27.4)
Binax NOW 67/73 (91.8) 69/73 (94.5)
RTI other than LD (controls)
Rapid U Legionella 3/89 (3.4) 3/89 (3.4)
SD Bioline 2/89 (2.2) 7/89 (7.9)
Binax NOW 0/89 (0) 0/89 (0)
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Rapid U test and Binax NOW test increased to 80.8% (59/73) (P = 0.25) and 94.5% 
(69/73) (P = 0.75), respectively, if the tests were reexamined after 45 min. The dif-
ferences in specificities between the three tests were not statistically significant. The 
Binax NOW test showed sensitivity levels significantly higher (P < 0.01) than those 
of the Rapid U and SD Bioline tests.
DISCUSSION
The characteristics of the first urinary antigen tests were published in the late 1970s 
[4,7]; and since then, numerous publications that have each described different tech-
niques have followed and together have provided evidence that confirms the value of 
urinary antigen detection for the diagnosis of infections caused by L. pneumophila 
serogroup 1 infections [4,8,9]. In general, none of those previous studies have dem-
onstrated great differences in the abilities of the different tests to detect L. pneumo-
phila antigen when nonconcentrated urine samples were tested. The specificities of 
the assays in the current evaluation were determined by using single urine specimens 
collected from 89 patients with pneumonia or respiratory tract infections of known 
(but not Legionella) etiology. Three control patients tested positive by the Rapid U 
test; two of these patients had proven pneumococcal pneumonia (blood and PAG), 
and one patient had S. pyogenes pneumonia (blood, sputum). Two control patients 
tested positive by the SD Bioline test, and both had proven pneumococcal pneumo-
nia (blood, PAG). For an infection of low prevalence, such as LD, test specificity is 
of paramount importance. Although the differences in the specificities between the 
three tests were not statistically significant, our data suggest that in a population 
with a 4% prevalence of LD (e.g., hospitalized patients with community-acquired 
pneumonia), even if it is assumed that the Rapid U and the SD Bioline Legionella 
antigen tests have 100% sensitivities, the predictive values of a positive result would 
only be about 55% and 65%, respectively. The data further indicate that the Binax 
NOW urinary antigen test, in concordance with the findings of previous studies, has 
excellent specificity, as no false-positive results were found. Based on prospective and 
retrospective studies with data from solitary cases, moderate to high urinary antigen 
test sensitivities have been described, ranging from 56 to 99% [10-14]. This may be 
explained by differences in test and patient characteristics, the serogroup with which 
the patient is infected, the timing of specimen collection in the course of the illness, 
and whether the urine is concentrated before it is tested. In a recent evaluation, Sohn 
et al. [15] evaluated the SD Bioline test using samples from 11 confirmed nosocomial 
infections with L. pneumophila and 88 respiratory tract infections caused by species 
other than Legionella. The 11 LD-positive urine samples included 4 samples from 
culture-proven cases and 7 samples from cases with a high single Legionella im-
munofluorescence assay titer and a positive sputum PCR result for Legionella. They 
reported a sensitivity and a specificity of the SD Bioline test of 81.8% (9/11) and 
100% (0/88), respectively.
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In this evaluation the majority of LD-positive patients were probably infected with 
L. pneumophila serogroup 1, making it difficult to draw any conclusions about the 
assay’s ability to detect L. pneumophila infections caused by other serogroups or 
Legionella species. Another drawback of the current evaluation is that we evaluated 
a relatively small group of patients; this could influence both the sensitivities and the 
specificities of these two new commercial kits. Despite these limitations, our study 
provides relevant data related to the clinical sensitivity and specificity levels of these 
two new commercial kits for the detection of L. pneumophila serogroup 1 antigen 
in urine.
In conclusion, the Binax NOW urinary antigen test is superior to the Rapid U test 
and the SD Bioline Legionella urinary antigen test for the diagnosis of infections 
caused by L. pneumophila serogroup 1. The performance of the SD Bioline test is 
below the acceptable level for any diagnostic assay.
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ABSTRACT
We evaluated a new immunochromatographic assay for the detection of Legionella 
pneumophila serogroup 1 antigen in urine. The results were compared with those 
obtained by the Binax NOW urinary antigen test. Sensitivity and specificity were 
respectively 91.5% and 95.6% for the Rapid U Legionella Plus Test and 91.5% 
and 100% for the Binax Now urinary antigen test. The sensitivity of the Rapid U 
Legionella Plus Test and Binax Now urinary antigen test increased to 93.0% and 
94.4%, respectively, if tests were reexamined after 45 min. The specificity of the 
Rapid U Legionella Plus Test decreased to 80.2% if tests were reexamined after 45 
min. Prolongation of the incubation time did not affect the specificity in the Binax 
Now urinary antigen test. Given the potential impact of misdiagnosis of LD, it would 
seem unwise to rely on this test for the diagnosis of LD.
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INTRODUCTION
Since antigen detection in urine has proved to be a sensitive and rapid method for 
detecting L. pneumophila serogroup 1, this technique has become one of the most 
frequently used tools for the diagnosis of Legionnaires’ disease (LD) [1]. Currently, 
there are several commercially available tests for the detection of L. pneumophila 
antigen in urine [2,3]. Commercial kits that use enzyme immunoassay (EIA) meth-
odologies have been available for several years and perform similarly. One immu-
nochromatographic (ICT) assay (Binax NOW Legionella Urinary Antigen Test) has 
similar sensitivity and specificity to EIA [2]. ICT assays have important advantages 
over conventional EIAs: the tests are simple to perform, do not require special labo-
ratory equipment, and results can be obtained within 15 minutes.
The aim of the study presented here was to evaluate a newly developed ICT urine 
antigen test (the Rapid U Legionella Plus Test, Diamondial, Sees, France), for its 
ability to detect L. pneumophila serogroup 1 in urine.
MATERIAL AND METHODS
We evaluated the ability of the new antigen test to diagnose LD in a well-described 
sample of patients with and without LD using frozen urine samples. Samples were 
collected between 1997 and 2005 and stored at –70°C until processing was per-
formed. We included 71 urine samples obtained from 71 patients with LD (cases). A 
case of LD was defined as a patient with pneumonia who had radiological signs of 
infiltration and laboratory evidence of infection with L. pneumophila. Laboratory 
evidence included one or more of the following criteria: isolation of L. pneumophila 
from a lower respiratory tract sample (LRT); a positive PCR result on a LRT sample 
using a 16S rRNA-based assay [4]; seroconversion to positive IgM and/or IgG an-
tibodies against L. pneumophila in paired acute-phase and convalescent-phase sera 
using a commercial ELISA (Serion ELISA; Institut Virion\Serion GmbH, Würzburg, 
Germany). All LD positive samples tested negative for pneumococcal antigen in urine 
(PAG; Binax NOW, Portland Maine).
Urine samples of 91 patients with respiratory tract infections caused by pathogens 
other than Legionella were tested in a similar manner to test specificity. All patients 
were tested for LD using a immunochromatographic assay (Binax NOW); all samples 
tested negative. The laboratory results for these patients tested with blood cultures 
(blood), PAG detection in urine (PAG) and sputum culture (sputum) were as fol-
lows: Streptococcus pneumoniae (n=52 patients: detected in sputum in 8 patients, 
in blood and PAG in 23, and in blood alone in 21), Haemophilus influenzae (n=10: 
blood, 3; sputum, 7), Moraxella catarralis (n=3: all sputum), Staphylococcus aureus 
(n=4: blood and sputum, 2; sputum, 2), Escherichia coli (n=2: blood and sputum, 1; 
sputum alone, 1), Acinetobacter baumannii (n=1: blood and sputum), Streptococcus 
pyogenes (n=2: both blood and sputum), Klebsiella pneumoniae (n=1: sputum), My-
cobacterium tuberculosis (n=3: all sputum), Pneumocystis jirovecii (n=1: Giemsa and 
56 Chapter 5
silver-stain positive). Twelve patients with a fourfold or greater rise in (complement-
fixating) antibodies against influenza A virus (n=3), adenovirus (n=1), Chlamydia 
psittaci (n=3), Mycoplasma pneumoniae (n=4) and parainfluenza virus (n=1) were 
included.
The presence of L. pneumophila antigen in urine samples was investigated using 
Rapid U Legionella Plus Test, a qualitative ICT assay. We compared the sensitivity 
and specificity of this test with that of a widely used ICT assay, the Binax Now 
urinary antigen test (Binax NOW). All tests were performed simultaneously and the 
results were calculated following the manufacturers’ instructions. However, to ensure 
maximum sensitivity for the urinary antigen test [5], all samples were reexamined 
after 60 min.
RESULTS
The results of testing are shown in table 1. Sensitivity and specificity were, respec-
tively, 91.5% (65/71; 95% CI 82%-96%) and 95.6% (4/91; 95% CI 89%-99%) for 
the Rapid U Legionella Plus Test and 91.5% (65/71; 95% CI 82%-96%) and 100% 
(0/91; 95% CI 95%-100%) for the Binax Now urinary antigen test. The sensitivity 
of the Rapid U Legionella Plus Test and Binax Now urinary antigen test increased 
to 93.0% (66/71; 95% CI 84%-97%) and 94.4% (67/71; 95% CI 86%-98%), re-
spectively, when tests were reexamined after 45 min. The specificity of the Rapid 
U Legionella Plus Test decreased to 80.2% (18/91; 95% CI 70%-87%) when tests 
were reexamined after 45 min. Prolongation of the incubation time did not affect the 
specificity of the Binax Now urinary antigen test.
Table 1: Results of ICT tests after 15 min and 1 hour of incubation. LD: Legionnaires’ disease, RTI: 
respiratory tract infection.
No. of patients with a positive test result/total number of patients (%)
15 min 1 hour
LD (cases)
Rapid U Legionella PLUS 65/71 (91.5) 66/71 (93.0)
Binax NOW 65/71 (91.5) 67/70 (94.4)
RTI other than LD (controls)
Rapid U Legionella PLUS 4/91 (4.4) 18/91 (19.8)
Binax NOW 0/91 (0) 0/99 (0)
DISCUSSION
The characteristics of the first urinary antigen tests were published in the late 1970s 
[6] and numerous publications have followed since then. In the study we conducted, 
the specificity of the assays was determined using single urine specimens collected 
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from 91 patients with pneumonia or respiratory tract infections of known aetiology 
other than Legionella.
The specificity of the tests differed; four patients with proven pneumococcal pneu-
monia tested postive in the Rapid U Legionella Plus Test; (2 patients positive by 
bloodculture and PAG; 2 patients positive by bloodculture) when tests were read 
after 15 minutes of incubation. Our data suggest that in a population with a 4% 
prevalence of LD, (e.g. hospitalized patients with community-acquired pneumonia), 
even assuming 100% sensitivity for the Rapid U Legionella Plus Test, the predictive 
value of a positive result would only be about 50%. The specificity of the Rapid U 
Legionella Plus Test decreased to 80.2% (95% CI 70%-87%) if tests were reexam-
ined after 45 minutes, underlining the importance of not reading the test after the 
recommended 15 minutes.
Based on prospective and retrospective studies, moderate to high urinary antigen 
test sensitivities have been described [2,3,7,8]. This may be explained by differences 
in test and patient characteristics, the serogroup with which the patient was infected, 
the timing of collection during the course of illness, and whether or not the urine was 
concentrated before testing. A major disadvantage of these tests is their inability to 
reliably detect organisms other than L. pneumophila serogroup 1, so development 
of a genus-wide urinary antigen would provide a distinct diagnostic advantage. The 
Legionella Urine Antigen EIA (Biotest) is intended to detect legionellae other than L. 
pneumophila serogroup 1, but it does so less reliably than it detects L. pneumophila 
serogroup 1 [8]. In our evaluation, the majority of LD positive patients were prob-
ably infected with L. pneumophila serogroup 1, which makes it difficult to draw 
any conclusions about L. pneumophila infections caused by other serogroups or 
Legionella species. Another drawback is that we evaluated a relatively small group 
of patients and we not concentrate our urine samples; this could influence both sen-
sitivity and specificity. Despite these limitations, our study provides relevant data 
related to the clinical sensitivity and specificity levels of a new commercial kit for the 
detection of L. pneumophila serogroup 1 antigen in urine.
In conclusion, both the Rapid U Legionella Plus Test and the Binax NOW test 
showed the same high degree of sensitivity (91.5%) when used with using non-
concentrated urine samples. False-positive test results occured with the Rapid U 
Legionella Plus Test, resulting in a positive predictive value of about 50%. Given the 
potential repercussions of misdiagnosis of LD, it would seem unwise to rely on this 
test for the diagnosis of LD.
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ABSTRACT
This study evaluated a new immunochromatographic assay (SAS Legionella Test) 
for its ability to detect Legionella pneumophila serogroup 1 antigen in urine. Results 
were compared with those obtained using the Binax Now urinary antigen test. Sen-
sitivity and specificity were estimated as 82.9% and 99.0%, respectively, for the SAS 
Legionella Test, and 91.4% and 100%, respectively, for the Binax Now urinary an-
tigen test. The sensitivity of both increased to 97.1% (P=0.009) and 94.2% (P=0.7), 
respectively, if tests were examined after 1 hour.
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INTRODUCTION
Legionnaires’ disease (LD) is a pneumonia caused by Legionella spp., which are 
ubiquitous Gram-negative bacilli found in (man-made) aquatic reservoirs. Legion-
ella spp. are responsible for 1 to 5% of cases of community-acquired pneumonia 
(CAP) requiring hospital admission [1,2]. Antigen detection in urine has proved to 
be a sensitive and rapid method for detecting L. pneumophila serogroup 1, and this 
technique is used widely for the diagnosis of LD [3]. To date, several commercially 
available tests have been evaluated for the detection of L. pneumophila antigen in 
urine [4,5,6].
The aim of the present study was to evaluate a newly developed immunochromato-
graphic urine antigen test (ICT) for the detection of L. pneumophila serogroup 1 in 
urine.
MATERIAL AND METHODS
The new antigen test was evaluated with frozen urine samples from a well-described 
sample of patients with and without LD. Samples were collected between 1997 and 
2005, and were stored at –70°C until processing was performed. The study investi-
gated 70 urine samples from 70 patients with LD (cases), defined as a patient with 
pneumonia and radiological signs of infiltration, who showed laboratory evidence 
of infection with L. pneumophila. Laboratory evidence included one or more of the 
following criteria: isolation of L. pneumophila from a lower respiratory tract sample 
(LRT sample); a positive PCR result on a LRT sample using a 16S rRNA based assay 
[7]; and seroconversion to positive IgM and/or IgG antibodies to L. pneumophila 
using a commercial ELISA (Serion ELISA; Institut Virion\Serion GmbH, Würzburg, 
Germany) with paired acute-phase and convalescent-phase sera. All LD positive sam-
ples tested negative for pneumococcal antigen in urine (PAG; Binax NOW, Portland, 
ME, USA). The laboratory results of these patients were (n(%) positive): serology 
53/57 (93%), isolation 7/17 (41%), PCR 37/37 (100%).
Urine samples from 99 patients with respiratory tract infections other than Legio-
nella were tested in a similar manner to determine specificity. These patients were 
diagnosed with infections caused by Streptococcus pneumoniae (n=60), Haemophi-
lus influenzae (n=10), Moraxella catarralis (n=3), Staphylococcus aureus (n=4), Es-
cherichia coli (n=2), Acinetobacter baumannii (n=1), Streptococcus pyogenes (n=2), 
Klebsiella pneumoniae (n=1), Mycobacterium tuberculosis (n=3), Pneumocystis 
jirovecii (n=1), influenza A virus (n=3), adenovirus (n=1), Chlamydia psittaci (n=3), 
Mycoplasma pneumoniae (n=4) and parainfluenza virus (n=1).
The presence of L. pneumophila antigen in urine samples was investigated using 
the SAS Legionella Test (SA Scientific, San Antonio, TX, USA), which is a qualitative 
ICT test. The sensitivity and specificity of the test were compared with the results 
obtained with a widely used ICT assay, the Binax Now urinary antigen test (Binax). 
All tests were performed simultaneously and the results were interpreted according 
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to the manufacturers’ instructions. However, to ensure maximum sensitivity for the 
urinary antigen tests [8], all samples were reexamined after 60 min. Fisher’s exact 
test was used to compare categorical data, with p<0.05 considered to be statistically 
significant
RESULTS
The results obtained are shown in table 1. Sensitivity and specificity were 82.9% 
(58/70) and 99.0% (1/99), respectively, after incubation of 10 min with the SAS Le-
gionella Test, and 91.4% (64/70) and 100% (0/99), respectively, after incubation for 
15 min with Binax Now urinary antigen test. The sensitivities of the SAS Legionella 
Test and Binax Now urinary antigen test increased to 97.1% (68/70) (P=0.009) and 
94.2% (66/70) (P=0.7), respectively, if the tests were reexamined after 50 and 45 
min, respectively. Prolongation of the incubation time did not affect the specificity 
of either test.
Table 1. Results of ICT tests after 10 min (SAS Legionella Test) or 15 min (Binax NOW) and 1 hour of 
incubation. LD: Legionnaires’ disease, RTI: respiratory tract infection.
No. of patients with a positive test result/total number of patients (%)
10-15 min 1 hour
LD (cases)
SAS Legionella Test 58/70 (82.9) 68/70 (97.1)
Binax NOW 64/70 (91.4) 66/70 (94.2)
RTI other than LD (controls)
SAS Legionella Test 1/99 (1.0) 1/99 (1.0)
Binax NOW 0/99 (0) 0/99 (0)
DISCUSSION
The characteristics of the first urinary antigen tests for L. pneumophila were reported 
during the late 1970s [9] and numerous reports since then have described various 
different techniques, which together provide evidence confirming the value of urinary 
antigen detection for the diagnosis of infections caused by L. pneumophila serogroup 
1. The capture antibody used in the majority of these assays is considered to be 
specific for L. pneumophila serogroup 1, and false-positive urinary antigen assay 
results are reported rarely [10]. The specificity of the assays in the current evalua-
tion was determined using single urine specimens collected from 99 patients with 
pneumonia or respiratory tract infections of known aetiology (but not Legionella). 
One control-patient with proven pneumococcal pneumonia (S. pneumoniae isolated 
from bloodculture and pneumococcal antigen positive) tested postive by the SAS 
Legionella Test.
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Based on prospective and retrospective studies using data from isolated cases, 
moderate-to-high urinary antigen test sensitivities have been described [4,6,11-15]. 
These variations may be explained by differences in test and patient characteristics, 
the serogroup infecting the patient, the timing of collection during the course of the 
illness, and whether the urine was concentrated before testing. A major disadvantage 
with these tests is their inability to reliably detect organisms other than L. pneumo-
phila serogroup 1, and development of a genus-wide urinary antigen would provide 
a distinct diagnostic advantage. The Biotest Legionella Urine Antigen EIA (Biotest, 
Dreieich, Germany) is intended to detect legionellae other than L. pneumophila 
serogroup 1, but it does so less reliably than it detects L. pneumophila serogroup 
1 [15]. In the present evaluation most LD positive patients were probably infected 
with L. pneumophila serogroup 1, making it difficult to reach conclusions concern-
ing infections caused by other serogroups or Legionella species. Another limitation 
was a relatively small group of patients that was evaluated, as this could influence 
both sensitivity and specificity. Despite these limitations, the study provided data 
showing that the SAS Legionella Test has a high degree of sensitivity and specific-
ity, with a sensitivity that increased significantly after a prolonged incubation time. 
Because prolongation of incubation does not affect the specificity, it is recommended 
that an incubation time longer than that recommended by the manufacturer is used 
routinely.
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INTRODUCTION
Streptococcus (S.) pneumoniae is the leading cause of community-acquired pneumonia 
(CAP) worldwide and a major cause of morbidity and mortality [1]. S. pneumoniae 
is probably also the leading cause of pneumonia of unknown etiology. The role of 
microbiological tests is in the detection of an etiologic agent causing infection so that 
directed therapy is permitted. However, the diagnosis of pneumococcal infections 
is relying heavily on culture of S. pneumoniae from blood or other normally sterile 
fluids and is limited by prior administration of antibiotics [2]. For these reasons, 
causative pathogens may remain unidentified in up to 50% of patients and broad 
spectrum antibiotic therapy may be continued unnecessarily for prolonged periods 
of time. The recent study by Genne et al. has shown that detection of urinary pneu-
mococcal antigen by using the Binax NOW S. pneumoniae antigen test (ICT test) is 
a useful technique for the rapid diagnosis of pneumococcal infections in adults [3]. 
We performed a retrospective study to compare the performance of the ICT test by 
use of selected non-concentrated urine samples from adult CAP patients. Approval to 
conduct the study was obtained from the St Elisabeth Hosptial Ethics Committee.
MATERIALS AND METHODS
The CAP patients were included in the study only if a urine sample was obtained 
within 48 h after hospital admission. The cases were adult patients (>16 years) from 
whom blood cultures S. pneumoniae were grown (n = 52), or patients from whom 
pneumococcal pneumonia was confirmed with positive sputum culture results (n = 
6). Controls (n = 136) were selected from adult patients presenting lower respiratory 
tract infection. A large proportion of urine samples were obtained from patients 
with proven legionnaires’ disease (n = 98) according to criteria used by the European 
Working Group on Legionella Infections (EWGLI; www.ewgli.org). The laboratory 
results of the remaining control patients were as follows: Haemophilus influenzae (n 
= 10), Moraxella catarrhalis (n = 3), Staphylococcus aureus (n = 4), Escherichia coli 
(n = 2), Acinetobacter baumannii (n = 1), Streptococcus pyogenes (n = 2), Klebsiella 
pneumoniae (n = 1), Mycobacterium tuberculosis (n = 3), Pneumocystis jirovecii (n = 
1). 12 patients were included who had a fourfold rise or more in complement-fixating 
antibodies against influenza A virus (n = 2), adenovirus (n = 1), Chlamydia psittaci (n 
= 3), Mycoplasma pneumoniae (n = 4) and parainfluenza virus (n =1).
RESULTS AND DISCUSSION
Fifty-eight cases were included (median age 55 years; range 16-85 years) and 136 
controls (median age 56 years; range 16-84 years). Pneumococcal urinary antigen 
was positive (after 15 minutes reading), in 40 of 58 pneumococcal cases and in 3 
of 136 controls, giving a test sensitivity of 69% (95% CI, 58 to 78%) and a test 
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specificity of 98% (95% CI, 93 to 99%) overall. The frequency of antigen detection 
was greater for bacteremic pneumococcal pneumonia (38 of 52 [73%]) than for 
non-bacteremic pneumococcal pneumonia (2 of 6 [33%]) (P = 0.07).
Of the three false-positive results in our study, two occurred with patients who 
might be considered at high risk for pneumococcal infection. One patient was a 
78-year old female admitted to the hospital with renal impairment, malaise, fever 
and shortness of breath. Chest radiography showed extensive bilateral consolidation 
of the lung. Bloodcultures remained negative, and in a sputum sample Haemophilus 
influenzae was cultured. She died a week after admission to the hospital. The sec-
ond patient was a 31-year old HIV-positive female admitted with a respiratory tract 
infection and a consolidation on a chest radiograph. Blood and sputum cultures 
were obtained but remained negative. Her condition improved after initiation of 
amoxicillin therapy (1000 mg iv per 6 hours) and she later showed a fourfold rise 
in complement-fixating antibodies against influenza A virus. The third patient was 
a 42-year old female admitted with an acute exacerbation of chronic pulmonary 
disease and bloodcultures yielding Haemophilus influenzae. None of these patients 
had nasopharyngeal swabs taken to detect pneumococcal carriage. It is possible that 
these patients had co-infection with S. pneumoniae.
Although selection bias may possibly have affected our sensitivity and specific-
ity results, our findings indicate that the sensitivity of the test is about 75% when 
positive blood cultures are used as the ‘gold standard’. These findings are similar to 
those of other investigators who have used the NOW S. pneumoniae urinary antigen 
test. Murdoch et al. studied 420 adults with CAP, including 20 patients with pneu-
mococcal bacteremia, 16 (80%) of whom had detectable urinary antigen levels [4]. 
In determining the test specificity, Murdoch et al. used 169 adult control patients 
with an admission diagnosis other than a respiratory or infectious disease and found 
that none had detectable pneumococcal antigen (specificity 100%). Dominguez et 
al. detected pneumococcal antigen in urine specimens of 82% of 28 patients with 
bacteremic pneumococcal pneumonia [5]. The study by Dominguez et al. also used 
control patients with pneumonia or bacteremia due to other organisms and reported 
a test specificity of 97% (2/71 tests positive). In the study by Genne et al., 67 adults 
with CAP were compared with 81 patients with suspected urinary tract infection to 
determine sensitivity and specificity of the ICT test [3]. An etiology could be found for 
22 patients (33%) using conventional methods and increased to 33 patients (49%) 
with the addition of the urinary antigen test. Nine out of 14 patients diagnosed with 
S. pneumoniae as etiologic agent for their CAP had detectable urinary antigen levels 
(sensitivity 64%; 1/81 positive control urine samples, specificity 99%). Pneumococ-
cal infection was diagnosed by ICT in 24% without an etiologic identification by 
conventional methods.
ICT appears to be a promising supplement to blood and sputum culturing for 
the etiology in adult CAP. Given its high specificity, this test can be considered an 
important tool for detecting S. pneumoniae in CAP, enabling the diagnosis of pneu-
mococcal pneumonia in as much as a quarter of cases. As such, these assays can have 
important implications for the choice of first-line antibiotic therapy in patients with 
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CAP. Although antibiotic treatment active against atypical pathogens is routinely 
recommended in CAP guidelines, such treatment was not superior to beta-lactam 
monotherapy, unless Legionella species was the cause of infection, in 2 recent meta-
analyses of treatment of CAP [6,7]. Recently, Guchev et al. [8] demonstrated that 
amoxicillin treatment could successfully be targeted by use of the ICT test in non-
severe CAP. Strålin and Holmberg [9] showed that patients with positive ICT test 
results had a significant higher success rate using beta-lactam monotherapy than 
did patients with negative results (success rate ICT positive patients: 92% (35/38), 
success rate ICT negative patients: 76% (87/114); p =0.034). Therefore, a positive 
ICT test result can support treatment with narrow-spectrum beta-lactam antibiot-
ics and can be used to prevent unnecessary broad antibiotic changes. In patients 
with severe CAP and a negative ICT result, diagnostic tests for conventional and 
atypical pathogens, including a urinary antigen test for the detection of Legionella 
pneumophila serogroup 1, are useful to gain support for the ongoing treatment or 
suggestions treatment alterations.
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ABSTRACT
Legionella pneumonia can be difficult to diagnose. Existing laboratory tests all have 
shortcomings, especially the ability to diagnose all Legionella spp. at an early stage. 
Detection of Legionella DNA in serum can be a valuable tool for the diagnosis of 
Legionnaires’ disease (LD). This report describes two patients with LD diagnosed by 
PCR using serum samples. In addition, quantification of L. pneumophila DNA using 
real-time PCR during the course of illness was carried out. The results obtained mir-
rored both the clinical condition and the C-reactive protein values during the course 
of illness. Quantification of Legionella DNA in serum using real-time PCR could be a 
valuable tool to monitor the effects of antimicrobial therapy in patients with LD.
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INTRODUCTION
Legionnaires’ disease (LD) is an acute pneumonia caused by Legionella spp. These 
Gram-negative bacilli are ubiquitous in both man-made and natural aquatic reser-
voirs. Although currently more than 48 Legionella species have been described, more 
than 90% of culture-confirmed clinical cases are caused by Legionella (L.) pneumo-
phila [1]. Legionella spp. are responsible for 1 to 5% of cases of community-acquired 
pneumonia (CAP) [2]. Clinically and radiographically, LD cannot be distinguished 
from pneumonia caused by other microbial pathogens. Because of the high mortality 
rate in patients with LD requiring hospitalization, early diagnosis to enable adequate 
antimicrobial treatment is potentially life-saving [3]. Diagnosis of LD can be quite 
difficult, and is based on phenotypic (culture, serologic testing and antigen detection 
in urine) and genotypic methods (PCR). Isolation of Legionella from respiratory 
secretions is considered the gold standard in case definition, but is not very sensitive 
(10 to 80% sensitivity), and a positive result is not available until at least 3 days of 
incubation. Another major limitation of sputum culture is that <50% of patients 
with LD produce sputum [4]. Serological testing has a high sensitivity and a high 
specificity, but it is of limited clinical value, as it may take up to 9 weeks for patients 
to develop detectable antibodies. For the detection of L. pneumophila serogroup 
1, urinary antigen tests have sensitivities in the range of 70%-100% and specifici-
ties approaching 100%, but these assays only detect L. pneumophila serogroup 1 
reliably [4,5]. Genotypic methods utilise PCR to detect the presence of Legionella-
specific DNA in respiratory secretions, urine and serum, and show varying degrees 
of sensitivity and specificity [4]. Diagnostic PCR assays have principally targeted 
specific regions within 16S [6,7] and 5S [8] rRNA genes and the macrophage inhibi-
tor potentiator (mip) gene [9,10]. PCR techniques have the potential to provide a 
rapid diagnosis of LD with use of readily obtainable specimens such as serum or 
urine [8,11,12].
In this report, we describe two patients with LD diagnosed using Legionella-specific 
real-time PCR on serum samples. In addition, a serial quantification of Legionella 
pneumophila DNA during the course of the illness was carried out. To our knowl-
edge, this is the first time that the sequel of quantifying Legionella pneumophila 
DNA during LD has been described.
CASE 1
In September 2005, a 67-year-old white male was admitted to the pulmonology de-
partment of the Amphia Hospital, Breda, The Netherlands, with a history of malaise, 
cough, fever and shortness of breath. He was a smoker with an mean consumption 
of 20 cigarettes per day. He did not take any medication and had not traveled re-
cently. Vital signs on arrival included blood pressure of 155/85 mmHg, heart rate 
117 beats/min, respiratory rate 30/min and temperature 40.7°C. Examination of the 
chest revealed decreased breath sounds and crackles in the right lung base, and a 
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chest radiograph showed extensive consolidation of the right lung. A complete blood 
count revealed a white blood cell count of 12,300 cells µl-1 and a C-reactive protein 
value (CRP) of 535 mg l-1. Antibiotic therapy with oral amoxicillin-clavulanic acid 
(625 mg every 8 hours), started by his general practitioner, was changed to intrave-
nous amoxicillin-clavulanic acid (1000/200 mg q.i.d.) plus erythromycin (1000 mg 
q.i.d.). Bacterial cultures for bacteria and fungi (sputum, blood) remained negative. 
Two days after admission his condition deteriorated and he was transferred to the 
intensive care unit (ICU) where he underwent intubation because of hypoxia and 
respiratory distress.
One day after admission at the ICU (day 2), a sputum and serum sample was tested 
for Legionella in real-time PCR. The serum (200 µl) was processed with MagNA 
Pure Total Nucleic Acid Kit (Roche Diagnostics). For the detection of Legionella in 
serum samples, an assay was used targeted at specific regions within the 5S rRNA 
gene [8], and detected in real-time using a TaqMan probe, Leg5S (6-carboxyflu-
orescein (FAM)-5’-CCGCGCCAATGATAGTGTGAGGC-3’-6-carboxytetrameth-
ylrhodamine (TAMRA)]. Real–time PCR was performed on a Abiprism®7900HT 
Sequence Detection System (Applied Biosystems). DNA was amplified according to 
the following parameters: after 2 min incubation at 50°C and 10 min denaturation 
at 95°C, amplification consisted of 50 cycles of 15 sec of denaturation at 95°C fol-
lowed by 1 min of annealing and extension at 60°C. Random serum samples from 
two healthy volunteers were included as negative controls after every four samples. 
In each run, a no-template control negative control was added. Sensitivity controls 
consisted of 10-fold dilutions of L. pneumophila DNA ranging from 1000 fg to 10 
fg. As internal control Phocid herpes virus 1 was added to the samples to monitor 
processing as well as PCR inhibition [13].
Both samples (sputum and serum) tested positive for Legionella. In addition, an 
immunochromatographic membrane test (Binax now; Binax) to detect L. pneumo-
phila serogroup 1 soluble antigens in urine was positive. Culture was carried out 
as follows; samples were plated on a buffered charcoal yeast extract agar (BCYE, 
Oxoid, Haarlem) and on a BCYE agar with cefamandole, polymyxin and anisomycin 
(BMPA, Oxoid, Haarlem, The Netherlands). Legionella-specific media were incu-
bated for 10 days at 35°C in a humidified atmosphere. Colonies that grew on BCYE 
agar but failed to grow on blood agar were expected to be Legionella spp. Further 
identification was carried out by determination of the L. pneumophila serogroups 
using a slide agglutination test (Dryspot Legionella Latex Test, Oxoid, Haarlem, 
The Netherlands). A lower respiratory tract sample (bronchoalveolar lavage) grew 
L. pneumophila serogroup 1. We collected consecutive serum samples to quantify 
Legionella pneumophila using Legionella-specific PCR. The threshold cycle value 
(Ct) is inversely proportional to the log of the amount of target DNA initially present 
and was calculated by using SDS software version 2.0 (Applied Biosystems). The 
results of Legionella-specific real-time PCR during the course of illness are outlined 
in Fig. 1. Antibiotic therapy was changed into ciprofloxacin (400 mg b.i.d.) plus 
erythromycin (1000 mg q.i.d.) on day 3 after admission to the ICU. His clinical con-
dition, however, did not improve significantly in the first days after ICU admission. 
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Despite appropriate treatment, he remained critically ill with unstable systemic blood 
pressure, and development of renal failure. Ct values mirrored the clinical condition 
and CRP-values during the course of illness; the first 4 days Ct values were stable at 
~29 in Legionella real-time PCR. On the 5th day after admission to the ICU depart-
ment, the patient’s condition stabilized, but on day six he deteriorated again and 
became hemodynamic unstable, despite inotropic drug support with serum urea and 
creatinine 23.6 mmol l-1 (ref 2.9-7.5) and 539 µmol l-1 (ref 55-95), respectively. This 
severe deterioration coincides with a decrease in Ct (an increase in bacterial load) on 
day 6. In addition to the hemodynamic support, rifampicin (600 mg b.i.d.) and acti-
vated protein C (Xigris) were added. The patient showed a remarkable improvement 
the following days and arterial oxygenation improved with radiographic resolution 
of infiltrates. Ct values increased the following days and all samples tested after day 
8 were negative in Legionella-specific real-time PCR. Two weeks after admission to 
the ICU he was transferred to the medium care department.
CASE 2
A 42-year-old white male was admitted to the pulmunology department of the St. 
Elisabeth Hospital, Tilburg, The Netherlands, with a history of cough, shortness of 
breath and mental confusion in October 2005. He smoked 25 cigarettes per day. Vital 
signs on arrival included blood pressure of 140/80 mmHg and temperature 37.6°C. 
Examination of the chest revealed crackles in the left lung base, and a chest radio-
graph showed consolidation of the left lung base. A complete blood count showed a 
white blood cell count of 6,800 cells µl-1 and a CRP of 315 mg l-1. Antibiotic therapy 
with oral ofloxacin (400 mg b.i.d.) was started. A serum sample taken on the first 
day after admission tested positive in real-time PCR for Legionella with a Ct of 
30. An immunochromatographic membrane test (Binax now; Binax, USA) to detect 
L. pneumophila serogroup 1 soluble antigens in urine was positive. Pleural fluid 
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Fig. 1. Results of C-reactive protein (a) measurements and real-time Legionella PCR (b) of serum from 
patient 1. The threshold cycle value (Ct) is inversely proportional to the log of the amount of target DNA 
initially present and was calculated by using SDS software version 2.0 (Applied Biosystems).
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obtained on day three after admission was cultured on Legionella-specific media and 
grew L. pneumophila serogroup 1. The patient responded after initiating therapy 
with ofloxacin; his condition gradually improved and CRP values dropped from 227 
mg l-1 on day 2 to 70 on day 8. The results of Legionella-specific real-time PCR 
showed an almost linear increase in Ct values (indicating a logarithmic decrease of 
bacterial DNA) in the course of time (Fig. 2) and mirrored the clinical condition and 
CRP values during the acute stage of infection. The patient was discharged home 14 
days after admission.
DISCUSSION
The main disadvantage with testing sputum samples is that <50% of patients with 
LD produce sputum. This has prompted investigation of the role of PCR for testing 
other sample types. The first report on the detection of Legionella DNA in serum 
was by Lindsay et al. using a conventional mip gene-based PCR assay using southern 
blotting with a Legionella-specific probe [10]. All patients with confirmed LD (5 
in total) tested positive in the acute and convalescent sera. This study included one 
convalescent serum sample that was positive for Legionella DNA 37 days after the 
onset of the patient’s symptoms. Murdoch et al. tested urine and serum samples 
from 28 patients with LD and 24 patients with pneumonia due to organisms other 
than Legionella spp. [12]. The majority of patients in this study were infected with 
organisms other than L. pneumophila serogroup 1. Legionella DNA was detected in 
serum samples in 12 of 28 patients (43%) with LD using a conventional 5S rRNA 
gene-based PCR assay. If used at the time of specimen collection, PCR would have 
detected an additional 11 cases in the acute phase of disease. Legionella DNA was 
not detected in samples from the control patients. In another report, Murdoch et 
al. used a guinea pig model and detected Legionella DNA in 55% of leukocyte 
samples and 28% of urine samples [14]. The sensitivity of the PCR was highest for 
samples collected within three days of inoculation. Matsiota-Bernard et al. detected 
L. pneumophila DNA in 12 serum samples from 41 patients with LD (29%) and 
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Fig. 2. Results of C-reactive protein (a) measurements and real-time Legionella PCR (b) of serum from 
patient 2. The threshold cycle value (Ct) is inversely proportional to the log of the amount of target DNA 
initially present and was calculated by using SDS software version 2.0 (Applied Biosystems).
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no Legionella DNA in 10 patients with pneumonia due to organisms other than 
Legionella [11]. In a recent report, a Legionella-specific 5S rRNA PCR on patient 
serum was positive in 80.5% of cases (54/67 patients), with a peak positivity at 6-10 
days after disease onset [8]. This peak corresponded with the urinary antigen peak, 
suggesting that circulating DNA coincides with the urinary antigen filtered from the 
blood by the kidneys. Unlike urinary antigen, the number of PCR positives decreased 
very slowly, perhaps as a result of the slow release of DNA from Legionella spp. 
surviving in macrophages. Murdoch and Chambers described the use of PCR in a 
patient with CAP caused by L. dumoffii in New Zealand [15]. Legionella DNA was 
detected in serial peripheral leukocytes, serum and urine samples when first collected. 
Buffy coat and urine samples remained positive up to 56 days after the onset of 
symptoms, whereas serum samples were positive from 10 up to 16 days after the 
onset of symptoms.
In New Zealand and Australia, there have been multiple cases of community-
acquired L. longbeachae CAP associated with exposure to soil and L. longbeachae is 
now recognised as the second most common cause of legionellosis [16,17]. Although 
CAP due to Legionella non-pneumophila species is rare in other parts of world, when 
specifically sought, unsuspected community-acquired infections may be uncovered. 
Recently, we described a patient who developed a CAP due to L. longbeachae diag-
nosed with PCR analysis of sputum and serum [18]. We concluded that, since most 
laboratory tests for Legionella cannot detect infections caused by non-pneumophila 
Legionella spp., culture on Legionella-selective media or PCR should be considered 
when diagnosing severe pneumonia in patients with an unknown etiology.
The decision to order diagnostic tests for Legionella infection is usually limited to 
at-risk patients or patients with severe pneumonia, and should consist of a urinary 
antigen test combined, if avaliable, with Legionella PCR on sputum and serum. This 
is, in our view, the best initial testing strategy that will detect all Legionella species 
and provide results within a time frame that will affect clinical management. Here, 
we describe two patients with LD diagnosed using Legionella-specific real-time PCR 
on serum samples. The association between disease progression and viral load is 
well established for infections with a number of viruses, particularly human im-
munodeficiency virus, hepatitis B virus and hepatitis C virus [19]. This is the first 
study in which real-time PCR has been used to monitor Legionella pneumophila 
DNA longitudinally in patients with LD. Detection of Legionella DNA in serum 
might reflect changes in bacterial load over time and may allow the assessment of the 
response of the patient to treatment. Further investigation of PCR-based diagnosis 
using serum samples is needed to establish its role in diagnosis and monitoring pa-
tients with LD.
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ABSTRACT
Legionella pneumonia can be difficult to diagnose. Existing laboratory tests all have 
shortcomings, especially in the ability to diagnose Legionnaires’ disease (LD) at an 
early stage of the disease in a specimen that is readily obtainable. The aim of this 
study was to assess the performance of PCR as a rapid diagnostic method and to 
compare the results of different PCR assays of serum samples from patients with LD. 
Samples included 151 serum samples from 68 patients with proven LD and 60 serum 
samples from 36 patients with respiratory tract infections other than Legionella. 
PCR assays were based on the 5S rRNA gene, 16S rRNA gene and the mip gene. The 
samples from patients with infections caused by pathogens other than Legionella all 
tested negative in PCR. Among the patients with proven LD 54.4% (37/68) tested 
positive in 5S rRNA PCR, 52.9% (36/68) in mip gene PCR and 30.9% (21/68) in 
16S rRNA PCR in the first available serum sample. The association between Ct 
value in 5S PCR positive serum samples (n=49) and C-reactive protein value was 
determined, and showed a strong negative correlation (r = -0.63, Pearson correlation 
coefficient, p <.0001). In addition to existing tests for the diagnosis of LD, detection 
of Legionella DNA in serum could be a useful tool for early diagnosis of LD caused 
by any Legionella species and serogroup, and has the potential to provide a diagnosis 
in a time frame that could affect initial infection management.
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INTRODUCTION
Legionnaires’ disease (LD) is an acute pneumonia caused by Legionella spp., which 
are Gram-negative bacteria ubiquitous in both man-made and natural aquatic res-
ervoirs. Legionella spp. are responsible for 1 to 5% of cases of community-acquired 
pneumonia (CAP) [1,2]. Although currently 48 Legionella species have been de-
scribed, more than 90% of culture-confirmed clinical cases are caused by Legionella 
(L.) pneumophila [3]. Legionella pneumonia can be difficult to diagnose because the 
signs and symptoms are nonspecific and do not distinguish Legionella infection from 
other common causes of pneumonia [4]. A definite diagnosis is important because 
it enables adequate antimicrobial treatment; delay in starting appropriate therapy 
has been associated with increased mortality [5]. Currently, the diagnosis of LD in 
patients with pneumonia is based on phenotypic (culture, serologic testing, antigen 
detection in urine) and genotypic methods (PCR) using respiratory specimens. Isola-
tion of Legionella from respiratory secretions is considered the gold standard in case 
definition, but is not very sensitive (10 to 80% sensitivity) and a positive culture is 
not normally available until 3 days post incubation [4,6]. Another major limita-
tion of culture is that fewer than one-half of patients with LD produce sputum [6]. 
Serological testing for Legionella infection is a valuable epidemiological tool but has 
little impact on clinical decision making because of the time delay before a result is 
available [4]. For the detection of L. pneumophila serogroup 1, urinary antigen tests 
have sensitivities in the range of 56%-99% and specificities approaching 100%. A 
major disadvantage with these tests is their inability to reliably detect organisms 
other than L. pneumophila serogroup 1 [4,7].
PCR-based methods can detect Legionella-specific DNA in respiratory secretions, 
with varying degrees of sensitivity and specificity [6, 8-10]. Application of PCR to 
nonrespiratory samples is particularly attractive, because this could circumvent the 
problem of patients who do not produce sputum samples [11,12]. In a recent report, 
a Legionella specific 5S rRNA PCR on patient serum was positive in 80.5% of cases 
(54/67 patients), with a peak positivity at 6-10 days after disease onset [13]. Unlike 
urinary antigen, the number of PCR positives decreased very slowly, perhaps as a 
result of the slow release of DNA from Legionella surviving in macrophages.
The aim of this study was to assess the performance of PCR as a rapid diagnostic 
method and to compare the results of different PCR assays in serum samples from 
patients with LD.
METHODS
Patients
Samples were collected between June 1999 and May 2005 at the following hospitals 
in The Netherlands: St. Elisabeth Hospital and TweeSteden Hospital, Tilburg; Pas-
teur Hospital, Oosterhout; TweeSteden Hospital, Waalwijk; Lievensberg Hospital, 
86 Chapter 9.1
Bergen op Zoom; Franciscus Hospital, Roosendaal, and Amphia Hospital, Breda. 
The samples were stored at -70°C until they were tested. A proven case of LD was 
defined as a patient with pneumonia, who showed radiological signs of infiltration, 
and who showed laboratory evidence of infection with L. pneumophila. Laboratory 
evidence included: (i) a single high value of IgM and/or IgG antibodies or seroconver-
sion for L. pneumophila serogroup 1 to 7 in paired acute-phase and convalescent-
phase sera using a commercial enzyme-linked immunosorbent assay (Serion ELISA; 
Institut Virion\Serion GmbH, Würzburg, Germany [14]), (ii) plus one or more of 
the following criteria: isolation of L. pneumophila from a respiratory tract sample; 
a positive urinary antigen test (Binax now; Binax, USA); a positive PCR result for L. 
pneumophila on a respiratory tract sample using a 16S rRNA assay [15].
In addition, 60 serum samples from 36 patients with respiratory tract infections 
other than Legionella were tested in a similar manner to serve as controls. All control 
patients tested negative for Legionella antigen in urine (Binax now; Binax, USA) 
and L. pneumophila serology (Serion ELISA). Controls consisted of 5 patients with 
CAP and positive bloodcultures with Streptococcus pneumoniae (5 samples) and 31 
patients with respiratory tract infections and a fourfold rise in (complement-fixating) 
antibody titer against influenza A virus, adenovirus, Chlamydia psittaci or Myco-
plasma pneumoniae (55 samples).
Bacterial strains
Validation of PCR assays was carried out using a panel of human-pathogenic and en-
vironmental Legionella spp. The following bacterial strains were used: Philadelphia-1 
(SG1) ATCC33152, Togus-1 (SG2) ATCC33154, Bloomington-2 (SG3) ATCC33155, 
L.A.-1 (SG4) ATCC33156, Dallas-1E (SG5) ATCC33216, Chicago-2 (SG6) 
ATCC33215, Chicago-8 (SG7) ATCC33823, Concord-3 (SG8) ATCC35096, IN-23 
(SG9) ATCC35289, Leiden-1 (SG10) ATCC43283, 797/PA/H (SG11) ATCC43130, 
570-CO-H (SG12) ATCC43290, 82A3105 (SG13) ATCC43736, 1169-MN-H (SG14) 
ATCC43703, L. anisa ATCC35292, L. birminghamensis ATCC43702, L. bozemanii-1 
ATCC33217, L. bozemanii-2 ATCC35545, L. brunensis, L. cherii ATCC35252, L. 
dumoffii ATCC35850, L. erythra ATCC35303, L. feeleii-1 ATCC35072, L. feeleii-2 
ATCC35849, L. gormanii ATCC33297, L. hackeliae-1 ATCC35250, L. israelensis 
ATCC43119, L. jamestowniensis ATCC35298, L. jordanis ATCC33623, L. long-
beachae-1 ATCC33462, L. longbeachae-2 ATCC33484, L. maceachernii ATCC35300, 
L. micdadei ATCC33218, L. moravica ATCC43877, L. oakridgensis ATCC33761, L. 
parisiensis ATCC35299, L. rubrilucens ATCC35304, L. sainthelensis ATCC35248, 
L. santicrusis ATCC35301, L. spiritensis ATCC35249, L. steigerwaltii ATCC35302, 
L. tucsonensis ATCC49180, L. wadsworthii ATCC33877. In addition, cultures of 
non-Legionella bacteria were analysed; Streptococcus pneumoniae ATCC49619, Bor-
detella pertussis Tohama strain, Bordetella parapertussis B24, Mycoplasma pneumo-
niae ATCC15293, Chlamydia pneumoniae ATCCVR1355, Acinetobacter baumannii, 
Pseudomonas aeruginosa ATCC27853 and Lactobacillus caseï. In addition, clinical 
specimens were tested from hospitalized patients with community-acquired respiratory 
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tract infections [16] and laboratory evidence for infection with Streptococcus pneu-
moniae (15), Haemophilus influenzae (10), Moraxella catarralis (4), Streptococcus 
pyogenes (1), Mycoplasma pneumoniae (10) and Chlamydophila pneumoniae (5).
PCR assays
For the detection of Legionella in serum samples three assays were used, targeted 
at specific regions within the 5S rRNA gene, the 16S rRNA gene, and the mip gene 
(table 1). The 5S PCR was based on the primers described by Lindsay et al. [13] and 
detected in real-time using a TaqMan probe Leg5S. Real–time PCR was performed on 
a Abiprism®7900HT Sequence Detection System (Applied Biosystems, Foster City, 
California, USA). DNA was amplified according to the following parameters: after 
2 min incubation at 50°C and 10 min denaturation at 95°C, amplification consisted 
of 50 cycles of 15 sec of denaturation at 95°C followed by 1 min of annealing and 
extension at 60°C.
Table 1: Primers and probes of PCR assays
Primers/probes sequence product size
5S rRNA PCRa 5S1 (forward 5’-ACTATAGCGATTTGGAACCA-3’)
5S2 (reverse 5’-GCGATGACCTACTTTCGCAT-3’) 104 bp
Leg5S (FAM-5’-CCGCGCCAATGATAGTGTGAGGC-3’-TAMRA)
mip PCR Mip-F1 (forward 5’-GCCAAGTGGTTTGCAATACAAA-3’)
Mip-R1 (reverse 5’-CTCGACAGTGACTGTATCCGATTT-3’)  80 bp
LPN-mip (FAM-5’-TAATCAATGCTGGAAATGGTGTTAAACCCG-3’-
TAMRA)
16S rRNA PCRb Leg-F1 (forward 5’-TACCTACCCTTGACATACAGTG-3’)
Leg-R1 (reverse 5’-CTTCCTCCGGTTTGTCAC-3’) 150 bp
LPN-1 (FAM-5’-AGTCCCCACCATCACAT-3’-MGB)
LSPP-1 (VIC-5’-CCGTAACGAGCGCAA-3’-MGB)
PhHV PCRc PhHV-F1 (forward 5’-GGCGAATCACAGATTGAATC-3’)
PhHV-R1 (reverse 5’-GCGGTTCCAAACGTACCAA-3’)  80 bp
PhHV-1 (VIC-5’-TTTTTTATGTGTCCGCCACCATCTGGATC-’3-
TAMRA)
bp, basepairs; MGB, minor groove binding protein (non-fluorescent)
a Primers according to Lindsay et al., 2004.
b According to van der Zee et al., 2002.
c According to Niesters, 2001.
DNA extraction
200 µl of sample was processed with MagNA Pure LC®, using the Total Nucleic 
Acid Kit (Roche Diagnostics) with an elution volume of 50 µl. 5 µl of the eluate was 
used as template in PCR.
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Controls
Serum samples from two healthy volunteers were included as negative controls and 
were processed after every 4 clinical samples. As internal control Phocid herpes virus 
(PhHV) was added to the samples to monitor processing as well as inhibition of 
PCR [17]. Detection of PhHV was included in the mip gene PCR. In each run a 
no-template control (mixcontrol) was included. Sensitivity controls in PCR consisted 
of 10-fold dilutions of L. pneumophila DNA ranging from 1000 fg to 10 fg (ap-
proximately 230 to 2,3 genome equivalents). Primers and probes were synthesized by 
Applied Biosystems (ABI, Nieuwerkerk a/d IJssel, The Netherlands).
Interpretation of results
Results obtained in real-time PCR were expressed as threshold cycle (Ct) values, cor-
responding to the cycle at which PCR enters the exponential phase. If no increase in 
fluorescent signal is observed after 50 cycles, the sample is assumed to be negative.
Statistical analysis
To determine the degree of linear relationship between inflammation [C-reactive 
protein (CRP) value] and Ct value, a Pearson correlation coefficient was calculated 
(http://statpages.org/).
RESULTS AND DISCUSSION
Although more than 90% of culture-confirmed clinical cases of LD are caused by 
Legionella pneumophila, some non-pneumophila Legionella species are also known 
to cause disease in humans [18]. PCR based diagnosis of Legionella is a sensitive 
method, but can be difficult with regard to discrimination of Legionella pneumophila 
from other Legionella species. Theoretically, 5S rRNA gene based PCR can detect 
all Legionella, but the primers have been reported to amplify other microorganisms 
[19]. The mip gene based PCR can detect all L. pneumophila but also may detect 
some non-pneumophila Legionella species. The 16S rRNA gene based PCR may 
provide the most clear discrimination between L. pneumophila and other Legionella 
species [15] although its theoretical specificity is no longer 100% due to the ongoing 
expansion of sequence data available in recent years. In this study the three PCR 
assays were revalidated. The analytical specificities and sensitivities of PCR assays 
were investigated as described in methods. With the 5S rRNA gene based PCR only 
Legionella species were detected. With the mip gene based PCR all serogroups of L. 
pneumophila were detected and L. israelensis. With 16S rRNA based PCR only L. 
pneumophila and Legionella species were detected; a 100% specificity of discrimina-
tion was observed. No PCR positives were found among non-Legionella bacteria 
tested. In clinical materials from patients with community-acquired pneumonia of 
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known etiology no Legionella spp. DNA was detected in any of the three assays. 
The sensitivity of the 5S rRNA based PCR assay was highest with a lower detection 
limit of 10 fg of chromosomal DNA. In the mip gene based assay, the lower detection 
limit was 100 fg, and 1000 fg was found as lower detection limit for the 16S rRNA 
based PCR.
In order to study the usefulness of serum for PCR-based diagnosis, we included 68 
patients with proven LD, with 151 serum samples taken in total. Cases included were 
68 adults (48 males and 20 females, male-female ratio 2.4) between 32 and 78 years 
old (mean age 54.0 years). The laboratory results of these patients were as follows: 
(positive/number tested [%]) serology 68/68 (100%), isolation 15/29 (52%), PCR 
26/26 (100%) and urinary antigen test 55/60 (92%). Since no records were made of 
the first day of illness, we arbitrarily designated the ‘acute-phase’ serum sampling as 
starting point of disease (day 0). Among the patients with proven LD 54.4% (37/68) 
tested positive in 5S rRNA PCR, 52.9% (36/68) in mip gene PCR and 30.9% (21/68) 
in 16S rRNA PCR in the first available serum sample. Among LD cases, 20 of 68 
(29.4%) tested positive in all three PCR’s (table 2), with mean Ct’s of 29.3, 31.5 and 
32.5, respectively, for 5S rRNA, mip and 16S rRNA gene based PCRs. Another 15 
(22.1%) patients were PCR positive in 5S rRNA and mip gene based PCR (mean Ct’s 
of 35.2 and 37.8) but negative in 16S rRNA based PCR, 1 patient (1.5%) was posi-
tive in both 5S rRNA and 16S rRNA based PCR (Ct of 35.4 and 45.0 respectively), 1 
patient was positive only in 5S rRNA based PCR (Ct 36.9) and 1 patient was positive 
only in mip based PCR (Ct 38.5). The detection-rate for all (non-inhibited) samples 
was 34.9% (49/149), 35.6% (48/149) and 16.8% (25/149) for 5S rRNA, mip gene 
and 16S rRNA based PCR respectively. In 2 samples (obtained from 2 patients) 
inhibition of PCR occured.
Failure to diagnose and treat LD early has been found to contribute to increased 
morbidity and mortality [5]. Existing laboratory tests lack sensitivity in detecting all 
cases of LD or provide only a retrospective diagnosis. The theoretical advantages of 
PCR for the detection of L. pneumophila DNA in serum are evident: serum samples 
are readily obtainable and can be processed within a working day. Our findings are 
largely in concordance with results previously reported [12]. For an illness of low 
prevalence such as LD the specificity of a test is an important parameter, and our 
results suggest that the positive predictive value obtained using PCR on serum is 
high. In contrast to the high sensitivity found by Lindsay et al. [13], the sensitivity 
of PCR found in our study was relatively low. Sensitivity of PCR is likely to increase 
when testing samples that are obtained early in the course of illness, when testing 
of more than one serum sample from each patient is performed and in patients with 
severe pneumonia, e.g. those with a pneumonia severity index (PSI) of 4 and 5. The 
urinary antigen test is less reliable in milder cases of LD, and it would be plausible 
that the same holds true for the detection of Legionella DNA in serum [7]. Because 
of the retrospective nature of our observations we were not able to investigate the 
relation between test sensitivity and severity of disease. However, the presence of 
L. pneumophila DNA in serum could correlate with an acute phase response as 
reflected in high CRP values [12]. The Ct value is inversely proportional to the log 
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Table 2. Data for patients with Legionnaires’ disease. UAG, urinary antigen test; interval, No of days since 
first serum sample; INH, inhibition of PCR; ND, not determined.
Patient 
no.
Serum 
no.
Age (y)/
gender
UAg PCR Serology Culture Interval 5Sa (Ct) mipa (Ct) 16S (Ct)
1 1 64/M + + + + 0 + (24.4) + (27.0) + (24.5)
2 22 + (35.1) + (41.5) -
3 80 - - -
4 89 - - -
2 5 46/M + + + ND 0 + (31.2) + (33.7) + (33.2)
6 13 - - -
7 21 - - -
3 8 57/M + + + ND 0 + (37.0) + (40.8) -
9 10 - - -
4 10 59/F + + + + 0 - - -
11 10 - - -
5 12 72/F + + + + 0 + (35.7) + (36.9) -
13 19 - - -
14 51 - - -
6 15 54/F + + + ND 0 + (30.5) + (32.9) + (34.7)
7 16 41/M + + + ND 0 + (36.2) + (41.8) -
8 17 41/M + ND + ND 0 + (34.8) + (38.2) + (43.7)
18 20 - - -
9 19 64/M + ND + ND 0 + (35.4) - + (45.0)
20 16 - - -
10 21 55/M + + + + 0 - - -
22 16 - - -
11 23 44/M + ND + ND 0 - - -
12 24 44/M + + + + 0 + (38.0) + (41.8) -
25 57 - - -
13 26 48/F + ND + - 0 - - -
27 28 - - -
28 42 - - -
14 29 42/F + ND + ND 0 - - -
15 30 69/F + ND + ND 0 - - -
31 8 - - -
16 32 74/M + + + - 0 + (26.4) + (29.4) + (26.9)
33 17 - - -
17 34 50/M + ND + ND 0 + (33.6) + (36.3) + (39.2)
35 11 - - -
18 36 56/F + ND + ND 0 + (30.2) + (32.7) + (32.5)
37 21 - - -
19 38 53/M + + + ND 0 + (27.5) + (29.9) + (28.0)
39 23 - - -
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Table 2. (continued)
Patient 
no.
Serum 
no.
Age (y)/
gender
UAg PCR Serology Culture Interval 5Sa (Ct) mipa (Ct) 16S (Ct)
20 40 32/F ND + + ND 0 + (27.4) + (29.6) + (28.4)
41 60 - - -
21 42 49/M ND + + ND 0 + (35.0) + (42.9) -
43 19 - - -
22 44 58/M + ND + ND 0 + (32.8) + (35.0) + (41.8)
45 17 - - -
23 46 57/F - + + ND 0 - - -
47 13 - - -
24 48 62/M - + + ND 0 - - -
49 12 - - -
25 50 43/M - + + ND 0 - - -
51 14 - - -
26 52 61/M + ND + ND 0 + (32.0) + (34.5) + (36.5)
53 5 - - -
27 54 43/M ND + + ND 0 - - -
55 15 - - -
56 28 - - -
28 57 40/M + ND + ND 0 + (31.0) + (33.1) + (32.7)
58 16 - - -
29 59 42/M + ND + ND 0 - - -
30 60 55/F + ND + ND 0 + (29.1) + (31.3) + (29.8)
61 13 - - -
62 19 - - -
31 63 57/M + ND + - 0 + (32.2) + (34.2) + (35.2)
32 64 51/M ND + + ND 0 - - -
65 40 - - -
33 66 64/M ND + + ND 0 - - -
67 15 - - -
34 68 65/M ND + + ND 0 + (30.6) + (33.1) + (31.9)
69 33 - - -
35 70 45/M + ND + + 0 + (38.4) + (38.1) -
71 11 - - -
36 72 69/F - + + + 0 - - -
73 6 - - -
37 74 73/F + ND + + 0 - - -
75 7 - - -
38 76 78/M + ND + - 0 + (32.8) + (34.6) -
77 15 - - -
39 78 45/M + ND + - 0 - + (38.5) -
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Table 2. (continued)
Patient 
no.
Serum 
no.
Age (y)/
gender
UAg PCR Serology Culture Interval 5Sa (Ct) mipa (Ct) 16S (Ct)
79 15 INH INH INH
80 23 - - -
40 81 43/F ND + + ND 0 + (36.9) - -
41 82 57/F - + + - 0 + (32.4) + (33.1) -
83 7 + (37.3) - -
42 84 53/M + ND + ND 0 - - -
43 85 58/M + ND + 0 - - -
86 14 - - -
44 87 55/M + ND + ND 0 - - -
88 58 - - -
45 89 34/M + ND + + 0 + (27.9) + (29.9) + (28.9)
90 5 + (35.7) + (39.4) -
91 45 - - -
46 92 68/M + ND + - 0 - - -
93 13 - - -
94 60 - - -
95 75 - - -
47 96 33/M + ND + - 0 - - -
48 97 54/M + ND + ND 0 - - -
98 26 - - -
49 99 56/M + ND + + 0 + (29.3) + (29.4) -
100 24 - - -
50 101 57/F + ND + - 0 + (38.6) + (37.7 -
102 31 - - -
51 103 56/F + ND + ND 0 + (32.8) + (35.0) + (38.8)
104 28 - - -
52 105 47/M + ND + + 0 + (32.3) + (34.4) + (40.1)
106 29 - + (38.1) -
53 107 54/M + ND + - 0 - - -
108 13 - - -
54 109 47/F + ND + + 0 - - -
55 110 53/M + ND + - 0 - -
56 111 57/F + ND + ND 0 + (33.1) + (35.0) + (41.1)
112 21 - - -
57 113 59/F + ND + + 0 + (36.3) + (40.1) -
114 28 - - -
115 38 - - -
58 116 62/M + ND + ND 0 + (34.7) + (35.3) + (38.5)
117 29 - - -
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Table 2. (continued)
Patient 
no.
Serum 
no.
Age (y)/
gender
UAg PCR Serology Culture Interval 5Sa (Ct) mipa (Ct) 16S (Ct)
59 118 50/M + ND + ND 0 + (35.1) + (35.5) -
119 12 - - -
120 14 - - -
60 121 46/M + ND + - 0 + (35.6) + (40.7) -
122 34 - - -
61 123 47/M + ND + - 0 - - -
62 124 63/M + ND + ND 0 - - -
125 22 - - -
63 126 43/M + ND + ND 0 - - -
64 127 60/M ND + + ND 0 + (33.4) + (37.4) -
128 22 - - -
65 129 64/M + ND + + 0 + (34.8) + (35.6) -
66 130 63/M + ND + ND 0 - - -
131 21 - - -
67 132 59/F + + + + 0 + (34.0) + (35.2) + (35.9)
133 1 + (34.2) + (34.9) + (34.0)
134 2 + (35.2) + (36.2) -
135 3 + (35.8) + (37.0) -
136 4 + (36.8) + (36.5) + (37.1)
137 5 + (37.5) + (37.4) -
138 6 + (37.6) + (39.7) + (37.2)
139 7 + (38.6) + (40.7) -
140 9 + (39.4) + (40.7) -
141 10 - - -
142 11 - - -
143 13 - - -
144 14 - - -
68 145 53/M + + + - 0 - - -
146 1 - - -
147 2 INH INH INH
148 3 - - -
149 4 - - -
150 6 - - -
151 7 - - -
a Among the patients with proven LD 54.4% (37/68) tested positive in 5S rRNA PCR, 52.9% (36/68) in 
mip gene PCR and 30.9% (21/68) in 16S rRNA PCR in the first available serum sample. The detection-rate 
for all (non-inhibited) samples was 34.9% (49/149), 35.6% (48/149) and 16.8% (25/149) for 5S rRNA, 
mip gene and 16S rRNA based PCR respectively. In 2 samples (obtained from 2 patients) inhibition of PCR 
occured.
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of the amount of target DNA initially present. In the current study, the association 
between Ct value in 5S PCR positive serum samples (n=49) and CRP value was 
determined and showed a strong negative correlation (r = -0.63, Pearson correlation 
coefficient, p <.0001). Wever et al. [20] studied the kinetics of L. pneumophila DNA 
in serum samples of patients with LD in relation to CRP using a mip gene based PCR. 
Fifteen hospitalized patients with LD were studied on day of admission up to 10 days 
thereafter. Serum samples obtained on day of admission were mip gene PCR positive 
in 7/11 (64%) patients and negative in 4/11 (36%) patients. Interestingly, the lowest 
Ct value (26.6) was found in a patient that died on day 5 following admission. On 
the day of admission, the average CRP level in the 7 patients with a mip PCR positive 
serum sample was 499 ± 144 mg/l (median ± SD) and 244 ± 97 mg in the 4 patients 
with a negative PCR result.
Currently, a positive culture, a positive urinary antigen test or a fourfould or greater 
rise in antibody titer against L. pneumophila is definitive of a confirmed case, and 
PCR positive samples are only classified as presumptive by the European Working 
Group on Legionella Infections (EWGLI). There is an apparant need for prospective 
studies to determine the exact sensitivity and specificity of PCR in patient samples. 
In our experience, PCR as a diagnosticum in patients with severe CAP is a sensitive 
and specific tool in patients who produce sputum. The high specificity is exampli-
fied by a recent investigation conducted at our laboratory [21]. In this case-control 
study, nose and throat samples from patients presenting with acute respiratory tract 
infections and matched controls were analysed for the presence of Legionella spp. by 
real-time 16S rRNA based PCR. Legionella DNA was not detected in any of the cases 
or controls. Although our definition of a proven case was different from that defined 
by EWGLI and included a positive PCR, the majority (97%; 65/67) of our patients 
would also be considered a proven case according to EWGLI criteria (table 2). We 
performed a retrospective, laboratory-based study, using serum samples from patients 
with proven LD and patients with respiratory tract infections other than Legionella. 
Ideally, a prospective study should be conducted to evaluate the value of Legionella-
specific PCR using consecutive serum samples in patients with (severe) pneumonia. 
However, our findings suggest that detection of L. pneumophila DNA in serum could 
be a valuable tool in addition to existing diagnostic tests for the rapid diagnosis of 
LD in the acute phase of disease, and has the potential to detect infections caused by 
any Legionella species and serogroup. The strong association between Ct value and 
CRP value suggest that application of PCR for the detection of Legionella should 
especially be considered in patients with severe pneumonia of unknown origin. In 
our view, the best initial testing strategy that will detect all Legionella species and 
provide results within a time frame that will affect clinical management consists of a 
urinary antigen test combined with Legionella PCR on sputum and serum.
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INTRODUCTION
In a recently published report, we assessed the performance of PCR as a diagnostic 
method and compared the performance of different PCR assays of serum samples 
from patients with Legionnaires’ disease (LD) [1]. Among the patients with proven 
LD, 54.4% tested positive in 5S rRNA PCR, 52.9% in mip gene PCR and 30.9% in 
16S rRNA PCR in the first available serum sample. We were not able to investigate 
the relationship between test sensitivity and severity of disease. However, the as-
sociation between Ct value in 5S PCR positive serum samples (n=49) and C-reactive 
protein value was determined, and showed a strong negative correlation (r = -0.63, 
Pearson correlation coefficient, p <.0001). As the urinary antigen test is less reliable 
in milder cases of LD, it would be plausible that the same holds true for the detection 
of Legionella DNA in serum [2]. The aim of the described study was to assess the 
sensitivity of PCR as a diagnostic method and to investigate a possible relationship 
between test sensitivity and the severity of disease.
MATERIAL AND METHODS
In this study, 68 outbreak-related patients (Bovenkarspel, The Netherlands) with 
confirmed LD according to the European Working Group for Legionella Infections 
(EWGLI) criteria were investigated [2,3]. To investigate the relationship between 
test sensitivity and severity of disease, the patients were divided into two clinical 
categories for pneumonia. Patients were classified as category 1 (mild pneumonia 
and moderately severe) and category 2 (severe pneumonia). LD was defined as se-
vere when two or more of the following conditions were present: 1) respiratory rate 
>30 /minute, 2) chest radiograph showing bilateral involvement or involvement of 
multiple lobes, 3) shock, 4) PaO2 <60 mmHg or arterial oxygen saturation <92%. A 
real-time assay targeted at specific regions within the 5S rRNA gene was used [1].
RESULTS
Samples included 136 serum samples obtained from 68 patients with LD. In one 
sample, inhibition of PCR occurred; this patient was excluded from the analysis. 
Among the patients with LD, 39% [26/67; 95% confidence interval (CI) 28 –51%] 
tested positive in PCR in the first available serum sample, and this number increased 
to 54% (36/67; 95% CI 42 –65%) if all serum samples were included in the calcula-
tions. The detection rate for all non-inhibited samples was 35% (47/135; 95% CI 27 
–43%). For 58 patients, data on disease severity were available. In patients with se-
vere pneumonia, 49% (19/39; 95% CI 34–64%) tested positive in the first available 
serum sample, increasing to 67% (26/39; 95% CI 51–79%) if all serum samples were 
included in the calculations. In patients with mild and moderately severe pneumonia, 
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37% (7/19; 95% CI 19–59%) tested positive in the first available serum sample, 
increasing to 53% (10/19; 95% CI 32–73%) if all serum samples were included.
DISCUSSION
The sensitivity of PCR on serum samples found in our study was relatively low 
compared to previous studies [1,4]. An important limitation of this study is the fact 
that the serum samples were stored at -20°C and thawed repeatedly before the PCR 
assays were applied. The storage and thawing probably influenced the stability of 
Legionella spp. DNA present in the samples. In addition, we only tested a relatively 
small number of patients in both groups; the calculated sensitivities are therefore 
more uncertain as indicated by the confidence intervals that are provided here. Al-
though we did observe a higher sensitivity in patients with more severe disease (49% 
vs 37%, p=0.4), these differences did not reach statistical significance. There is a 
need for larger, prospective studies to determine the role and added value of PCR 
on serum samples, and to further investigate the relationship between test sensitivity 
and the severity of disease.
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ABSTRACT
Reported here is the case of a previously healthy 67-year-old man who was admitted 
to the intensive care unit with pneumonia caused by Legionella longbeachae. The 
organism was identified by 16S rRNA-based PCR assay and sequence-based typing. 
PCR performed on an acute serum sample revealed a single elevated IgM antibody 
titer of 1:512 against non-pneumophila Legionella spp. The patient fully recovered 
following the initiation of appropriate antibiotic treatment. Since most current labo-
ratory tests for Legionella spp. cannot detect infections caused by non-pneumophila 
Legionella, culture on Legionella-selective media or PCR should be considered when 
diagnosing severe pneumonia of unknown etiology.
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INTRODUCTION
The genus Legionella, family Legionellaceae, includes over 40 different species of 
fastidious gram-negative bacilli, with over 60 described serogroups. These organ-
isms are ubiquitous in environmental and man-made watersystems, and many have 
been shown to cause human disease. Infection with Legionella spp. can present as 
severe pneumonia with or without multisystemic disease and high mortality, but it 
can also present as a self-limiting flu-like illness [1]. The vast majority of such cases 
(approximately 90%) are due to L. pneumophila, while a minority is due to other 
species, most commonly L. micdadei, L. bozemanii, L. dumoffii, and L. longbeachae 
[2–4]. The majority of confirmed infections involving non-pneumophila Legionella 
spp. have occurred in immunosuppressed patients [3].
We report here the case of a patient who developed community-acquired pneumo-
nia (CAP) due to L. longbeachae. In this case, the infection would have remained 
undiagnosed if PCR analysis of sputum had not been performed. To the best of our 
knowledge, this is the first description of pneumonia due to Legionella longbeachae 
in an immunocompetent patient in The Netherlands.
CASE REPORT
In July 2003, a 67-year-old previously healthy white male was admitted to the 
emergency department (Diaconessenhuis, Meppel, The Netherlands) with a history 
of malaise, cough, fever and shortness of breath. His history included non-insulin-
dependent diabetes mellitus. Vital signs on arrival included blood pressure of 80/40 
mmHg, pulse rate 120 beats/min, respiratory rate 30/min, and temperature 39.4°C. 
Examination of the chest revealed decreased breath sounds and crackles in the right 
lung base, and a chest radiograph showed extensive consolidation of the right lung. 
A complete blood count revealed a leukocyte count of 14,900 cells/µl with 17% 
segmented neutrophils, 77% band forms, 5% lymphocytes, and 1% monocytes and 
a C-reactive protein value (CRP) of 387 mg/l. Broad-spectrum antibiotic therapy 
with amoxicillin-clavulanic acid (1000/200 mg every 6 h) plus erythromycin (1000 
mg every 6 h) was started. The patient was transferred to the intensive care unit 
where he underwent intubation because of hypoxia and respiratory distress. One 
day after admission, erythromycin was stopped and replaced by levofloxacin (500 
mg every 12 h).
An immunochromatographic membrane test (Binax now; Binax, Portland, ME, 
USA) to detect L. pneumophila serogroup 1 soluble antigens in urine had been per-
formed, but the result was negative. Serological tests to detect Mycoplasma pneumo-
niae, Chlamydia spp. and Legionella pneumophila as well as PCR to detect Myco-
plasma pneumonia and Chlamydia pneumoniae were all negative. Bacterial cultures 
of sputum and blood for the detection of bacteria and fungi remained negative.
Since Gram stain showed numerous leukocytes without bacteria, the possibility 
of non-pneumophila legionellosis was considered. A sputum sample taken on day 2 
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after admission was cultured on Legionella-specific media (buffered charcoal yeast 
extract agar with and without antibiotics at the Laboratory for Infectious Diseases, 
Groningen, The Netherlands). No growth was observed after 10 days of incubation 
in a humidified atmosphere at 37°C. The sample was also sent to a reference labora-
tory for the performance of Legionella-specific real-time PCR. The PCR used was a 
dual-color two-probe 16S-based PCR assay with probes specific for L. pneumophila 
and Legionella spp. [5]. The sputum sample tested positive for non-pneumophila Le-
gionella spp. with a cycle treshold (Ct) of 24. Sequence analysis of the PCR product 
(Base Clear, Leiden, The Netherlands) was done and compared to those submitted 
to the GenBank database using BLAST (http://www.ncbi.nlm.nih.gov/BLAST/). The 
aligned amplification product showed a 100% match with Legionella longbeachae.
An acute-phase serum sample was tested using PCR and an immunofluorescence 
assay for the detection of IgM and IgG antibodies against Legionella spp. (Legio-
nella species IFA, Vircell microbiologists, Santa Fe, Granada, Spain). The serum 
sample tested positive for non-pneumophila Legionella spp. with a Ct of 40. Samples 
were tested for L. pneumophila types 1–6, L. pneumophila types 7–14 and non-
pneumophila Legionella spp. according to the manufacturer’s instructions. The 
results showed a single elevated IgM titer of 1:512 and an IgG titer of 1:64 for non-
pneumophila Legionella spp., indicating the presence of acute disease. Cross-reactive 
antibodies for L. pneumophila IgM and IgG occurred, but did not exceed a titer of 
1:16 (Table 1).
Table 1 Serological results obtained using a commercial immunofluorescent assay to detect Legionella spp.
Antigen Serum dilution
1:16 1:32 1:64 1:128 1:256 1:512 1:1024
L. pneumophila sg 1–6
IgM Eq – – – – – –
IgG Eq – – – – – –
L. pneumophila sg 7–14
IgM + – – – – – –
IgG Eq – – – – – –
L. non-pneumophila spp.
IgM + + + + + + –
IgG Eq + + Eq – – –
+, positive; –, negative; Eq, equivocal; sg, serogroup
The patient responded slowly following the initiation of antibiotic therapy, but his 
condition improved and his C-reactive protein values dropped from 402 mg/l on day 
1 after admission to the ICU to 81 mg/l on day 8. He was discharged to the medium 
care department on day 15 and left the hospital 3 weeks after admission. The source 
of the L. longbeachae infection in this patient was not investigated.
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DISCUSSION
CAP due to non-pneumophila Legionella spp. is rare. The majority of Legionella in-
fections diagnosed in humans is caused by L. pneumophila. A multinational study of 
CAP identified 508 culture-confirmed cases [6]. L. pneumophila was responsible for 
the greatest percentage of these cases (91.5%), followed by L. longbeachae (3.9%) 
and L. bozemanii (2.4%). The remainder of cases were due to L. micdadei, L. feeleii, 
L. dumoffii, L. wadsworthii, and L. anisa.
When specifically sought, unsuspected community-acquired Legionella infections 
may be uncovered. Investigators in Ohio, USA, reported seven culture-confirmed 
cases of community-acquired L. bozemanii pneumonia from a single institution over 
a 5-year period [7]. In a subsequent study on CAP of unknown etiology, 14% of 
patients showed seroconversion to Legionella spp. [8]. In Australia, there have been 
multiple cases of community-acquired L. longbeachae pneumonia associated with 
exposure to soil, and L. longbeachae is now recognised as the second most common 
cause of legionellosis [9, 10]. The majority of these cases occurred in gardeners, and 
commercially available potting soils were found to be colonised with L. longbeachae. 
The precise mode of transmission from soil is unknown.
Infection with Legionella spp. does not present with a distinctive clinical syn-
drome; it cannot be reliably differentiated from pneumonia due to other bacterial 
pathogens on the basis of signs, symptoms or laboratory findings [11]. Moreover, 
many infections with non-pneumophila Legionella spp. may be unrecognized be-
cause submission of sputum samples for Legionella culture is not a standard practice 
in the evaluation of CAP. Gram stains of respiratory secretions revealing leucocytes 
but few or no bacteria in combination with a lack of growth on routine bacterial 
cultures should suggest the possibility of Legionella infection.
In the case of our patient, only one sputum sample was submitted for Legionella-
specific culture, and it tested negative. Considerable interlaboratory variation has 
been documented for the ability to culture Legionella, and estimated sensitivities of 
sputum culture range from less than 10% to 80% and vary according to different 
comparison standards and the individual laboratories [12, 13]. Non-pneumophila 
Legionella strains are easily missed in clinical specimens because the media used to 
detect them often have decreased sensitivity for their isolation, especially if antibiot-
ics are added [14]. The Legionella urinary antigen test, which is widely used as a 
diagnostic screening test for Legionella infection, does not reliably detect infection 
due to Legionella spp. other than that due to L. pneumophila serogroup 1 [12, 13]. 
Serologic methods to diagnose L. pneumophila infections are highly sensitive [1] 
but their utility is generally limited to epidemiologic studies, due to the amount of 
time needed to detect seroconversion. The sensitivity and specificity of detecting 
seroconversion to Legionella spp. other than L. pneumophila is uncertain. While 
seroconversion can be used for the diagnosis of infection due to other species, such 
diagnoses should be regarded as presumptive unless there are supporting microbio-
logic or epidemiologic data [1, 3].
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When testing lower respiratory tract samples, PCR has repeatedly been shown to 
have a sensitivity equal to or greater than culture [15–17]. For this reason, and given 
the major shortcomings of other diagnostic tests for Legionella infection, PCR could 
be considered the test of choice for legionellosis in patients producing sputum. Legio-
nella DNA can also be detected in serum obtained from patients with Legionnaires’ 
disease and the sensitivity of this method ranges between 30% and 80.5% [13, 18].
Failure to diagnose and treat Legionnaires’ disease early has been found to con-
tribute to increased morbidity and mortality [19]. The array of antimicrobial agents 
useful for the treatment of infections caused by Legionella spp. is limited. This is 
mainly due to the fact that these organisms are obligate intracellular pathogens and, 
to be effective, the drugs must be able to penetrate into phagocytic cells. The vast 
majority of clinical experience in the treatment of Legionella infection involves L. 
pneumophila. However, other Legionella spp. share similar in vitro susceptibility 
patterns [3].
We successfully treated our patient with levofloxacin, which is the best-studied 
fluoroquinolone antibiotic agent for the treatment of Legionella infection to date. In 
a study by Yu et al. [20], data from six clinical trials including almost 2000 patients 
were analyzed to determine the efficacy of levofloxacin in patients with CAP due to 
Legionella spp. A total of 75 (3.8%) patients were infected with a Legionella sp., and 
more than 90% of these infections had resolved clinically at the post-therapy visit 
conducted 2–14 days after treatment termination. No deaths were reported for any 
patient with Legionnaires’ disease treated with levofloxacin in any of the studies.
In conclusion, we have described a case of CAP in an immunocompetent patient 
caused by L. longbeachae, which was identified using PCR analysis and sequence-
based typing and treated successfully with levofloxacin. Since most laboratory tests 
to detect Legionella cannot identify infections caused by non-pneumophila spp., 
culture on Legionella-selective media or PCR should be considered when diagnosing 
patients with severe pneumonia of unknown etiology.
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ABSTRACT
Our aim was to investigate the occurrence and identity of Legionella spp. in Dutch 
tap water installations using culture, real-time PCR and sequence analysis. The PCR 
assays used were a 16S rRNA gene based PCR with both a Legionella species specific 
probe and a L. pneumophila specific probe and a L. pneumophila-specific PCR based 
on the sequence of the mip gene. A total of 357 water samples from 250 locations in 
The Netherlands was investigated. The detection rates of Legionella spp. were 2,2% 
(8 of 357) by culture, and 87,1% (311 of 357) by PCR. The majority of samples was 
found to contain Legionella species other than L. pneumophila. These comprised 
of Legionella Like Amoebal Pathogens (LLAPs), L. busanensis, L. worsliensis and 
others. Fourteen (3,9%) samples were positive for L. pneumophila by either culture, 
16S rRNA based PCR and/or mip based PCR. It is apparent from this study that 
Legionella spp. DNA is ubiquitous in Dutch potable water samples. Our findings fur-
ther suggest that LLAPs and viable but nonculturable (VBNC) Legionella represent 
a large proportion of the population in man-made environments.
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INTRODUCTION
Legionellae are intracellular parasites of freshwater protozoa and use a similar mech-
anism to multiply within mammalian cells. These bacteria cause respiratory disease 
in humans when a susceptible host inhales aerosolized water containing the bacteria 
or aspirates water containing the bacteria [1]. Most cases of legionellosis can be 
traced to human-made aquatic environments where the water temperature is higher 
than ambient temperature [2]. In these thermally altered aquatic environments the 
balance between protozoa and bacteria can shift, resulting in rapid multiplication of 
Legionellae, which in turn can translate into human disease. In The Netherlands in 
1999 a large outbreak of Legionnaires’ disease at a flower show occurred, with 188 
patients of which 23 patients died [3]. This demonstrated the potential public health 
risk of the presence of Legionella pneumophila in water, especially when usage leads 
to aerosols. In order to prevent such outbreaks, the Dutch government tightened 
up regulations about admissible concentrations of Legionella spp. in Dutch water 
installations in public buildings.
A variety of methods, including guinea pig inoculation, fluorescent-antibody (FA) 
techniques, culture techniques, FISH, and PCR-based assays, have been applied to 
detect L. pneumophila in environmental samples [4]. Culture methods enable the 
quantitative detection of culture-able bacteria and isolation of strains is commonly 
used but has a number of limitations. Culture requires a long incubation period, 
and the recovery is often reduced by antibiotics and sample treatment. Studies have 
demonstrated that culture-based estimates of the concentration of L. pneumophila 
in concentrated water samples are imprecise and of low sensitivity [5]. Recovery of 
Legionella spp. from water samples is often hampered by overgrowth of colonies of 
rapidly growing non-Legionella background. Several non-pneumophila Legionella 
spp. grow poorly on BCYE agar [6].
Recently, new methods for detection of Legionella spp. in water have been devel-
oped to overcome the limitations of culture. PCR methodology has been used based 
on the 16S rRNA gene [7,8,9], 5S rRNA gene [10,11,12], or on the macrophage 
infectivity potentiater (mip) gene [7,10,12,13]. PCR techniques have the advantage 
of fast acquisition of results, detection of non-culturable legionellae, and easier han-
dling of large numbers of samples.
Our aim was to investigate the occurrence and identity of Legionella spp. in Dutch 
tap water installations using culture, real-time PCR and sequence analysis.
MATERIAL AND METHODS
Bacterial strains
In order to test in vitro sensitivity and specificity a list of bacterial strains was used 
as shown in Table 1.
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Table 1. Legionella strains investigated by 16S rRNA and mip PCR assays
Species and serogroup Strain or reference
L. pneumophila
 1. (Philadelphia 1)
 2. (Togus 1)
 3. (Bloomington2)
 4. (Los Angeles 1)
 5. (Dallas 1E)
 6. (Chicago 2)
 7. (Chicago 8)
 8. (Concord 3)
 9. (IN 23)
 10. (Leiden 1)
 11. (797/PA/H)
 12. (570-CO-H)
 13. (82A3105)
 14. (1169-MN)
ATCC33152
ATCC33154
ATCC33155
ATCC33156
ATCC33216
ATCC33215
ATCC33823
ATCC35096
ATCC35289
ATCC43283
ATCC43130
ATCC43290
ATCC43736
ATCC43703
Legionella spp.
 L. anisa
 L. birminghamensis
 L. bozemanii-1
 L. bozemanii-2
 L. brunensis
 L. cherii
 L. dumoffii
 L. erythra
 L. feeleii-1
 L. feeleii-2
 L. gormanii
 L. hackeliae-1
 L. israelensis
 L. jamestowniensis
 L. jordanis
 L. longbeachae-1
 L. longbeachae-2
 L. maceachernii
 L. micdadei
 L. moravica
 L. oakridgensis
 L. parisiensis
 L. rubrilucens
 L. sainthelensis
 L. santicrusis
 L. spiritensis
 L. steigerwaltii
 L. tucsonensis
 L. wadsworthii
ATCC35292
ATCC43702
ATCC33217
ATCC35545
ATCC 43878
ATCC35252
ATCC35850
ATCC35303
ATCC35072
ATCC35849
ATCC33297
ATCC35250
ATCC43119
ATCC35298
ATCC33623
ATCC33462
ATCC33484
ATCC35300
ATCC33218
ATCC43877
ATCC33761
ATCC35299
ATCC35304
ATCC35248
ATCC35301
ATCC35249
ATCC35302
ATCC49180
ATCC33877
Non-Legionella bacteria
 Streptococcus pneumoniae
 Bordetella pertussis
 Bordetella parapertussis
 Mycoplasma pneumoniae
 Chlamydia pneumoniae
 Acinetobacter baumannii
 Pseudomonas aeruginosa
 Lactobacillus caseï.
ATCC49619
Tohama strain
B24
ATCC15293
ATCCVR1355
ATCC27853
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Water samples
A total of 357 water samples were collected from 250 public buildings (mainly 
company buildings and schools) at different locations throughout The Netherlands 
between August and December 2001. 352 samples were obtained from potable water 
(346 cold water and 6 hot water) taps. One sample was obtained from a cooling 
tower, and 4 water samples were collected from large aerosol generating devices 
(e.g. air-conditioning). Water samples were collected in sterile 1000 ml polyethylene 
bottles and samples were delivered to the laboratory within one day. For potable 
water samples, the first 1000 ml of water from tapwater faucets was drained into a 
bottle. This first draw sample was not used for analysis. The water was then allowed 
to run for approximately 60 seconds, and the second draw of 1000 ml of water was 
used for microbiological analysis. For non-potable samples from such sources as 
cooling towers, 250-500 ml water from the bottom or side of the vessel or reser-
voir was collected. No disinfectant treatment was used. After use, the bottles were 
rinsed with sterile water and autoclaved at 121°C for 20 minutes. The temperature 
during transport was between 10-20°C. 500 ml samples were filtered through 0.2 
µm polycarbonate membranes (Merck, Darmstadt, Germany), and the filtrate was 
resuspended in 1 ml of sterile distilled water.
Culture
Both 0.1 ml of the filtrate was plated on a buffered charcoal yeast extract agar 
(BCYE) and on a BCYE agar with glycine, vancomycin, polymixin and cyclohexim-
ide (GVPC, Oxoid, Haarlem, The Netherlands) and incubated for 7 days at 35°C in 
a humidified atmosphere. Colonies that grew on BCYE agar but failed to grow on 
blood agar were expected to be Legionella spp. Further identification was carried 
out by determination of the L. pneumophila serogroups using a slide agglutination 
test (Microscreen®, Microgen bioproducts, Camberly Surrey, United Kingdom). A 
distinction was made between L. pneumophila serogroup 1 and Legionella pneumo-
phila serogroup 2-14.
Sample preparation for PCR
To minimize inhibition of PCR amplification, 200 µl of the filtrate was processed 
with MagNA Pure®, using the Total Nucleic Acid Kit (Roche Diagnostics) with an 
elution volume of 50 µl. 5 µl of the eluate was used as template in the PCR.
PCR assays
For the detection of Legionella spp. in water samples two separate assays were used. 
The primers of the first assay were based on the 16S rRNA gene as was described 
previously [14]. In short, primers Leg1 (forward 5’-TACCTACCCTTGACATA-
CAGTG-3’) and Leg2 (reverse 5’-CTTCCTCCGGTTTGTCAC-3’) were used to 
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obtain a 200 bp amplicon. Real-time detection was done with a Legionella genus 
specific fluorescent probe (LSPP: VIC-5’-GGTTGCGTCGTTACG-3’) conjugated to 
a minor groove binder (MGB). A L. pneumophila specific fluorescent MGB probe 
(LPN: FAM -5’-GAGTCCCCACCATCACATG-3’) was used on the complementary 
DNA strand.
So as not to miss L. pneumophila in mixed Legionella populations in water, we 
developed a L. pneumophila-specific PCR based on the sequences of the mip gene 
in addition. Primers Mip-F1 (forward 5’-GCCAAGTGGTTTGCAATACAAA-’3) 
and MipR1 (reverse 5’-CTCGACAGTGACTGTATCCGATTT-’3) were chosen with 
PrimerExpress (ABI), amplifying a 80 bp fragment. Real-time detection was done with 
TaqMan probe Lpn-mip (FAM-5’-TAATCAATGCTGGAAATGGTGTTAAACCCG-
3’-TAMRA).
Controls
In both assays negative controls were included. Sensitivity controls consisted of 10-
fold dilutions of L. pneumophila DNA ranging from 1000 fg to 10 fg (approximately 
230 to 2,3 genome equivalents). L. bozemanii has one mismatch with the L. pneu-
mophila specific probe and is used to guard the border of discrimination between L. 
pneumophila and non-pneumophila species. 1000 fg of L. bozemanii DNA served 
as control in the 16S rRNA based PCR for discrimination between L. pneumophila 
and other Legionella species. As internal control Phocine Herpes Virus (PhHV) was 
added to the samples to monitor processing as well as PCR inhibition, and detection 
of PhHV was included in the mip PCR. Primers PhHV-F1 and PhHv-R1 amplified 
a 80 bp amplicon that was detected in real-time with TaqMan probe PhHV-1 (VIC-
5’-TTTTTTATGTGTCCGCCACCATCTGGATC-’3-TAMRA). All primers and 
probes were synthesized by Applied Biosystems (ABI, Nieuwerkerk a/d IJssel, The 
Netherlands).
PCR conditions
The PCR mixture for the 16S rRNA PCR assay contained 5 µl of sample DNA, 
10 pmol of each primer Leg 1 and Leg 2, 3 pmol of each of probes Lsp-1 and 
Lpn-1, 12,5 µl TaqMan Universal Master Mix (ABI, Nieuwerkerk a/d IJssel, The 
Netherlands), 1µl bovine serum albumin (BSA;10 mg/ml) per sample (New England 
Biolabs, Beverly, USA) and PCR grade sterile water to a final volume of 25 µl. The 
PCR mixture for the mip gene based PCR contained 5 µl of sample DNA, 5 pmol of 
primer MIP-F2, 7.5 pmol of primer MIP-R2, 3.75 pmol of probe MIP-2, 10 pmol of 
each primer PhHv-R1 and PhHv-F1, 3.75 pmol of probe PhHv-1, 12,5 µl TaqMan 
Universal Master Mix (ABI, Nieuwerkerk a/d IJssel, The Netherlands), 1µl BSA (10 
mg/ml) per sample (New England Biolabs, Beverly, USA) and PCR grade sterile water 
to a final volume of 25 µl. Real–time PCR was performed on a Abiprism®7900HT 
Sequence Detection System (Applied Biosystems, Foster City, California, USA). DNA 
was amplified according to the following parameters: after 2 min incubation at 50°C 
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and 10 min denaturation at 95°C, amplification consisted of 50 cycles of 15 sec of 
denaturation at 95°C followed by 1 min of annealing and extension at 60°C. Results 
were expressed as threshold cycle values (Ct), corresponding to the cycle at which 
PCR enters the exponential phase. If no increase in fluorescent signal is observed 
after 50 cycles, the sample is assumed to be negative.
Identification of non-pneumophila Legionella spp.
Identification of 90 non-pneumophila Legionella PCR positives (6 culture positives 
and 84 PCR positives) was done by PCR reamplification and sequence analysis of 
the 200 bp 16S rRNA gene fragment (Base Clear, Leiden, The Netherlands). The 
sequences obtained were compared with those submitted to the GenBank database 
by using BLAST (http://www.ncbi.nlm.nih.gov/BLAST/).
RESULTS
Specificities of PCR assays
The specificities of both the 16S rRNA gene based PCR and the mip gene based PCR 
were investigated using a panel of human-pathogenic and environmental Legionella 
listed in Materials and Methods. Also a panel of non-Legionella bacteria was inves-
tigated. With the 16S rRNA gene based PCR only Legionella species were detected, 
and the probes correctly discriminated between Legionella pneumophila and non-
pneumophila Legionella species. With the mip gene based PCR all serogroups of L. 
pneumophila were detected. No PCR positives were found among non-Legionella 
bacteria. A 100% specificity of each PCR assay was observed.
Sensitivities of PCR assays
The sensitivity of the 16S rRNA based PCR was highest with a lower detection 
limit of 10 fg of chromosomal DNA. As the genome of one Legionella spp. consists 
of approximately 4.3 fg DNA [7], we can calculate an estimated equivalent of 200 
legionellae/ l. In the mip gene based PCR assay, the lower detection limit was 100 fg, 
the theoretical equivalent of approximately 2000 legionellae/ l.
Evaluation of results on water samples using culture and real-time PCR
In the analysis of the water samples, the detection rates of Legionella spp. were 
87,1% (311 of 357) by PCR and 2,2% (8 of 357) by the culture method (Table 2). 
A total of 14 water samples (3,9%) was positive for L. pneumophila. Of these 14 
samples one was positive in both PCR (mip- and 16S rRNA gene based assays) and 
culture (serogroup 1, 190 CFU/L), 7 samples in mip- and 16S rRNA gene based assay 
but not in culture, and 4 samples only in 16S rRNA PCR. The mean Ct value of these 
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4 samples was lower compared to mip gene based PCR positive samples, reflecting 
the higher sensitivity of the 16S rRNA PCR. One L. pneumophila positive sample 
was positive in culture (serogroup 2-14, 110 CFU/L) but reacted with the genus 
specific probe in the 16S rRNA based PCR. A total of 298 water samples (83,5%) 
was positive for L. non-pneumophila spp. Of these 298 samples 6 were positive in 
both 16S rRNA based PCR and culture (average 556 CFU/L, range 50-2600 CFU/L), 
291 positive only in 16S rRNA based PCR and one sample tested positive in both 
mip- and 16S rRNA based PCR. We found eight (2,2%) water samples contained 
inhibitors of PCR amplification. The sample obtained from a cooling tower was posi-
tive for L. non-pneumophila spp. in PCR, but negative in culture. Four water samples 
were collected from large aerosol generating devices; two culture negative samples 
contained inhibitors of PCR amplification, one sample was L. non-pneumophila spp. 
positive in PCR but negative in culture, and one sample was negative in both PCR 
and culture.
Table 2. Results of Legionalla spp. detection by 16S rRNA based PCR assay, mip based PCR assay, and 
culture. Lspp; Legionella non-pneumophila spp., Lpneu; L. pneumophila, Ct; cycle treshold value, +; 
positive result, -; negative result
16S rRNA PCR mip PCR
((mean) Ct)
Culture Number of
Samples (%)
Conclusion
Lspp.((mean) Ct) Lpneu ((mean) Ct)
+(29) +(33) +(36) + 1 (0,3%) L. pneumophila
+(30) +(32) +(35) - 7 (2,0) L. pneumophila
+(32) +(34) - - 4 (1,1%) L. pneumophila
+(29) - - + 1 (0,3%) L. pneumophila
+(28) - - + 6 (1,7%) L. non-pneumophila
+(33) - +(37) - 1 (0,3%) L. (non)-pneumophila
+(30) - - - 291 (81,5%) L. non-pneumophila
- - - - 38 (10,6%) negative
Inhibited 8 (2,2%)
357 (100%) Total
Sequence analysis results
The 84 samples originating from 51 locations that were positive for Legionella non-
pneumophila spp. in the 16S rRNA PCR were analysed by sequencing (Table 3). 
31 aligned amplification products showed 98%-100% match with Legionella Like 
Amoebal Pathogens (LLAPs), 27 with L. busanensis, and 11 with L. worsliensis. Two 
sequences showed homology to uncultured bacteria WCHA-76, and GOUTA10, 
which are like Legionella spp. members of the Proteobacterium family. Cultured 
strains were identified with PCR and sequence analysis as L. dumoffii (1), L. donald-
sonii (1), L. anisa (1), L. erythra (1) and L. worsliensis (2).
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Table 3. Results of identification by sequence analysis of the 200 bp 16S rRNA gene-fragment
Species (% match) Genbank accession nr. mutation position N=
LLAP 1 (100%)
LLAP 1 (99%)
LLAP 14 (100%)
L. adelaidensis (99%)
L. birminghamiensis (100%)
L. busanensis (100%)
L. busanensis (99%)
L. erythra (100%)
L. macheachernii (98%)
L. parisiensis (99%)
L. parisiensis (98%)
L. shakespearei (100%)
L. worsliensis (100%)
L. worsliensis (99%)
WCHA1-76 (100%)
GOUTA10 (100 - 97%)
X97355
X97355
U66104
Z49716
Z49717
AF424887
AF424887
Z32638
AF227161
Z49731
U59697
Z49736
Z49739
Z49739
AF050529
AY050582
G → A
T → C
G → A
C → A
G → A
G → A
G → A
G → C
T → C
1112
1112
1119
1017
1112
1068
1110
1137
1112
22
 5
 4
 1
 1
 8
19
 1
 2
 1
 1
 1
 9
 2
 2
 5
Total 84
DISCUSSION
Theoretically, PCR would present the method of choice for the detection of Legio-
nella species in water, as has been suggested before [7]. PCR is equally sensitive for 
all Legionella spp., and facilitates handling of a large number of samples. The major 
difference between culture and PCR found in our study may be due to a number of 
reasons. First, recovery rates obtained by culture are usually noticeably less than 
100%, especially in potable waters [12]. Culture requires a panel of differential and 
selective media, and has a relatively low sensitivity, ranging from between 10 to 80% 
in clinical materials [15]. Growth for Legionella pneumophila is better on standard 
media used for primary isolation than for Legionella non-pneumophila spp. [6]. It has 
also been recognized that filtration or centrifugation of large water sample volumes 
results in a loss of up to 90% of culturable Legionella spp. [7,13]. The significance 
of the large percentage of PCR positive water samples remains unclear. Legionellae 
detected by PCR may also present non-viable cells or Legionella DNA which is not 
infectious to humans. Even amplification and detection of non-Legionella DNA can-
not be completely excluded, since alignment of the target sequences of the primers 
can never exclude all environmentally occurring, known and unknown, bacteria. 
Therefore, the high PCR signals should be critically interpreted.
In our study we found only six samples positive for Legionella non-pneumophila 
spp. by culture. The recovery rate seems to correspond with PCR quantification since 
culture positives showed lower Ct values compared to culture negatives, although the 
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differences are difficult to interpret because of the low numbers of culture positive 
samples. In this study, 31 aligned amplification products showed 98%-100% match 
with Legionella Like Amoebal Pathogens (LLAPs). LLAPs may be human pathogens, 
but proving this is difficult because they cannot be detected by conventional culture 
techniques used for Legionella spp. Moreover, several authors have reported that 
Legionella bacteria are able to enter a viable but non-culturable (VNBC) state, which 
may account for the fact that Legionella spp. cannot be cultured from cooling towers 
suspected to be the source of Legionellosis [16].
One L. pneumophila positive sample was positive in culture (serogroup 2-14, 110 
CFU/L) but reacted with the genus specific probe in the 16S rRNA based PCR. This 
finding can be explained by the presence of mixed Legionella spp. populations in 
water, and has been suggested previously [13]. A drawback of the dual-color two 
probe 16S based PCR is that with mixed Legionella spp. populations in the same 
sample, amplification is favoured towards the predominant species. We found that 
when the ratio of Legionella non-pneumophila spp. / L. pneumophila exceeds 100 
in the PCR reaction, L. pneumophila DNA was not amplified to a detectable level. 
Another example of a mixed Legionella spp. population may be presented by one 
sample that tested positive in the mip gene based PCR (and is therefore considered L. 
pneumophila positive) and was positive with only the Legionella genus probe in the 
16S rRNA gene based PCR.
Minimization of inhibition with bovine serum albumin (BSA) has been successfully 
used in previous studies [13,17]. We found eight (2,2%) water samples contained 
inhibitors of PCR amplification. Without the addition of BSA, up to 25% of water-
samples tested inhibitory in our laboratory (data not shown).
Our results are in concordance with those found by Wullings and van der Kooij [4]. 
They studied the occurrence of Legionella spp. in water collected from 82 ground-
water supplies and 16 surface water supplies, covering 67% of the total drinking 
water production in the Netherlands. Legionella was detected with 16S rRNA based 
quantitative real-time PCR in all samples of treated water, and no Legionella was 
found with the culture method. A phylogenetic analysis of 16S rRNA gene sequences 
of 202 clones, obtained from a selection of samples, showed a high similarity with 
Legionella sequences in the GenBank database. A total of 40 (33%) of the 16S rRNA 
gene sequences obtained from treated water were identified as described Legionella 
species and types, including L. bozemanii, L. worsliensis, LLAPs, L. quateirensis, 
L. waltersii, and L. pneumophila. 16S rRNA gene sequences with a similarity of 
below 97% from described species were positioned all over the phylogenetic tree of 
Legionella. The authors conclude that a large diversity of yet-uncultured Legionellae 
are common members of the microbial communities in ground and surface water 
supplies.
Although an association between the extent of Legionella contamination in water 
(using culture, expressed as CFU/l) and the occurrence of legionellosis has been de-
scribed, an association with the exact concentration of Legionella spp. remains un-
clear. Quantification of Legionella spp. recovered from a single water outlet has been 
shown to have no relevance to occurrence of the disease: increased risk appeared 
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associated with the extent of colonisation with Legionella pneumophila [18,19]. 
However, this finding may also be due to the fact that estimates of the concentration 
of Legionella spp. in concentrated water samples, when using culture, are imprecise 
and of low sensitivity. The role of non-pneumophila Legionella species as human 
pathogens is largely unknown mainly due to currently used diagnostic methods and 
because submission of sputum samples for Legionella spp. culture is not a standard 
practice in the evaluation of community-acquired pneumonia (CAP). Furthermore, 
the Legionella urinary antigen test, which is widely used as a diagnostic screening 
test for Legionella infection, does not detect infection due to Legionella species, other 
than that due to L. pneumophila serogroup 1 [1]. Infections seem to be very rare, 
and are reported mainly in severely immunocompromised patients. It is not clear 
whether these non-pneumophila Legionella species are inherently less pathogenic 
than L. pneumophila. Many species are pathogenic for amoebae, share virulence 
genes with L. pneumophila, and multiplication within amoebae has been shown to 
be linked to pathogenicity [20]. The role of LLAPs as human pathogens is largely 
unknown. Rowbotham et al. [21] isolated LLAP 1 from the sputum of an 82-year-old 
woman with persistent pneumonia by cocultivation with Acanthamoeba polyphaga. 
The patient demonstrated a fourfold rise in antibody titer to the bacteria from the 
infected amoebae. He thereafter screened over 5000 serum samples submitted for 
Legionella antibody testing, and found that 10 patients met criteria for infection 
with LLAPs [22]. Our findings suggest that LLAPs and VBNC Legionella spp. could 
represent a large proportion of the population in man-made environments and may, 
although not likely, constitute an unrecognized reservoir for disease.
CONCLUSIONS
Legionella spp. DNA is ubiquitous in Dutch tap water installations and uncultured 
Legionella spp. are part of the indigenous microbial community. The unique growth 
requirements of Legionella spp., the ability to enter a VBNC state and the association 
of LLAPs with amoebae complicates the detection of Legionella spp. in potable water 
using standard microbiological techniques. Elucidation of the properties of these or-
ganisms is needed to assess their potential public health significance and explain the 
conditions favouring their growth in aquatic environments. Therefore, prospective 
studies using culture and validated PCR methodologies are necessary to determine 
the exact role of non-pneumophila Legionella species as a human pathogen.
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ABSTRACT
The role of Legionella spp. in the aetiology of acute respiratory infections (ARIs) 
is largely unknown. In this case-control study, conducted in a general practitioner 
setting during 2000 and 2001, nose and throat samples from patients presenting with 
ARIs (n = 230) and controls (n = 200) were analysed for the presence of Legionella 
spp. by real-time PCR. Legionella DNA was not detected in any of the cases or 
controls. Thus, Legionella spp. do not seem to play a role in patients presenting with 
ARIs, nor were they present in patients who visited their general practitioner for 
complaints other than ARIs.
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INTRODUCTION
Legionella spp. are an important cause of community-acquired and nosocomial pneu-
monia. Since the first description of Legionella pneumophila, more than 40 species 
of Legionella have been identified, approximately half of which have been isolated 
from patients [1]. Infection with Legionella spp. can present as a severe pneumonia, 
with or without multisystem disease and high mortality, but can also present as a 
self-limiting influenza-like illness. Many individuals who seroconvert to Legionella 
are entirely asymptomatic [1,2].
Acute respiratory infections (ARIs) are a major cause of morbidity and mortality 
worldwide. Various infectious agents, especially viruses, have been associated with 
clinical syndromes ranging from mild disease, such as the common cold, to more 
severe conditions, such as pneumonia. However, no aetiological agent is found in 
a large percentage of cases [3]. Although ARIs are very common, there is only one 
report on the prevalence of Legionella spp. as a cause of community-acquired infec-
tions in general practice [4]. This may be because the diagnosis is not considered, 
existing diagnostic tests are insensitive, or legionellosis is distributed unevenly across 
the world. In The Netherlands, c. 200 cases of severe legionellosis are reported annu-
ally to the health authorities [5].
The aim of this study was to assess the frequency of Legionella spp. in nose and 
throat samples of patients presenting with ARIs in general practice.
MATERIAL AND METHODS
In The Netherlands, more than 100 general practitioners (GPs) participate in nation-
wide surveillance of respiratory pathogens and influenza-like illnesses, coordinated 
by the Netherlands Institute for Health Services Research (NIVEL, Utrecht, The 
Netherlands) [6]. The GPs register all patients with influenza-like illness and other 
ARIs. ARIs without influenza-like illness are defined as respiratory infections with 
acute onset (< 5 days) and coryza, sore throat and ⁄ or cough. Twenty GPs partici-
pated in the present study and were requested to collect a nose and throat sample 
from patients with ARIs without influenza-like illness (case). A corresponding con-
trol was also sampled within 7 days, defined as an individual who consulted the GP 
for a complaint other than ARIs, who was in the same age category as the case (0–4, 
5–14, 15–24, 25–44, 45–64 or > 65 years), was not a member of the same household 
as the case, and had not received antibiotics or antiviral therapy in the preceding 14 
days. A nose and a throat swab were placed together in 4 mL of Hanks’ balanced 
salt solution containing gelatin, lactalbumin, yeast and antibiotics (GLY medium), 
and sent to the central laboratory by regular mail. Swabs for bacterial culture were 
also taken.
The primers and probes of the Legionella PCR assay were based on the 16S rRNA gene 
as described previously [7]. In brief, nucleic acid isolation was performed with a pro-
teinase K lysis protocol, and primers Leg1 (5’-TACCTACCCTTGACATACAGTG-3’) 
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and Leg2 (5’-CTTCCTCCGGTTTGTCAC-3’) were used to obtain a 200-bp 
amplicon. Real-time detection of the fragment was done with a Legionella genus-
specific fluorescent probe conjugated to a minor groove binder (LSPP-VIC: 5’-GGT-
TGCGTCGTTACG-3’). An L. pneumophila-specific fluorescent minor groove binder 
probe was used on the complementary DNA strand (LPN-FAM: 5’-GAGTCCCCA-
CCATCACATG-3’). Inhibition was monitored in a separate assay by amplifying a 
phocine herpes virus, and negative controls were included to monitor processing 
and cross-contamination. Sensitivity controls comprised ten-fold dilutions of L. 
pneumophila DNA (1000 fg to 10 fg), while 1000 fg of Legionella bozemanii DNA 
served as a control for discrimination between L. pneumophila and other Legionella 
spp. Real-time PCR was performed with an ABI Prism 7900HT Sequence Detection 
System (Applied Biosystems, Foster City, CA, USA).
RESULTS
Nose and throat samples from 230 cases and 200 controls were collected between 
October 2000 and November 2001. The median age of the cases was 35 years (range 
0–87 years), and 104 (45%) of them were male. The median age of the control 
patients was 36 years (range 0–86 years), and 76 (38%) of them were male. Evidence 
of at least one infectious agent was found in 146 (63%) of the cases, compared to 44 
Table 1. Frequency of detection of specific infectious agents in 230 cases of acute respiratory tract infection 
and 200 control patients.
Pathogen Cases
n (%)
Controls
n (%)
Influenza virus type A 25 (10) 2 (1)
Influenza virus type B 7 (3) 0 (0)
Parainfluenza type 1 3 (1) 0 (0)
Parainfluenza type 2 0 (0) 0 (0)
Parainfluenza type 3 2 (1) 0 (0)
Rhinovirus 61 (25) 23 (11)
Adenovirus 2 (1) 0 (0)
Coronavirus 20 (8) 11 (5)
Respiratory syncytial virus 6 (3) 2 (1)
Human metapneumovirus 5 (2) 0 (0)
Enterovirus 7 (3) 3 (1)
Chlamydia pneumoniae 2 (1) 0 (0)
Mycoplasma pneumoniae 3 (1) 1 (0)
Beta-hemolytic streptococci 20 (9) 4 (2)
One or more of the above 146 (63) 44 (22)
Negative 84 (37) 156 (78)
Total 230 (100%) 200 (100%)
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(22%) of the controls (Table 1). Real-time PCR failed to detect Legionella DNA in 
any of the samples from either the patients with ARI or the control group. Inhibition 
of the PCR occurred with one sample.
DISCUSSION
ARIs are the most common diseases seen in the community and a frequent reason to 
consult a GP. Knowledge of the causes of respiratory infections continues to evolve, 
with recognition of new pathogens [8], but no aetiological diagnosis is established 
in a large percentage of cases [3]. It might be expected that Legionella spp. could 
play a role in ARIs, as they are ubiquitous in the aquatic environment and artificial 
water systems, and can cause a variety of diseases, ranging from asymptomatic cases 
to severe life-threatening pneumonia [1,9]. Upper respiratory signs and symptoms, 
such as a dry cough and sore throat, have been reported in cases of Legionnaires’ 
Disease [10], and a previous study [4] found serological evidence of infection with 
Legionella spp. in 11.2% of patients who presented with a febrile respiratory tract 
infection. However, observations based solely on antibody seroconversion should be 
viewed with scepticism, as the sensitivity and specificity of serology for Legionella 
spp. other than L. pneumophila have not been validated, and cross-reactions with 
other organisms may occur [1,11,12].
Culture on buffered charcoal yeast extract (BCYE) plates is the standard method 
for the laboratory diagnosis of Legionella infections, but has its limitations. Isolates 
are identified by a combination of colony and Gram’s stain morphology, and reactions 
with specific antibodies. However, because of the fastidious nature of the organism 
and problems inherent in specimen collection, culture of clinical specimens may have 
a sensitivity as low as 10% [11]. Moreover, several non-pneumophila Legionella spp. 
tend to grow poorly on BCYE agar [13]. Nucleic acid amplification techniques are 
attractive tools for detection of Legionella spp. in clinical samples, as they are able 
to detect all legionellae and provide results rapidly. Several studies have found that 
PCR methods have a higher rate of detection than culture-based methods [14–16]. In 
the present study, the assay sensitivity was 10 fg for all Legionella spp., equivalent to 
two bacterial cells ⁄ reaction.
Throat swabs have been used successfully to detect respiratory pathogens such as 
Mycoplasma pneumoniae [17], Chlamydia pneumonia [17,18] and Legionella spp. 
[16,17] by PCR. In contrast to a previous report based on serological observations 
[4], Legionella spp. were not detected in the nose or throat of patients with ARIs in 
general practice, and no evidence was found for asymptomatic carriage of Legionella 
spp. in the upper respiratory tract.
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ABSTRACT
The aetiology of acute exacerbations in COPD (AECOPD) is heterogeneous and 
still under discussion. Serological studies have suggested that Mycoplasma pneu-
moniae, Chlamydophila pneumoniae, and Legionella pneumophila may play a role 
in AECOPD. We investigated the presence of these atypical pathogens in sputum 
samples in patients with stable COPD and those with AECOPD using real-time PCR. 
This study was part of a randomised, double blind single centre study, and a total 
of 248 sputum samples from 104 COPD patients were included. In total, 122 stable 
state sputa and 126 exacerbation sputa were tested. Of the 122 stable state sputa, all 
samples were negative for M. pneumoniae and C. pneumoniae DNA, whereas one 
sample was positive for Legionella non-pneumophila DNA. Of the 126 exacerba-
tion sputa, all samples were negative for M. pneumoniae and C. pneumoniae DNA, 
whereas one sample was positive for Legionella non-pneumophila DNA. We inves-
tigated the possible relationship between presence of atypical pathogens in patients 
with stable COPD and in those with AECOPD using real-time PCR and found no 
indication for a role of Legionella spp, C. pneumoniae or M. pneumoniae in stable 
moderately severe COPD and in its exacerbations.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and 
mortality in adults. According to the Global Burden of Disease Study, COPD is the 
fifth most common disease and fourth leading cause of death in the world [1]. The 
chronic course of this disease is frequently accompanied by acute exacerbations, 
characterized by an acute sustained worsening of the patient’s condition from a 
stable state, beyond normal day-to-day variations which may warrant additional 
treatment [2]. Morbidity and mortality in COPD patients are, for the most part, 
related to acute exacerbations of COPD (AECOPD), which occur one to three times 
a year on average.
The aetiology of AECOPD is heterogeneous and still under discussion. For many 
years, there has been controversy whether bacteria play a role in AECOPD, and 
thus, whether antibiotics play a role in disease management [3,4]. Several studies 
have shown an association between the presence of certain bacterial species such as 
Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae and 
AECOPD [3]. However, these potential pathogenic micro-organisms (PPMO) were 
also present in sputa obtained from COPD patients with stable disease [5]. Apart 
from these bacterial PPMO it was also shown that viral infections, with a prominent 
role for rhinoviruses, might trigger at least one-third of AECOPD [6]. Little is known 
about the presence of these viral PPMO in sputa obtained from COPD patients with 
stable disease.
The term “atypical pathogen” most commonly refers to Mycoplasma (M.)pneu-
moniae, Chlamydophila (C.) pneumoniae, and Legionella (L.)pneumophila. The role 
of these bacteria in AECOPD remains unclear. Serological studies suggest that these 
atypical pathogens may play an important role in AECOPD [7-17]. However, the 
interpretation of the role of these atypical pathogens in AECOPD is not easy since 
these organisms are difficult to cultivate from respiratory tract specimens. Also, vari-
ability among authors exists in the reliability and interpretation of the results of se-
rological assays. Molecular diagnostic techniques, such as polymerase chain reaction 
(PCR), have become useful tools for the etiological diagnosis of lower respiratory 
tract infections [18]. It can detect minute amounts of nucleic acids from potentially 
all PPMO, does not depend on the viability of the target microbe, is probably less 
affected by previous antimicrobial therapy than are culture-based methods, and can 
provide results quickly. For patients with pneumonia molecular techniques offer 
distinct advantages over conventional tests for the detection of M. pneumoniae, C. 
pneumoniae and Legionella spp. [18,19].
We investigated the presence of these atypical pathogens in sputum samples in 
patients with stable COPD and those with AECOPD using real-time PCR.
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PATIENTS AND METHODS
Patients
From May 1999 through March 2000, patients were recruited from the outpatient 
pulmonary clinic of the Medisch Spectrum Twente, a 1150-bed teaching hospital 
in Enschede, the Netherlands, as described previously [5,20]. The patients met the 
following criteria: (i) a clinical diagnosis of stable COPD, as defined by the American 
Thoracic Society criteria; (ii) no history of asthma; (iii) no exacerbation in the month 
prior to enrolment; (iv) current or former smoker; (v) age between 40 and 75 years; 
(vi) a baseline prebronchodilator forced expiratory volume in 1 s (FEV1) of 25 to 
80% predicted; (vii) a prebronchodilator ratio of FEV1 to inspiratory vital capacity 
value of 60% or less; (viii) reversibility value of FEV1 postinhalation of 80 µg of 
ipratropium bromide via a metered dose inhalator with Aerochamber of 12% the 
predicted value or less; (ix) a total lung capacity that was higher than the predicted 
total lung capacity minus 1.64 x the standard deviation; (x) no maintenance treatment 
with oral steroids or antibiotics; (xi) no medical condition with a low survival rate or 
serious psychiatric morbidity (e.g., cardiac insufficiency or alcoholism); (xii) absence 
of any other active lung disease (e.g., sarcoidosis). The hospital’s medical ethical 
committee approved this study. All patients provided written informed consent.
Study protocol
This study was part of a randomised, double blind single centre study, investigating 
the role of inhaled corticosteroids in COPD [20]. From this study, spontaneously 
expectorated sputum samples of patients were obtained at 0, 4, 7, and 10 months 
in stable disease and an additional sputum sample was collected at each hospital 
visit for an acute exacerbation of COPD. Clinically, exacerbations were defined as 
worsening of respiratory symptoms that made the patient contact the study office 
resulting in treatment by the study physician.
Sputum samples
Sputa were collected at scheduled visits to the outpatient department and in cases of 
exacerbation. Spontaneously expectorated sputum was collected in sterile vials and 
processed in the laboratory within 4 h after collection. Total sputum samples were 
homogenized by incubation at 37°C for 15 min with an equal volume of 0.1% di-
thiothreitol. Gram-stained sputum samples were examined microscopically and had 
to contain <105 epithelial cells per mL-1 (i.e., <1 epithelial cell per high-power field) 
to be considered as representative bronchial samples. Polymorphonuclear cell count 
was not one of the criteria.
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DNA extraction
200 µl of sputum was processed with the NucliSens® easyMAG™ platform, (bio-
Mérieux, La Balme Les Grottes, France) with an elution volume of 50 µl according 
to the manufacturer’s instructions. 5 µl of the eluate was used as template in PCR. 
DNA was stored at -20°C until PCR was performed.
PCR assays
For the detection of C. pneumoniae an assay based on the nucleotide sequences of 
VD2 and VD4 of the ompA gene of C. pneumoniae was used [21]. For the detection 
of Legionella two separate assays were used, targeted at specific regions within the 5S 
rRNA and the mip gene. The primers of the first Legionella spp. PCR-probe assay is 
based on the primers described by Lindsay et al. [22], and detected in real-time using 
a TaqMan probe Leg5S [23]. The second PCR was a L. pneumophila-specific PCR 
based on the sequences of the mip gene [23]. For the detection of M. pneumoniae 
an assay based on the P1 adhesin gene was used [24]. In short, primer M1 (forward 
5’GGT CAA TCT GGC GTG GAT CT 3’) and M2 (5’ TGG TAA CTG CCC CAC 
AAG C 3’) were used to obtain a 66 bp amplicon. Real-time detection was done with 
a fluorescent Taqman probe (5’TCCCCC GTT GAA AAA GTG AGT GGG T’ FAM). 
Real–time PCR for all assays was performed on a Abiprism®7900HT Sequence 
Detection System (Applied Biosystems, Foster City, California, USA). Results were 
expressed as threshold cycle values (Ct), corresponding to the cycle at which PCR 
enters the exponential phase; Ct values are proportional to the negative logarithm 
of the initial amount of input cDNA. If no increase in fluorescent signal is observed 
after 50 cycles, the sample is assumed to be negative.
RESULTS
104 patients (median age 63 years; range 45-75 years; 86 men, 18 women) provided 
a total of 248 sputum samples. 122 samples were obtained during stable disease and 
126 sputa were obtained during AECOPD. 76 patients provided both stable state and 
AECOPD samples, 18 patients provided stable state samples only, and 10 patients 
provided AECOPD samples only. Because a substantial percentage of patients were 
unable to spontaneously expectorate an adequate sputum sample, and because we 
only used microscopically representive sputum samples, the number of stable state 
sputa is lower than theoretically expected. Of the 122 stable state sputa, all samples 
were negative for M. pneumoniae and C. pneumoniae DNA, whereas one sample 
was positive for Legionella non-pneumophila DNA (positive in 5S rRNA based PCR, 
negative in mip gene based PCR, Ct value 40). Of the 126 exacerbation sputa, all 
samples were negative for M. pneumoniae and C. pneumoniae DNA, whereas one 
sample was positive for Legionella non-pneumophila DNA (positive in 5S rRNA 
based PCR [Ct value 43], negative in mip gene based PCR). The Legionella positive 
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samples were obtained from different patients. In both Legionella positive samples S. 
pneumoniae was cultured a level of growth of >105 cfu/ml.
DISCUSSION
The possible relationship between the presence of atypical pathogens and the aetiol-
ogy of AECOPD in patients with stable COPD and in those with AECOPD was 
investigated using real-time PCR. No indication was found of a role for Legionella 
spp., C. pneumoniae or M. pneumoniae in COPD. Several potential contributions 
of bacterial infection to the aetiology, pathogenesis, and clinical course of COPD 
can be identified. With regards to microbial patterns and their possible involvement 
in the aetiology of AECOPD, it is a common view that Haemophilus influenzae, 
Streptococcus pneumoniae, and Moraxella catarrhalis are the leading pathogens. 
Viruses have also been shown to cause acute exacerbations, frequently working as 
co-pathogens together with bacterial pathogens [3,25]. Recently, extensions of this 
concept have been provided. In several studies serological evidence of C. pneumoniae, 
Legionella spp. and M. pneumoniae playing a role as a pathogen or co-pathogen in 
acute exacerbations has been reported [7-17]. One of the major issues not addressed 
in any of the seroepidemiologic studies is the correlation of serology with infection 
as defined either by isolation of the organism in culture or by PCR. The lack of 
standardization for performance of serological test has made the interpretation of 
these published data from different laboratories in COPD patients difficult and, in 
our view, debatable.
M. pneumoniae is a common cause of community-acquired pneumonia [2]. Lieber-
man et al. found M. pneumoniae to be the cause of AECOPD in 34 out of 240 (14%) 
hospitalised patients [7], higher than other reports about the microbiological aetiol-
ogy in AECOPD. In 24 of these 34 patients (71%), there was serological evidence of 
infection with at least one other respiratory agent in addition to M. pneumoniae. Pa-
tients that received antibiotics against M. pneumoniae did not have a better outcome 
in terms of a shorter hospital stay. The trend was actually in the opposite direction, 
the mean length of hospitalisation for AECOPD was 1.2 days less (5.3 versus 4.2 
days). In three older studies, M. pneumoniae as possible aetiology in AECOPD was 
identified in 0.5% - 2.4% of AECOPD [26-28]. In a more recent study, Soler et al. 
did not find a single case of infection due to M. pneumoniae in a group of patients 
with severe COPD [29]. M. pneumoniae is a fastidious organism, and culture is 
time-consuming, and lacks sensitivity. Consequently, the laboratory diagnosis of M. 
pneumoniae infection has largely relied on commercially available serological tests, 
most often enzyme immunoassays (EIAs), microparticle agglutination assays (MAG) 
and the complement fixation test (CFT). However, few of these commercial assays 
have appropriate performances in terms of sensitivity and specificity, and therefore 
some authors consider nucleic acid amplification the preferred diagnostic procedure 
for the diagnosis of M. pneumoniae infections [30].
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In a study by Lieberman et al., 17% of hospital admissions for AECOPD showed 
serological evidence of acute infection with Legionella spp. [9]. Our findings are in 
concordance with those found by Soler et al. who found no serological evidence for 
infection with L. pneumophila in a group of patients with severe COPD [29]. An 
exhaustive review of AECOPD studies that have focused on the search of an aetio-
logical agent by means of invasive procedures, such as bronchoscopic techniques, 
shows that Legionella spp. have never been identified using culture [2]. A disadvan-
tage of serological testing is the inability to accurately detect all Legionella spp. and 
serogroups. Although seroconversion to L. pneumophila serogroup 1 is generally 
regarded as being highly diagnostic, the sensitivity and specificity of seroconversion 
to other species and serogroups has not been rigorously confirmed [19,31]. Legio-
nella colonization in COPD patients has never been detected and does not seem to 
be a risk factor for exacerbations in these patients. Of all pneumonia pathogens, 
Legionella non-pneumophila spp. probably presents the greatest risk for contamina-
tion measured in PCR, given the organism’s ubiquitous environmental presence [18]. 
Because of the high Ct values observed in both samples, amplification and detection 
of environmental Legionella DNA cannot be completely excluded.
C. pneumoniae has been reported to cause between 4% -16% of AECOPD, an 
observation based almost solely on serological evidence [14-17]. Studies of C. pneu-
moniae in COPD are complicated by several observations. Use of cell culture for 
detection of C. pneumoniae is technically demanding and time-consuming, and cell 
cultures generally have a low yield. As a consequence, the diagnosis of C. pneumoniae 
infection largely relies on serological testing using microimmunofluorescence (MIF). 
The pitfalls in C. pneumoniae serological testing are well known. Reports from dif-
ferent laboratories are highly variable and adequate evaluations compared to a “gold 
standard” are lacking, which had led for calls for more standardized approaches 
in diagnostic testing [32]. Background rates of seropositivity by MIF can also be 
very high in some adult populations, sometimes exceeding 80% [33]. In addition, 
smoking is associated with increased levels of serum antibodies to C. pneumoniae 
in patients with and without COPD and serological conversion occurs even in the 
absence of symptoms [2, 21]. In 1988 it was reported that patients with coronary 
artery disease carry significantly more anti C. pneumoniae immunoglobulin G (IgG) 
and IgA antibodies in their bloodstream than healthy controls [34]. Although initial 
reports were positive, the later ones, often prospectively designed and adjusted for 
known cardiovascular risk factors, showed a negative or weak positive association 
overall between seropositivity for C. pneumoniae and atherosclerosis. Methodology 
has a strong impact on the possible association between C. pneumoniae and athero-
sclerosis: detection of the link between C. pneumoniae and coronary artery disease 
depends on the serologic methodology chosen [35-37].
Our PCR results are in disagreement with those reported by Blasi et al. which 
showed that C. pneumoniae DNA detection is associated with higher rates of ex-
acerbation and airway microbial colonisation in patients with COPD [38]. Of the 
42 patients enrolled, those whose respiratory samples were C. pneumoniae DNA 
PCR positive (38%) had a significantly greater number of pathogens on sputum 
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culture than PCR negative patients. Blasi et al. also found that C. pneumoniae posi-
tive patients (in stable COPD) had a greater tendency towards frequent exacerbation, 
although this difference in exacerbation frequency between the two groups was small 
(0.6 exacerbations per year). In a smaller, but similar study, Seemungul et al. found 
no relationship between C. pneumoniae DNA detection in the airway at exacerba-
tion and exacerbation frequency [39]. The reported discrepancy in PCR positivity 
on respiratory samples between our study and that of Blasi et al. may be due to a 
number of reasons, including differences in PCR techniques used (real-time instead 
of conventional, differences in DNA polymerases, decontaminate with dUTP-uracil-
DNA glycosylase, the use of specific probes, inclusion of sufficient controls, and the 
use of molecular grade water [35, 36]), and differences in study design and study 
population. In the current authors’ view, real-time PCR is the current standard in 
the clinical microbiology laboratory, and the question of cross-contamination occurs 
whenever a nested PCR is performed. In this sense, the results of studies that use 
nested PCR to determine the prevalence of C. pneumoniae will always be question-
able [40].
We only included patients with less severe COPD (GOLD classification of severity 
stage I and II) and therefore the prevalence of atypical pathogens might be differ-
ent in patients with more severe disease. However, we don’t think this explains the 
differences found in our study as compared to other serology based studies. In our 
view, the serological evidence of C. pneumoniae, Legionella spp. and M. pneumoniae 
playing a role as a pathogen or co-pathogen in AECOPD simply reflects the principal 
methodological problems of diagnosing such infections. The use of a less specific di-
agnostic method for the detection of a pathogen, will, from a statistical point of view, 
increase the likelihood of false-positive reactions. Concern for serology specificity 
is even higher when a large percentage of other co-infecions are also serologically 
identified [7-10].
Although it is difficult to draw general conclusions or even indications for standard 
care on the basis of the results of the present study, the current data provide indi-
rect evidence against the clinical practice of prescribing antibiotics to patients with 
AECOPD. From the results of the present study it can be concluded that in patients 
with less severe COPD antibiotics directed at atypical pathogens are not necessary. 
However, prospective controlled trials are needed to really address the question of 
the effectiveness of antibiotic therapy directed against atypical respiratory pathogens 
and AECOPD.
In summary, in using real-time PCR to search for an association between the pres-
ence of atypical pathogens in patients with stable chronic obstructive pulmonary 
disease and in those patients with acute exacerbations of the disease, no indication 
was found of a role for Legionella spp., C. pneumoniae or M. pneumoniae in stable, 
moderately severe chronic obstructive pulmonary disease and in its exacerbations. 
The present study indicates that nonstandardised serology might introduce a false 
association between atypical pathogens and acute exacerbations of chronic obstruc-
tive pulmonary disease.
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Detection of Respiratory Viruses and Legionella spp. by Real-Time 
Polymerase Chain Reaction in patients with Community-Acquired 
Pneumonia
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ABSTRACT
We conducted a study on oropharyngeal swabs obtained from a group of hospi-
talised patients with community-acquired pneumonia (CAP). Oropharyngeal swab 
specimens from 242 adults admitted to hospital with CAP were tested. In total, one 
or more etiologic agents were identified by real-time PCR in 55 (23%) patients. 
The most frequently detected pathogens were coronavirus (17%), parainfluenza 
virus (6%) and influenza virus (4%). Overall, viral pathogens were identified by 
conventional techniques in 7 (2%) patients, and real-time PCR in 50 (21%) patients 
(p<0.0001). The diagnostic yield increased from 137 cases (57% of patients using 
conventional microbiological assays) to 158 cases (65% of patients using real-time 
PCR assays and conventional microbiological assays; p=0.06). L. pneumophila PCR 
was positive in only 3 out of 11 cases (27%) of Legionnaires’ Disease (LD). This study 
demonstrates that real-time PCR can increase the number of microbiological detec-
tion of respiratory pathogens, mainly a result of detection of respiratory viruses.
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INTRODUCTION
Attempts to determine the relative roles of bacterial and viral pathogens as etiologi-
cal agents of community-acquired pneumonia (CAP) have yielded widely divergent 
results [1,2,3]. It is known that in studies on the etiology of CAP, in up to 50% of 
patients the etiologic agent cannot be identified [2]. Moreover, in daily practice, the 
cause of CAP is identified in only 6% of outpatients and 25% of inpatients [2]. For 
many respiratory pathogens, especially viruses, PCR has been shown to be more 
sensitive than conventional microbiological methods [4,5]. Therefore, this technique 
could help to increase the number of microbiological diagnosis for patients with 
CAP. In a recent prospective study [1] that evaluated the diagnostic yield of different 
microbiological tests (culture of sputum, bronchoalveolar lavage, and blood; detec-
tion of Legionella pneumophila and pneumococcal antigen in urine; serology for the 
detection of antibodies against respiratory pathogens such as Mycoplasma pneumo-
niae, and Chlamydia pneumoniae) in hospitalised patients with CAP, a pathogen 
was identified in 158 (60%) patients, with Streptococcus pneumoniae (n=97) being 
the most common causative agent. However, the microbiological yield in this study 
might have been higher if investigations such as PCR for viral pathogens and atypical 
pathogens (e.g. Legionella spp.) had been performed. Therefore, we conducted a 
study on oropharyngeal swabs obtained from this group of hospitalised CAP patients 
[1] to evaluate if the use of real-time PCR for detection of respiratory viruses and 
Legionella spp. would increase the diagnostic yield.
MATERIAL AND METHODS
Patients
Oropharyngeal swab specimens from 242 adults admitted to hospital with CAP were 
tested for the presence of respiratory viruses and Legionella spp. The patients were 
recruited as part of a prospective study, performed between December 1998 and No-
vember 2000 in the Departments of Pulmonary Diseases and Internal Medicine of the 
Medical Centre Alkmaar, a 900-bed teaching hospital [1]. This study was primarily 
set up to evaluate the effects of long and short term antimicrobial therapy. Patients 
who fulfilled the following criteria were enrolled in the study after giving written 
informed consent: (i) age ≥18 years, (ii) clinical presentation of an acute illness with 
one or more of the following symptoms suggesting CAP: presence of fever (≥38.0°C), 
dyspnoea, coughing (with or without expectoration of sputum), chest pain; and (iii) 
presence of new consolidation(s) on chest radiograph. Patients were excluded from 
the study if any of the following criteria applied: presence of severe immunosuppres-
sion (HIV infection, prednisolone >35 mg/day or other immunosuppressive agents); 
presence of malignancy, pregnancy or lactation, documented severe allergy to antibi-
otics, presence of obstruction pneumonia, development of pneumonia within 8 days 
after hospital discharge.
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Conventional microbiological investigations
Sputum specimens were obtained at admission for Gram stain (presence of >25 poly-
morphonuclear leucocytes and <10 squamous epithelial cells at ×100 magnification), 
semiquantitative culture, and detection of S. pneumoniae capsular antigen (latex ag-
glutination test; Murex Diagnostics, Dartford, UK). A test to detect pneumococcal 
antigen (PCA; NOW ICT Streptococcus pneumoniae; Binax) in sputum was per-
formed on adequate and inadequate sputum samples. Three sets of blood cultures 
were obtained within 1 h after admission, and a urine sample for detection of L. 
pneumophila serogroup 1 (Legionella Urinary Antigen EIA; Binax, Portland, ME, 
USA) was obtained. Bronchoalveolar lavage (BAL) and protected specimen brush 
(PSB) sampling were performed, after informed consent, if patients did not expecto-
rate sputum within 24 h after admission or in case of treatment failure. BAL fluids 
(BALF) and PSB specimens were processed for Gram stain, semiquantitative culture, 
and detection of S. pneumoniae capsular antigen (latex agglutination test). Thora-
centesis was performed if pleural fluid was present; this material was investigated by 
Gram stain, latex agglutination test for detection of PCA, and culture for aerobic 
and anaerobic bacteria. If pleural fluid was detected in the emergency room, it was 
obtained for microbial investigation before the administration of antibiotic therapy. 
Urine samples obtained from all patients at admission were analysed for the presence 
of S. pneumoniae cell-wall antigen (NOW ICT Streptococcus pneumoniae; Binax), 
and were further tested after 50-fold concentration.
Serological investigation was performed using an enzyme-linked immunoassay (Se-
rion ELISA Classic; Virion, Wurzburg, Germany). Blood samples were drawn on days 
1 and 14 of treatment for the detection of antibodies to Mycoplasma pneumoniae, 
Chlamydia pneumoniae, L. pneumophila serogroup 1–7, influenza A and B virus, 
parainfluenza virus 1–3, respiratory syncytial virus, and adenovirus. On day 28, a 
third blood sample for serological investigation was taken if an inconclusive increase 
in antibody level was observed between the first two samples. Samples were tested, 
and the results were interpreted in accordance with the package inserts provided with 
the assays.
Definitive aetiology was defined as follows: (i) identification of an aetiologic agent 
from blood and/or pleural fluid, (ii) the detection of L. pneumophila serogroup 
1 antigen in urine, (iii) the presence of S. pneumoniae antigen in pleural fluid, or 
(iv) a significant increase in antibody level of L. pneumophila serogroup 1–7, M. 
pneumoniae, C. pneumoniae, influenza A and B, parainfluenza virus 1–3, respira-
tory syncytial virus, or adenovirus. Presumptive aetiology was defined as (i) positive 
culture of sputum, BALF, or PSB specimen by semiquantitative methods, (ii) detec-
tion of S. pneumoniae antigen in urine, sputum, BALF, or PSB specimen, or (iii) a 
single elevated IgM level of >17 U/ml for M. pneumoniae. In the current study the 
results obtained in real-time PCR are compared to the overall results in conventional 
microbiology, i.e. both presumptive and definitive micriobiological aetiology.
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Real-time PCR
In addition to specimens described earlier, oropharyngeal swab specimens were 
obtained at admission with dacron polyester tipped swabs. After collection, swabs 
were placed in 5 ml of Hanks’ Balanced Salt Solution (MP products, Amersfoort, 
The Netherlands) and stored at -70°C. Nucleic acids were extracted using the total 
nucleic acid protocol with the MagNA pure LC nucleic acid isolation system (Roche 
Diagnostics). Each sample was eluted in 100 µL of buffer, which was sufficient for 
all PCR analyses. For the detection of Legionella two assays were used, targeted 
at specific regions within the 5S rRNA gene (detects all Legionella species) and the 
mip gene (only detects L. pneumophila) [6]. For the detection of respiratory viruses 
(influenza virus A and influenza virus B, respiratory syncytial virus, human coro-
navirus 229E and OC43, human metapneumovirus, parainfluenza 1-4 and human 
rhinoviruses), cDNA was synthesized using the one-step Quantitect RT-PCR kit 
(Qiagen) and commercially obtained primers (RealAccurate Respiratory RT PCR 
Kit, Pathofinder, Maastricht, the Netherlands). Primers and probes for influenza 
virus A and influenza virus B [7], respiratory syncytial virus [8], human coronavirus 
229E and OC43 [9], and human metapneumovirus [10] were modified from those 
described in the cited literature. The modifications made are proprietary. Reverse 
transcription was carried out for 30 min at 50°C. Subsequently, real-time PCR was 
performed using primers and probes of the RealAccurate Respiratory RT PCR Kit on 
an Abiprism®7900HT Sequence Detection System (Applied Biosystems) according 
to the manufacturer’s protocol.
RESULTS
Conventional diagnostic analyses yielded at least one potential pathogen in specimens 
from 137 (57%) out of 242 included patients (table 1). The most common pathogen 
was S. pneumoniae, present in 88 (36%) patients, followed by M. pneumoniae in 16 
(7%) patients, L. pneumophila in 11 (4%), and Haemophilus influenzae in 11 (4%) 
patients. A mixed infection, consisting of the combination of two or more respiratory 
pathogens, was present in 15 (6%) patients.
In total, one or more etiologic agents were identified by real-time PCR in 55 (23%) 
patients (table 1). One of the 242 tested samples was found to contain inhibitory 
compounds. The most frequently detected pathogens were coronavirus (19 patients 
[8%]), parainfluenza virus (15 [6%]) and influenza virus (11 [4%]). Overall, viral 
pathogens were identified by conventional techniques (serology) in 7 (2%) patients, 
and real-time PCR in 50 (21%) patients (p<0.0001). There was no agreement be-
tween PCR and serology in the 7 serology positive patients; PCR was negative in 5 
patients, and PCR positive for coronavirus in 2 patients.
In 21 patients, no microbiological agent was found with conventional diagnostic 
methods, but these patients had a positive PCR result, increasing the diagnostic yield 
from 137 cases (57% of patients) to 158 cases (65% of patients; p=0.06). The single 
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pathogens detected were Legionella spp. (1), influenza virus (5), coronavirus (5), 
parainfluenza virus (5), respiratory syncytial virus (2), human metapneumovirus (1) 
and human rhinovirus (1). In one out of 21 patients a mixed viral infection of influ-
enza virus and parainfluenza virus was detected.
Table 1. Results of etiologic investigations for hospitalised patients with CAP in a study to detect respiratory 
viruses and Legionella spp. by real-time PCR.
Pathogen(s), according to
etiologic detection method(s)
no. (%)
of patients
(n = 242)
Conventional diagnostic techniques
Streptococcus pneumoniae 88 (36)
Haemophilus influenzae 11 (4)
Mycoplasma pneumoniae 16 (7)
Legionella pneumophila 11 (4)
Staphylococcus aureus  6 (3)
Moraxella catarrhalis  2 (1)
Chlamydia pneumoniae  1 (0)
Adenovirus  4 (2)
Parainfluenza virus  2 (1)
Respiratory syncytial virus  1 (0)
Mixed 15 (6)
Other  9 (4)
TaqMan-based real-time PCR
Influenza virus 11 (4)
Coronavirus 19 (8)
Rhinovirus  3 (1)
Parainfluenza virus 15 (6)
Respiratory syncytial virus  3 (1)
Human metapneumovirus  2 (1)
Mixed viral etiology  3 (1)
Legionella pneumophila  3 (1)
Legionella spp.  2 (1)
Inhibited  1 (0)
Pathogens associated with mixed infections are also counted individually.
The combined results of conventional diagnostic analyses and real-time PCR, yielded 
a mixed infection in 43 out of 242 patients (18% [table 2]). The most common found 
copathogens were influenza virus, coronavirus and parainfluenza virus.
L. pneumophila PCR was positive in 3 out of 11 cases (27%) of Legionnaires’ 
Disease (LD) (table 3). Real-time PCR identified 2 additional cases of infection with 
Legionella species: in one patient it was the only etiologic agent found, the other 
was a possible co-infection with S. pneumoniae (positive sputum culture, negative 
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Table 2. Combined results of conventional diagnostic testing and real-time PCR for the detection of 
respiratory viruses and Legionella spp. in hospitalised patients with CAP.
Positive only in conventional diagnostic testing, single pathogen detected No. (%) of patients 
(n=242)
Streptococcus pneumoniae 61 (25)
Haemophilus influenzae 9 (4)
Mycoplasma pneumoniae 7 (3)
Legionella pneumophilaa 6 (3)
Staphylococcus aureus 3 (1)
Adenovirus 1 (0)
Otherb 6 (2)
Positive only in conventional diagnostic testing, 2 pathogens detected
Streptococcus pneumoniae + Mycoplasma pneumoniae 6 (2)
Other mixed etiologyc 6 (3)
Positive only in TaqMan-based real-time PCR positive, single pathogen detected
Influenza virus 5 (2)
Coronavirus 5 (2)
Rhinovirus 1 (0)
Parainfluenza virus 5 (2)
Respiratory syncytial virus 2 (1)
Human metapneumovirus 1 (0)
Legionella spp. 1 (0)
Positive only in TaqMan-based real-time PCR positive, two pathogens detected
Influenza virus + parainfluenza virus 1 (0)
Positive in both conventional diagnostic testing and TaqMan-based real-time PCR, two pathogens detected
Streptococcus pneumoniae + influenza virus 3 (1)
Streptococcus pneumoniae + coronavirus 7 (3)
Streptococcus pneumoniae + rhinovirus 1 (0)
Streptococcus pneumoniae + parainfluenza virus 5 (2)
Streptococcus pneumoniae + Legionella spp. 1 (0)
Legionella pneumophila + coronavirus 1 (0)
Legionella pneumophila + respiratory syncytial virus 1 (0)
Legionella pneumophila + parainfluenza virus 1 (0)
Legionella pneumophila + influenza virus 1 (0)
Moraxella catarrhalis + rhinovirus 1 (0)
Moraxella catarrhalis + human metapneumovirus 1 (0)
S. aureus + coronavirus 1 (0)
Parainfluenza virus + coronavirus 1 (0)
Klebsiella pneumoniae + parainfluenza virus 1 (0)
Positive in both conventional diagnostic testing and TaqMan-based real-time PCR, three pathogens detected
Streptococcus pneumoniae + parainfluenza virus + coronavirus 1 (0)
Legionella pneumophila + Mycoplasma pneumoniae + coronavirus 1 (0)
S. aureus + adenovirus + coronavirus 1 (0)
Mycoplasma pneumoniae + influenza virus + coronavirus 1 (0)
a Three L. pneumophila samples were confirmed in RT-PCR.
b Other single pathogens found: Escherichia coli (1), Citrobacter freundii (1), Pseudomonas aeruginosa (1), 
Staphylococcus haemolyticus (1), Haemophilus parainfluenzae (1).
c Other combinations found: Streptococcus pneumoniae + adenovirus (1), Haemophilus influenzae + parainfluenza 
virus (1), Haemophilus influenzae + Pseudomonas aeruginosa (1), Mycoplasma pneumoniae + S. aureus (1), 
Chlamydia pneumoniae + respiratory syncytial virus (1), adenovirus + parainfluenza virus (1).
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pneumococcal urinary antigen test). Thus, compared to results found with the uri-
nary antigen test, a calculated agreement, sensitivity, and specificity of 96%, 27%, 
and 99%, respectively, was found for PCR on oropharyngeal samples.
Table 3. Results of 241 non-inhibited samples tested with PCR on throat samples for the detection of 
Legionella specific DNA in patients with and without Legionnaires’ disease (LD). Samples were tested for 
Legionella spp. DNA in 5S rRNA based PCR and L. pneumophila in mip gene based PCR.
LD
Positive Negative
PCR positive 3   2
PCR negative 8 228
A calculated agreement, sensitivity, and specificity of 96%, 27%, and 99%, respectively, was found for PCR 
on throat swab samples.
DISCUSSION
This study demonstrates that real-time PCR can increase the number of microbiologi-
cal detection of respiratory pathogens in patients with CAP from a little more than 
a half of the cases to nearly two thirds of patients. This increase was mainly a result 
of the detection of respiratory viruses, especially influenza virus, parainfluenza virus 
and human coronaviruses, which were not detected by serology. Respiratory virus 
infections were detected in 2% of cases, with conventional microbiological methods, 
but that rate increased tenfold with the addition of PCR. The results of this study are 
in agreement with several reports that describe the increased sensitivity of PCR for 
detection of respiratory viruses [5,8,11] compared to serology. Previous studies using 
conventional methods have achieved a microbiological detection rate of 52%-83% in 
CAP patients [2]. The reality of clinical practice is that the majority of patients with 
CAP undergo very few diagnostic tests for an etiological agent, other than blood tests 
(including serology) and, if available, bacterial sputum cultures. Rapid assessment of 
a viral and bacterial etiology is now possible with novel sensitive and highly specific 
real-time PCR assays. Despite impressive development over the last years, none of 
these assays is yet readily available or in widespread routine use. This situation may 
change soon with the introduction of commercial nucleic acid amplification assays 
specific for the diagnosis of respiratory tract infections [12,13].
As in most other studies on hospitalized patients with CAP, S. pneumoniae was 
the leading bacterial organism detected (in 36% of cases). Legionella is implicated 
in 0.5%-6% of CAP cases in most hospital-based series [14,15]. Although the fre-
quency of Legionella infection in this study (5%) is similar to that in some other 
studies, these infection rates are probably higher than what is normally expected in 
The Netherlands because an epidemic occurred during the study period [16].
That only a single causative pathogen is responsible for the episode of CAP in 
an individual has long been assumed [14]. However, we identified more than one 
pathogen in 18% of patients. The issue of mixed infection remains unresolved. The 
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frequency of this phenomenon vary between studies for a number of reasons, most 
importantly depending on the diagnostic methods used. While many studies show a 
frequency of <10% of cases, as many as 27% [17] has been recorded as due to mixed 
infection in one study. When more than one organism is detected both may have 
contributed to the pneumonia. However, in most cases it is more likely that one agent 
may have been the initiating factor, e.g. by damaging the bronchial mucosa, and that 
it is the other organism that has caused the pneumonia. The relative importance 
of these two mechanisms is not yet known. Furthermore, a potentially pathogenic 
micro-organism can be detected without having involvement in the disease.
It is hard to determine the clinical significance of respiratory viruses as primary or 
secondary causes of CAP. A case-control method was used in a recent Dutch trial to 
estimate the incidence of acute respiratory tract infections in patients visiting their 
general practitioners (to determine the etiologic agents) and to test the hypothesis that 
asymptomatic persons with subclinical infection may act as sources of transmission. 
One of the interesting findings of the Dutch study was the fact that the researchers 
found potential pathogens in 30% of control subjects. Because we did not include 
control subjects we were unable to investigate whether a causal relationship between 
airway complaints and detected pathogens exists.
The rapid detection of respiratory viruses by immunofluorescence has lead to re-
ductions in the duration of hospital stay and antibiotic use among children [18]. 
Whether the recent developments in diagnostic testing have a beneficial impact on 
the management of adult patients with lower respiratory tract infections is less clear. 
Oosterheert et al. [11] conducted a randomized controlled trial involving 107 adults 
with lower respiratory tract infections at 2 Dutch hospitals. All patients had upper 
respiratory tract samples tested by real-time PCR for common respiratory viruses, 
M. pneumoniae, C. pneumoniae, and L. pneumophila. In the intervention group, 
results of the real-time TaqMan PCR had to be reported as soon as possible to the 
appropriate clinicians. In the control group, real-time PCR was performed, but re-
sults of PCR analysis were not made available to the treating physicians. All patients 
were followed up for up to 4 weeks, and the main outcome measures were change in 
antibiotic therapy, clinical outcome, and treatment costs. The main findings of this 
study were that real-time PCR significantly increased the diagnostic yield, compared 
with conventional diagnostic tests alone, but did not reduce antibiotic use, duration 
of hospital stay, or treatment costs. Indeed, treatment costs were much higher in 
the intervention group, and reporting of real-time PCR results led to partial or total 
cessation of antibiotic therapy for only 6 of 55 patients. Oosterheert et al. concluded 
that clinicians are hesitant to discontinue antibiotic therapy based on a virus-positive 
PCR result because they are waiting for bacterial culture results, which are available 
later than the PCR results, or the fear for a mixed infection. Therefore, it is doubtful 
that more rapid reporting of PCR results will lead to improved cost-effectiveness, 
unless bacterial results are made available just as rapid.
The sensitivity of PCR will vary with the sample type tested. For pneumonia, 
both respiratory and nonrespiratory samples have been used. Most studies have 
evaluated lower respiratory tract samples (especially sputum and bronchoalveolar 
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lavage samples), which are likely to have the highest diagnostic yield [19]. A major 
limitation of lower respiratory samples is that they may be difficult to obtain, and 
invasive procedures, such as bronchoscopy, are only performed for a few selected 
patients. For some pathogens that do not colonize the oropharynx, throat swab or 
oral wash samples may be useful and are usually easy to obtain. PCR has repeatedly 
been shown to have a sensitivity equal to or greater than culture in patients with 
LD, when used tot detect Legionella in sputum or bronchoalveolar lavage samples 
[19]. Oropharyngeal swabs may also be a suitable sample for PCR testing, but this 
application has only been evaluated in one very small study, in which 5 of 6 samples 
from patients with LD tested positive [20]. Templeton et al. [21], detected L. pneu-
mophila by PCR in two of 10 oropharyngeal swabs which were negative in culture; 
in these patients a recent Legionella infection was proven by serology. We detected L. 
pneumophila in only 3 throat samples out of 11 samples obtained from 11 patients 
with proven LD. This further indicates that oropharyngeal swabs are not reliable 
sample for Legionella PCR.
Not much is known about the incidence of sporadic community-acquired Legion-
ella non-pneumophila spp. infections, but these are considered to be extremely rare 
in immunocompetent patients [22]. We detected two Legionella non-pneumophila by 
PCR in two patients. However, the interpretation of these results is problematic, and 
must be applied with caution. The predictive values of PCR testing of nasopharyngeal 
or oropharyngeal swab samples for Legionella spp. are not yet sufficiently character-
ized. Of all the common pneumonia pathogens, Legionella species probably presents 
the greatest risk for PCR contamination, given the organism’s environmental habitat 
[23]. This was reflected by the detection of a co-pathogen in one sample, and the high 
Ct values obtained in both samples (37 and 38).
In conclusion, this study demonstrates that real-time PCR can increase the number 
of microbiological detection of respiratory pathogens, mainly a result of detection of 
respiratory viruses. Although detection of Legionella spp. is possible, oropharyngeal 
swabs are not suitable as a reliable sample for Legionella PCR. To better define the 
importance of Legionella non-pneumophila spp. in CAP, further studies employing 
culture and PCR on lower respiratory tract samples need to be performed.
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ABSTRACT
The main aim of our study was to determine the added value of PCR for the diagnosis 
of Legionnaire’s disease (LD) in routine clinical practice. Specimens where samples 
submitted for routine diagnosis of pneumonia from December 2002 to November 
2005, which included PCR analysis of lower respiratory tract samples for the detec-
tion of Legionella spp. Patients were evaluated if, in addition to PCR, results of one 
or more of the following diagnostic tests were available: (i) culture for Legionella 
spp. on BCYE agar, (2) detection of L. pneumophila antigen in urine specimens and 
(3) paired serum samples for detection of antibodies to L. pneumophila. Of the 155 
evaluated patients, 41 (26%) fulfilled the European Working Group on Legionella 
Infections (EWGLI) criteria for a confirmed case of LD. After discrepancy analysis, 
the estimated sensitivity, specificity, positive predictive value, and negative predictive 
value were 82%, 95%, 44% and 99% for the 16S rRNA assay, and 86%, 100%, 
100% and 99% for the mip-gene specific PCR, respectively. LD was diagnosed by 
urinary antigen testing alone in 35 patients, the same number as diagnosed by 16S 
rRNA based PCR. With the mip gene PCR two more cases of LD (37; NS) were 
detected. By combining urinary antigen test and and mip-gene PCR LD was diag-
nosed in an additional 5 (14%) patients compared to the use of the urinary antigen 
test alone. The addition of a Legionella pneumophila specific mip-gene PCR to the 
routine use of a urinary antigen test is useful in patients with suspected LD who 
produce sputum, and might allow the early detection of a significant number of extra 
patients.
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INTRODUCTION
Since the initial description of Legionnaires’ disease (LD) in 1976, Legionella (L.) 
pneumophila has been increasingly recognized as a pathogen causing both commu-
nity-acquired and nosocomial pneumonia [1,2,3]. Legionella spp. are responsible 
for 1 to 5% of cases of community-acquired pneumonia (CAP) [3,4,5]. Infection of 
humans usually occurs via inhalation of aerosols from a variety of man-made water 
systems. Although currently 50 species of Legionella [1,2] are recognized, only 19 
Legionella species have been documented as human pathogens on the basis of their 
isolation from clinical material. Although potentially all Legionella spp. may cause 
human disease, the majority (92%) of clinical cases are caused by L. pneumophila 
[5]. Microbiological diagnosis is warranted, as LD is clinically not distinguishable 
from other pneumonias. Timely and appropriate treatment improves the prognosis 
and can be achieved by rapid diagnosis [6].
Legionellae are slow-growing fastidious bacteria, and successful culture requires 
selective media and prolonged incubation periods. Culture on buffered charcoal 
yeast extract (BCYE) plates is the gold standard for the laboratory diagnosis of LD. 
Considerable interlaboratory variation has been documented for the ability to cul-
ture legionellae [2,7]. Serological diagnosis is also commonly used, and a sensitivity 
of 41 to 91% has been reported [2,7]. Unfortunately, a diagnosis by a fourfold im-
munoglobulin G (IgG) or IgM titer increase can only be made retrospectively, and 
rarely influences the initial treatment of the patient [2,8,9]. Therefore there is a need 
for additional tests to diagnose LD in the early stage of disease.
The urinary antigen test and nucleic acid amplification tests (NAAT), most often 
PCR, are useful for this purpose. Urinary antigen testing is now an established and 
valuable rapid tool for the diagnosis of LD particularly in regions where L. pneu-
mophila serogroup 1 is the most common cause of the disease. These tests provide 
results within 30 minutes and have sensitivities between 60% and 100% for patients 
with LD due to L. pneumohila serogroup 1 [10-13]. However, because these assays 
only detect a limited number of serogroups of L. pneumophila, some authors sug-
gest that total dependence on this diagnostic assay may miss up to 40% of cases of 
LD [2].
Nucleic acid amplification techniques are attractive tools for detection of legionel-
lae in clinical samples, as they detect all Legionella spp. and provide rapid results. 
Most diagnostic PCR assays have specific target regions within the 16S rRNA genes 
[14-19], the 23S-5S spacer region [20], 5S rDNA [17], or the macrophage inhibitor 
potentiator (mip) gene [14, 19, 21, 22, 23, 24, 25, 26]. Thus far, results obtained 
from in vitro evaluations and small patient series have been encouraging. When 
testing samples from the lower respiratory tract, PCR has repeatedly been shown 
to have a sensitivity equal to or greater than culture [17, 18, 27, 28]. However, 
false positive results have been reported [27,28], and the potential of false-positive 
results may have hindered a more widespread application of PCR. A problem with 
the interpretation of these “false positive” results is the question whether these are 
truly false-positive or whether the reference method failed, e.g. because less common 
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legionellae are not as easily detected by conventional methods [29]. It is difficult to 
solve this issue and at present, there are no well designed studies available that have 
determined the exact sensitivity and specificity of Legionella PCR in patients with 
pneumonia of unknown etiology.
At the Regional Public Health Laboratory, located at the St. Elisabeth Hospital, 
Tilburg, The Netherlands, we have used a repertoire of conventional diagnostic tests 
(serology, culture, urine antigen testing) as well as Legionella specific PCR (targeted 
at the 16S rRNA gene and mip gene) for several years. This study compares the re-
sults obtained with PCR with those of conventional testing on samples from patients 
suspected of having LD. The two main objectives of our study were the following. 
First, to determine the performance of PCR compared to that of conventional diag-
nostic tests in terms of sensitivity and specificity. Second, to evaluate the additional 
value of a Legionella-specific PCR for the diagnosis of LD, compared to the urinary 
antigen test.
MATERIALS AND METHODS
Patients
All data were collected retrospectively from the laboratory information system of the 
Regional Public Health Laboratory, located at the St. Elisabeth Hospital, Tilburg, 
The Netherlands. Specimens consisted of samples that were submitted for routine 
diagnosis of pneumonia from December 2002 to November 2005, which included 
PCR analysis of lower respiratory tract samples for the detection of Legionella spp. 
The conventional diagnostic testing (serology, urinary antigen, culture), PCR (16S 
rRNA and mip gene based) and the DNA extraction procedure were performed with 
identical protocols on all patient samples during this time period. The following 
lower respiratory samples were included: sputa, endotracheal aspirates, lung biopsy 
samples, and bronchoscopic specimens. PCR results obtained from throat swabs, 
pleural fluid or serum samples were not included for the present analysis. The pa-
tients were all hospitalized, suffered from symptoms compatible with pneumonia 
and showed radiological signs of infiltration. Samples were included from patients 
for whom, in addition to PCR, results of one or more of the following diagnostic tests 
for Legionella infection were available: (i) culture for Legionella spp. on buffered 
charcoal yeast extract (BCYE) agar supplemented with α-ketoglutarate, (2) detec-
tion of L. pneumophila antigen in urine specimens and (3) paired serum samples for 
detection of IgM and IgG antibodies to L. pneumophila. The criteria for paired sera 
were the following: acute-phase sera were taken between 0 and 15 days after hospital 
admission and convalescent-phase sera were collected at least 21 days later. Only 
the first available respiratory sample from a particular patient was included, and all 
other additional results (if available) were excluded from the analysis.
A case of confirmed Legionella pneumonia was defined according to the European 
Working Group on Legionella Infections (EWGLI) criteria. Laboratory evidence 
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included one or more of the following criteria: (i) Isolation of Legionella spp. from a 
respiratory sample. (ii) Presence of L. pneumophila antigens in urine specimens. (iii) 
Seroconversion for IgM and/or IgG antibodies to L. pneumophila in paired acute-
phase and convalescent-phase sera.
METHODS
Culture
Each specimen was aliquoted into two samples, one was sent to the molecular biol-
ogy laboratory for PCR, and the other was applied to BCYE agar and BCYE agar 
with polymyxin B, anisomycin, and vancomycin (Oxoid, Haarlem, The Netherlands). 
Lower respiratory tract specimens were plated undiluted. Specimens were processed 
upon receipt. The plates were incubated at 35°C with 70 to 80% relative humidity. 
All cultures were examined daily for 7 days before final reporting of results. Visible 
colonies were subcultured onto a BCYE agar plate and a blood agar plate with 5% 
sheep blood (Oxoid, Haarlem, The Netherlands). Bacteria that grew on BCYE agar 
but not on a blood agar plate were considered possible Legionella spp. and were 
tested with a slide agglutination test (Dryspot Legionella Latex test, Oxoid, Haarlem 
The Netherlands). The latex test allows separate identification of L. pneumophila 
serogroup 1 and serogroups 2-14 and detection of seven other Legionella species (L. 
longbeachae 1 & 2, L. bozemanii 1 & 2, L. dumoffii, L. gormanii, L. jordanis, L. 
micdadei, L. anisa). If the agglutination with the isolate was negative, the organism 
was sent to the molecular laboratory for further identification.
Urinary antigen detection
Presence of L. pneumophila antigens in urine specimens was determined with a 
qualitative immunochromatographic assay (Binax now; Binax, USA).
Serology
Seroconversion for IgM and/or IgG antibodies to L. pneumophila in paired acute-
phase and convalescent-phase sera was determined using a commercial enzyme-linked 
immunosorbent assay (ELISA) (L. pneumophila serotype 1 to 7 antibodies, Serion 
ELISA; Institut Virion\Serion GmbH, Würzburg, Germany). The antigens in this test 
are prepared from cultures of different L. pneumophila serogroups and subtypes: 
serogroup 1 Knoxville and Philadelphia subtype, serogroup 2 Togus-1 subtype, se-
rogroup 3 Bloomington-2 subtype, serogroup 4 Los Angeles-1 subtype, serogroup 
5 Dallas-1 subtype, serogroup 6 Chicago-2 subtype, and serogroup 7 Chicago-8 
subtype.
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Extraction of DNA from respiratory samples
(i) Sample preparation. Prior to DNA isolation, all respiratory samples were pro-
cessed with MagNALyser® (Roche Diagnostics) according to the manufacturer’s 
instructions.
(ii) DNA extraction. After treatment with MagNALyser®, 200 µl of sample was 
processed in the MagNA Pure LC® isolation robot, using the Total Nucleic Acid 
isolation Kit (Roche Diagnostics) with an elution volume of 50 µl. 5 µl of the eluate 
was used as template in PCR. The remainder of the eluate was stored at -20°C, the 
remainder of the original sample was stored at -70°C.
(iii) Control material. As internal control Phocid Herpes Virus (PhHV) was added to 
the samples to monitor processing, DNA extraction and inhibition of PCR. Detec-
tion of PhHV was included in the mip gene PCR. In each run a no-template control 
(mixcontrol) was included. Sensitivity controls in PCR consisted of 10-fold dilutions 
of L. pneumophila DNA ranging from 1000 fg to 10 fg (approximately 230 to 2,3 
genome equivalents). 1000 fg of L. bozemanii DNA served as control in the 16S 
rRNA based PCR for discrimination between L. pneumophila and other Legionella 
species. Primers and probes were synthesized by Applied Biosystems (ABI, Nieu-
werkerk a/d IJssel, The Netherlands).
Real-time PCR
Between December 2002 and November 2005 two Legionella-specific PCR assays 
were used, targeted at specific regions within the 16S rRNA gene and the mip gene, 
as described previously [30]. In the dual-color two probe 16S rRNA based PCR 
assay primers Leg1 (forward 5’-TACCTACCCTTGACATACAGTG-3’) and Leg2 
(reverse 5’-CTTCCTCCGGTTTGTCAC-3’) were used to obtain a 200 bp am-
plicon. Real-time detection was done with a Legionella genus specific fluorescent 
probe (LSPP: VIC-5’-GGTTGCGTCGTTACG-3’) conjugated to a minor groove 
binder (MGB). A L. pneumophila specific fluorescent MGB probe (LPN: FAM -5’-
GAGTCCCCACCATCACATG-3’) was used on the complementary DNA strand. In 
the L. pneumophila-specific PCR based on the sequences of the mip gene, primers 
Mip-F1 (forward 5’-GCCAAGTGGTTTGCAATACAAA-’3) and MipR1 (reverse 5’-
CTCGACAGTGACTGTATCCGATTT-’3) were used to obtain a 80 bp amplicon. 
Real-time detection was done with TaqMan probe Lpn-mip (FAM-5’ TAATCAAT-
GCTGGAAATGGTGTTAAACCCG-3’-TAMRA). When inhibition of the PCR reac-
tion was observed, DNA extraction and PCR were repeated. If inhibitors of the PCR 
reactions could not be removed, the result was reported as inhibited in the laboratory 
information system.
PCR conditions
Real–time PCR was performed on a Abiprism®7900HT Sequence Detection System 
(Applied Biosystems, Foster City, California, USA). DNA was amplified according to 
the following parameters: after 2 min incubation at 50°C and 10 min denaturation at 
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95°C, amplification consisted of 50 cycles of 15 sec of denaturation at 95°C followed 
by 1 min of annealing and extension at 60°C.
Interpretation of PCR results
Results of the real-time PCR were expressed as threshold cycle (Ct) values, cor-
responding to the cycle at which PCR enters the exponential phase. If no increase in 
fluorescent signal is observed after 50 cycles, the sample is assumed to be negative. 
Results obtained with conventional testing for Legionella spp. were compared to 
those found in real-time PCR. Three PCR results were available: (1) the result of the 
16S based PCR assay, (2) the result of the mip-based PCR assay and (3) the official 
reported result in the laboratory information system. The dual-color two probe 16S 
based PCR assay is positive for L. pneumophila if double amplification curves are 
obtained (both probes react). When non-pneumophila Legionella species are ampli-
fied, only one amplification curve is present since the L. pneumophila specific probe 
cannot bind. A postive result in the mip gene PCR is considered positive for L. 
pneumophila. All positive results in mip and/or 16S PCR were confirmed in a second 
PCR run after a second DNA isolation of the respiratory sample.
Discrepant analysis
To resolve possible false-positive results of PCR, the samples showing discordant 
results were further tested. A maximum of three additional tests, depending of the 
amount of sample available, were performed to determine whether the positive PCR 
test results could be confirmed. Three approaches were taken:
(i) Approach 1: repeat testing for confirmation of positive results. As outlined 
above, all positive results in mip and/or 16S PCR were confirmed in a second PCR 
run after a second DNA isolation procedure of the respiratory sample.
(ii) Approach 2: use of a different PCR for confirmation. For the confirmation of 
Legionella positivity in respiratory samples the following PCR assays were used: (1) 
the result of the 16S based PCR assay for mip PCR positive samples, (2) the result of 
the mip-based PCR assay for samples positive for L. pneumophila in 16S rRNA PCR, 
(3) a Legionella spp. assay targeted at specific regions within the 5S rRNA gene [30], 
and (4) the results of two different assays targeted at the mip and 16S rRNA gene, 
performed at a different Laboratory [28].
(iii) Approach 3: confirmation of 16S rRNA PCR positive discrepant results by 
sequencing. Identification of discordant Legionella non-pneumophila PCR positives 
was attempted by PCR reamplification and sequence analysis of the 200 bp 16S 
rRNA gene fragment. The primers used for sequencing analysis of DNA samples 
with discrepant results were the same as outlined above; Leg1 and Leg 2. Sequence 
analysis of the 16S rRNA gene fragment was performed at Base Clear, Leiden, The 
Netherlands. The sequences obtained were compared with those submitted to the 
GenBank database by BLAST (http://www.ncbi.nlm.nih.gov/BLAST/).
A result was considered confirmed if it was reproducible (approach 1) and if it was 
positive for Legionella in approach 2 and/or 3.
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Statistical analysis
Clinical sensitivity and specificity of the assays were determined using two-by-two 
contingency tables. Diagnostic sensitivity was defined as the fraction of the patients 
correctly identified in PCR as having LD. The agreement, sensitivity and specificity of 
the separate PCR assays and the final PCR results were determined by comparing the 
results with those obtained with isolation, serology and urinary antigen testing. The 
agreement represents the proportion of samples similarly classified by conventional 
techniques and PCR. Samples that were inhibited in PCR were not included in the 
calculations. Confidence intervals were determined using the adjusted Wald method.
RESULTS
Patients characteristics
Samples were obtained between November 2002 and December 2005. A total of 155 
patients fulfilled the criteria outlined in materials and methods and were available for 
evaluation in this study. Of the included patients, 95 (62%) were men, with a mean 
age of 57 years (range 23-85 years) and 60 were women with a mean age of 60 years 
(range 25-85 years). Of the 155 included patients, 41 (26%) fulfilled the EWGLI 
criteria for a confirmed case of LD. The median age of the 41 confirmed LD patients 
was 55 years (range 23 to 74 years), and the male:female ratio was 2.2:1 (28 men, 
13 women). The median age of non-LD patients was 60 years (range 24 to 85 years), 
and the male:female ratio was 1.4:1 (67 men, 47 women).
Microbiological tests
The diagnosis of LD was confirmed by culture in 21 cases, urine antigen test in 
35 cases, and serologic testing in 12 cases (table 1). In 26 cases, two or more tests 
were positive (two tests, 24 patients; three tests, 2 patients). In 2 (1.3%) of the 155 
samples tested with PCR, inhibitors of the PCR reaction could not be removed, 
despite repeated DNA extraction. Thus, a total of 153 patients were included in the 
calculations. A total of 44 out of 153 patients tested were positive in PCR (29%), 21 
out of 119 tested had a positive culture (18%), 35 out of 139 tested had a positive 
urinary antigen (25%) and 12 out of 37 tested were positive in serology (32%) (table 
1). Of a total of 35 confirmed LD patients tested, 21 patients had a positive culture, 
giving an estimated test sensitivity of 60% (95% confidence interval [CI], 44 to 
74%). Out of a total of 39 confirmed LD patients tested, 35 patients had a positive 
urinary antigen, giving an estimated test sensitivity of 90% (95% CI, 76 to 97%). 
Out of a total of 12 confirmed LD patients tested, 12 patients had positive serology, 
giving an estimated test sensitivity of 100% (95% CI, 71 to 100%). Out of a total 
of 41 confirmed LD patients tested, 36 patients were positive by PCR, giving an 
estimated test sensitivity of 88% (95% CI, 74 to 95%).
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Table 1. Positive diagnostic tests results for 41 confirmed cases of LD according to EWGLI criteriaa
Culture Urinary antigen Fourfold rise in titer PCRb
Culture 21/35 19/31  3/10 20/32
Urinary antigen 19/21 35/39  7/10 33/36
Fourfold rise in titer 3/3 7/7 12/12 10/10
PCR 20/21 33/35 10/12 36/41
aThe table is read in columns as follows: 21 patients had a positive culture out of a total of 35 confirmed LD 
patients tested; of these 21 culture positive patients, 19 were positive by urinary antigen out of 21 tested, 3 
had a fourfold rise in titer out of 3 tested, 20 were positive by PCR out of 21 tested.
bPCR = polymerase chain reaction.
Agreement, sensitivity and specificity of real-time PCR compared to conventional 
test results
Results of samples tested with PCR were compared in patients with and without 
Legionnaires’ disease (LD), according to EWGLI criteria (Table 2). Among all 153 
patients included, 42 tested positive in 16S rRNA gene based PCR, with a mean Ct 
values of 32 (range 19-44), and 38 tested positive in mip gene-based PCR, with a 
mean Ct value of 30.8 (range 21-42).
Table 2. Results of samples tested with PCR for the detection of Legionella specific DNA in patients with 
and without Legionnaires’ disease (LD). Total PCR test result: the official reported result in the laboratory 
information system.
16S rRNA PCR mip PCR Total PCR test result
Positive Negative Positive Negative Positive Negative
LD positive: 41 34 (A)   7 (C) 36   5 36   5
LD negative: 112  8 (B) 104 (D)  2 110  8 104
Total: 153
A calculated agreement, sensitivity, and specificity of 90%, 83% (95% CI, 68 to 
91%), and 93% (95% CI, 86 to 97%), respectively, was found for 16S rRNA based 
PCR, 95%, 88% (95% CI, 74 to 95%), and 98% (95% CI, 93 to 100%), respec-
tively, was found for the mip gene based PCR assay, and 92%, 88% (95% CI, 74 to 
96%), and 93% (95% CI, 86 to 97%), respectively, was found for the total PCR test 
result as it was reported in the laboratory information system.
Discrepant analysis
Discrepant analysis was performed for samples positive in PCR and negative in con-
ventional testing (Table 3). Using additional tests, 2 out of 8 potential false positives 
in 16S rRNA PCR are reclassified and shift from cell B (false positive) to cell A 
(true positives) in table 2, and 2 out of 2 are reclassified as true positives in mip 
gene PCR. The total number of confirmed LD cases increased from 41 to 44. In 16S 
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rRNA PCR, the total number of true positives changed from 34 to 36, and the total 
number of false positives changed to 6. The sensitivity and specificity of 16S rRNA 
PCR changed to 82% (36/44) and 95% (103/109), respectively. In mip gene PCR, 2 
false positives were reclassified. The total number of true positives changed from 36 
to 38, and the total number of false positives changed to 0. The sensitivity of mip 
gene based PCR decreased to 86%, but the specificity increased to 100% (109/109) 
after discrepant analysis.
Results of PCR in comparison with the urinary antigen test
(i) 16S rRNA-based PCR
139 patients were tested by both the urinary antigen test and PCR. A total of 35 
patients tested positive for Legionella urinary antigen, 30 of these patients were also 
positive in 16S rRNA based PCR. 104 patients tested negative for Legionella urinary 
antigen, 93 of these patients were also negative in PCR. Of the 11 urinary antigen 
negative and PCR positive patients, 3 fulfilled the criteria of a confirmed case of LD 
(2 culture positive, 1 serology positive). Eight urinary antigen test negative, PCR 
positive patients were not confirmed with conventional diagnostics. After discrepant 
analysis, 2 patients were considered true positives and 6 samples false positives (table 
3). Thus, a total of 35 patients were diagnosed in both urinary antigen testing and 
16S rRNA PCR.
(ii) mip-gene-based PCR
A total of 35 patients tested positive for Legionella urinary antigen, 32 of these 
patients were also positive in mip gene-based PCR. 104 patients tested negative for 
Legionella urinary antigen, 99 of these patients were also negative in PCR. Of the 5 
urinary antigen negative, PCR positive patients, 3 fulfilled the criteria of a confirmed 
case of LD (2 culture positive, 1 serology positive). Two urinary antigen test nega-
tive, PCR positive patients were not confirmed with conventional diagnostics. After 
discrepant analysis, both patients were considered true positives. Thus, 35 patients 
were diagnosed using the urinary antigen test and 37 in mip gene based PCR. The 
combination of both tests (urinary antigen test and mip-gene PCR) diagnosed a total 
of 40 patients with LD.
DISCUSSION
From the late 1970s until the late 1980s, options for testing for LD were limited to 
culture, serology and urinary antigen testing. Since the 1990s, many nucleic acid 
amplification tests (NAATs) have been described for the detection of Legionella spp. 
in respiratory specimens [15-28]. In addition to in-house PCR tests, commercial kits 
are becoming available as well [32]. PCR offers several theoretical advantages such 
as a high sensitivity, rapid availability of results, and the potential to detect infec-
tions caused by various serogroups of Legionella pneumophila as well as Legionella 
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species. However, few studies have addressed the practical value of PCR in routine 
clinical microbiology laboratories. We performed a retrospective, laboratory-based 
study in which results obtained with PCR were compared to those of conventional 
testing for Legionella on samples sent to our laboratory from patients suspected of 
having LD.
Of the 155 samples tested, 2 (1.3%) were shown to inhibit the PCR. Of the 153 
patients from whom non-inhibiting samples were obtained, 41 (27%) fulfilled the 
EWGLI criteria for a confirmed case of LD. The sensitivity and specificity of the 16S 
rRNA based PCR were 83%, and 93%, respectively. Sensitivity and specificity of the 
mip-gene based PCR assay (P>.5) were 88%, and 98%, respectively. Eight potential 
false-positives were detected in the 16S rRNA based PCR, and 2 in the mip-gene 
based PCR, respectively. The interpretation of the performance of PCR as a diag-
nostic test is hindered by the lack of a suitable “gold standard”. Because sensitivity 
of conventional testing is not 100%, we suspected that estimates of PCR specificity 
might be biased downward since a number of PCR-positive specimens from infected 
persons would be misclassified as uninfected if the conventional test failed to de-
tect Legionella. Researchers have used discrepant analysis in an effort to correctly 
characterize the apparent false-positive results as true-positives or false-positives, on 
the basis of a confirmation test applied to conventional test-negative, PCR-positive 
specimens [33]. A proportion of PCR-positive results were confirmed, and these 
results are considered true Legionella infections; two patients were positive for L. 
pneumophila, and one patient was diagnosed with a Legionella non-pneumophila 
spp. Using the results of the discrepancy analysis, and assuming a prevalence of 5% 
of Legionella spp. in patients with pneumonia, the recalculated sensitivity, specificity, 
positive predictive value, and negative predictive value were 82%, 95%, 44% and 
99% for the 16S rRNA assay, and 86%, 100%, 100% and 99% for the mip-gene 
specific PCR, respectively.
As routine diagnostics are more directed to the detection of L. pneumophila, the 
importance of Legionella non-pneumophila may be underestimated. Based on se-
rological studies, some authors suggest that sporadic non-pneumophila Legionella 
species may cause a considerable proportion of community-acquired pneumonia 
[34]. However, the results obtained in our study show that L. pneumophila is the 
predominant species, and detection of non-pneumophila Legionella species is rare. 
One patient, admitted with a severe community-acquired pneumonia (CAP) with 
unknown etiology, tested positive for a non-pneumophila Legionella species in both 
16SrRNA and 5S rRNA based PCR [35]. Nucleotide sequence analysis of the 16S 
rRNA gene amplification product showed 100% match with L. longbeachae. So, in 
a group 153 patients that was thoroughly investigated by conventional and various 
NAAT tests there was probably one case (0.6%) of infection with a non-pneumophila 
Legionella species.
Despite discrepant analysis, 6 false positive results occurred in 16S rRNA PCR. 
Because LD is a relatively rare disease, 5% false positive test results is unaccept-
able for a diagnostic test, since this results in a positive predictive value of 50%. 
PCR quality assessment studies have also recorded false-positive results. The quality 
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performance of 46 participating laboratories for the detection of Legionella spp. 
by two quality control (QC) exercises was investigated in 2004 and 2005 [36]. 
In-house methods were used by 93% of participants. The rate of false positivity 
(panel members negative for Legionella spp.) ranged from 4.0% in 2004 to 8.2% in 
2005. Laboratories should comply with stringent quality control requirements, and 
this QC study underlines that NAAT have not yet been properly standardized in all 
laboratories. Laboratory workers and clinicians must be cautious when interpret-
ing results obtained from these types of assays and should not hesitate to question 
results which are unexpected based on clinical presentation and local epidemiology. 
The occurence of false-positive Legionella testing described here also demonstrates 
the value of routine confirmatory testing procedures, because such protocols can be 
beneficial in rapidly detecting problems with diagnostic assays.
After discrepant analysis, no false-positive results were obtained with the L. 
pneumophila specific mip-gene PCR. The usefulness of a diagnostic test is strongly 
influenced by local Legionella epidemiology. L. pneumophila serogroup 1 is the pre-
dominant cause of LD in The Netherlands, and infection with this organism is easier 
to diagnose than is infection with other Legionella species and serogroups. PCR and 
the urinary antigen test are able to provide a diagnosis in a time frame that is helpful 
in the acute stage of disease. Because urinary antigen assays only detect a limited 
number of serogroups of L. pneumophila, some authors have suggested that total 
dependence on this diagnostic assay in LD may miss a significant proportion of cases 
[2]. Although this may be true in distinct geographic regions where only a minority 
of infections are caused by L. pneumophila serogroup 1, urinary antigen testing 
is a fast, easy to use test with high sensitivity and optimal degree of specificity in 
regions where L. pneumophila serogroup 1 is the most common cause of the disease. 
With the urinary antigen test, LD was diagnosed in 35 patients, the same number 
as diagnosed by 16S rRNA based PCR. The main problem with 16S rRNA PCR, 
however, was a high proportion of false-positive results, making confirmation (using 
a different PCR target or sequence analysis) necessary. A reliable “acute” diagnosis 
seems virtually impossible with 16S rRNA based PCR. Although with the mip gene 
PCR we detected more cases of LD, enhancing the etiologic diagnosis of LD patients 
with 4% in the acute stage of disease, this difference was not found to be statistically 
significant. However, with the combination of a urinary antigen test and mip-gene 
PCR LD was diagnosed in 40 patients, eg. in 14% (5/35) more compared to the use 
of the urinary antigen test alone (35/139 vs 40/139; p=0.58).
The amount of laboratory and microbiological work-up needed should be de-
termined by the severity of pneumonia. Mild pneumonia does not usually require 
any further microbiological studies [37]. For patients with mild LD, sensitivities 
for the urinary antigen test range from 40–53%, whereas for patients with severe 
LD, who need immediate special medical care, the sensitivities reach 88–100% [13]. 
In regions, as for instance The Netherlands, where L. pneumophila serogroup 1 
are the most frequent Legionella species causing disease, urinary antigen detection 
in urine is recommended for patients with severe CAP and in patients where this 
infection is clinically or epidemiologically suspected. In case of a negative antigen 
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test, Legionella specific PCR should be considered in severe pneumonia of unknown 
etiology. In regions where legionellae other than L. pneumophila serogroup 1 are 
important pathogens, current urinary antigen tests are still useful but should not be 
used as the sole diagnostic tool.
This study has some important limitations. We performed a retrospective, labora-
tory- based evaluation. The PCR assays have been evaluated in a selected patient 
population, and therefore the performances of the tests that were evaluated may have 
been confounded. Ideally these tests should be studied prospectively and performed 
in all patients to make a more reliable estimate of the added value of each test. In 
addition, we performed confirmatory nucleic acid amplification testing and sequence 
analysis. The logic behind confirmatory testing is based upon two assumptions. The 
assumptions are that failure to confirm a positive result means the initial positive re-
sult was likely a false positive and that confirming the initial positive result increases 
confidence that it was a correct result. A problem is that by applying discrepant 
analysis, the test under evaluation is used to define a true-positive result, and new 
tests under evaluation should ideally be compared to an independent gold standard. 
In addition, discrepant analysis involves post-hoc testing of specimens that were 
positive in the initial evaluation, and such selective testing of specimens is biased in 
favour of the new test. However, discrepant analysis allowed us to identify positive 
specimens as actually containing multiple properties (detection of multiple genes, 
sequence analysis) of the organism under question, which in our view meets as a 
reasonable criterium for detecting the organism.
The use of diagnostic molecular techniques has been so widely publicized that 
increasing pressure has been placed on clinical microbiology laboratories to apply 
these techniques, especially since kits are being made commercially available. The 
great enthusiasm aroused by nucleic acid detection methods in LD is tempered by the 
knowledge that the expectations concerning their superior sensitivity and specificity 
have not yet been fulfilled for all pathogens, in all PCR assays. Although the 16S 
rRNA-based PCR performed well in an in vitro evaluation, the results from this 
study suggest a clinical specificity lower than that reported previously [30]. The mip 
gene-based PCR used in this study is a reliable, sensitive and highly specific technique, 
suitable for detection of L. pneumophila in respiratory samples. The combination of 
a urinary antigen test and mip-gene PCR diagnosed more patients with LD compared 
to the use of the urinary antigen test alone. Early recognition of patients with LD is 
essential; the recognition of a single case may be the sentinel event that leads to the 
recognition of other cases and the contaminated point source. We therefore conclude 
that the addition of a Legionella pneumophila specific mip-gene PCR is useful in 
patients with suspected LD who produce sputum, and might allow the early detec-
tion of a significant number of extra patients.
Prospective studies are needed that directly compare multiple PCR assays available 
against reference tests in larger samples. The results of such comparisons would be 
more helpful to clinicians and microbiologists, who are faced with having to choose 
among many new tests, and might help to establish standard PCR methods that are 
robust enough to be used outside the setting of a research laboratory.
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The key role of diagnostic tests in clinical microbiology is the accurate and timely 
detection of an etiologic agent(s) causing infection to enable clinicians to provide the 
most effective therapy in an early stage. Unfortunately, the ideal test for Legionella 
spp. does not exist. Although diagnostic methods have improved during the 30 years 
since L. pneumophila was first described, no currently available test is able to detect 
all Legionella spp. timely with optimal sensitivity and specificity.
Serological tests for Legionniares’disease (LD) were frequently used as diagnostic 
test, especially in the time after the discovery of LD. The need for testing paired 
serum samples collected at least 3 weeks apart has diminished the use of serology, 
although it remains a valuable tool for the definitive diagnosis [1,2]. Indirect im-
munofluorescent assays (IFA) and enzyme-linked immunosorbent assays (ELISA) 
are the most commonly used methodologies for Legionella serology [3]. The ELISA 
technique generally shows higher sensitivity [4,5,6] and better characteristics in 
terms of both automation and objective measurement than IFA. Diagnosis requires 
both acute and convalescent sera, because an antibody response may take up to 12 
weeks (and sometimes longer) to develop [1]. The availability of commercial ELISA 
and IFA kits has resulted in an increasing use of these tests, despite that only few 
studies determining their sensitivity and specificity are available. In chapter 2 we 
evaluated commercial IFA and ELISA assays (Vircell, S.L., Santa Fé, Granada, Spain) 
in a well described population of patients with and without LD. We included 129 
serum samples of 65 patients with proven LD (cases), and 50 serum samples of 29 
patients with respiratory tract infections other than Legionella (controls). Also, we 
determined the agreement, sensitivity and specificity of the different VIRCELL assays 
in comparison to a validated ELISA assay (SERION classic ELISA L. pneumophila 
serogroup 1 to 7 assay). Samples were tested for L. pneumophila serogroup 1, IgM 
and IgG antibodies by an IFA procedure, L. pneumophila serogroup 1, IgM and IgG 
antibodies by ELISA, and L. pneumophila serogroup serogroups 1-6 in an IgM plus 
IgG combined ELISA assay, according to the manufacturer’s instructions.
Clinical sensitivity and specificity were respectively 75% and 97% for IFA IgM 
and 65% and 88% for IFA IgG, 92% and 100% for ELISA IgM, 43% and 97% for 
ELISA IgG and 91% and 100% for IgM plus IgG combined ELISA. If the new test to 
be evaluated, the Vircell assays, are compared to the alloyed standard, Serion ELISA, 
the calculated agreement, sensitivity, and specificity are 79%, 66% and 89%, respec-
tively, for IFA IgM, and 75%, 59% and 84%, respectively, for IFA IgG, 90%, 97%, 
and 83%, respectively, for the Vircell IgM ELISA, 82%, 55%, and 96%, respectively, 
for the Vircell IgG ELISA, and 94%, 96%, and 92%, respectively, for the Vircell IgM 
and IgG combined ELISA.
That the ELISA techniques showed an equal or greater sensitivity than the IFA 
was not surprising, this was already reported in previous comparisons [3,5,6]. High 
sensitivity is important in an assay, since the assay should detect the greatest possible 
number of patients with LD. However, a more important test variable for an illness 
of low prevalence, such as LD, is the specificity [3,7]. In a study by Rojas et al. [4], 
Vircell ELISA for IgM, Vircell ELISA for IgG plus IgM, and Vircell IFA for IgM 
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detected 72%, 61% and 51%, respectively, of outbreak-related patients. Our evalu-
ation included patients from various sources in a non-epidemic setting and therefore 
differs from studies on patients in an epidemic setting, where only a single L. pneu-
mophila strain is evaluated. In addition, outbreak-related studies, with a relatively 
high prevalence of the disease, provide insufficient information regarding the positive 
predictive value of serological assays. Our results indicate that the predictive value of 
a positive diagnostic result obtained by the Vircell IgM IFA and the Vircell IgG IFA 
will be low when used in a population with a low prevalence of LD. The Vircell IgM 
ELISA and the IgM-plus-IgG ELISA show high sensitivity and specificity and there-
fore a reliable serodiagnosis can be made using these assays. The Vircell IgG ELISA 
shows moderate sensitivity, but high specificity, and could be included together with 
IgM or IgM-plus-IgG for optimal clinical decision making.
A strength of the evaluation is that we used a well described population of patients 
with proven LD. An important shortcoming is the inclusion of only a small group 
of patients with respiratory tract infections other than LD as control patients, which 
could influence the specificity figures. Also, the majority of LD-positive patients 
were infected with L. pneumophila serogroup 1, making it impossible to conclude 
anything for L. pneumophila infections caused by other serogroups. Although most 
serological assays yield good sensitivity and specificity data [1,3,8,9], the delay in the 
development of a measurable antibody response constitutes a major drawback for 
clinical decision making in the acute patient.
Chapter 3 describes a case of probable LD in which the diagnosis was complicated 
by the presence of cross-reacting antibodies to Coxiella burnetii, emphasizing the 
need for cautious interpretation of antibody titers for members of the family Coxiella 
and Legionella. In the acute stage of disease, results of ELISA for L. pneumophila 
were negative, but elevated antibody levels of IgM (74 U/ml) were found. These 
were higher compared to what can be expected from the prevalence of measured 
Serion ELISA IgM antibodies in the normal population [10]. Because Legionella and 
Coxiella are responsible for similar clinical syndromes, this may lead to an incorrect 
diagnosis and probably less effective treatment. This underscores the importance of 
a laboratory professional that reports laboratory results with both awareness of the 
laboratory procedures that have been performed and knowledge of the consequences 
of these results for the patients involved.
A urinary antigen test for the diagnosis of LD caused by L. pneumophila serogroup 1 
was made available in the early 1980s [11,12,13], and its use has increased consider-
ably in recent years. This test is sensitive and highly specific, and it allows a rapid 
diagnosis of LD. Rapidity of diagnosis is an important advantage of the urinary 
antigen test, because it means that cases can be detected early in the course of infec-
tion, when treatment decisions can be influenced. There is still a need to develop an 
antigen capture assay that for detection of infections with any species and serogroup 
of Legionella. The urinary antigen test has replaced other diagnostic methods and is 
now the major test both in the Netherlands and in Europe [2,14]. Its use may have 
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led to a selection towards diagnosis of L. pneumophila serogroup 1 infections [15] 
with concomitant underestimation of the number of infections caused by other L. 
pneumophila serogroups and other Legionella spp. The most important feature of 
this test is its >99% specificity, a requirement for a test for a relatively rare disease.
In Part 2 the evaluation of several newly developed immunochromatographic 
urinary antigen tests for the detection of L. pneumophila serogroup 1 in urine is 
described. The tests were evaluated on stored (frozen) urine samples from a well-
described sample of patients with and without LD. The results were compared with 
the Binax NOW urinary antigen test.
In chapter 4 the sensitivities and specificities were estimated to be 71% (95% con-
fidence interval [95% CI], 60 to 80%) and 97% (95% CI, 90 to 99%), respectively, 
for the Rapid U test (Diamondial, Sees, France); 32% (95% CI, 22 to 43%) and 99% 
(95% CI, 92 to 100%), respectively, for the SD Bioline test (SD Bioline test; Standard 
Diagnostics, Inc., Kyonggi-do, Korea); and 92% (95% CI, 83 to 97%) and 100% 
(95% CI, 95 to 100%), respectively, for the Binax NOW test. The sensitivities of the 
Rapid U test and Binax NOW test increased to 81% (59/73; 95% CI, 70 to 88%) 
(p = 0.25) and 95% (69/73; 95% CI, 86 to 98%) (p = 0.75), respectively, if the tests 
were reexamined after an hour of incubation. Prolongation of the incubation time 
did not affect the specificity for the Rapid U and Binax NOW test.
The manufacturer of the Rapid U test adapted their test, and we evaluated this new 
test (Rapid U Plus test), described in chapter 5. Sensitivity and specificity were esti-
mated to be 92% (65/71; 95% CI 82%-96%) and 96% (4/91; 95% CI 89%-99%) 
for the improved test. The sensitivity of both the Rapid U Legionella Plus Test and 
Binax NOW urinary antigen test increased to 93% (66/71; 95% CI 84%-97%) if 
tests were reexamined after 45 min. Prolongation of the incubation time significantly 
affected the specificity of the Rapid U Legionella Plus Test: it decreased to 80% 
(18/91; 95% CI 70%-87%). Again, prolongation of the incubation time did not af-
fect the specificity in the Binax NOW urinary antigen test in this evaluation. We can 
conclude that the Binax NOW urinary antigen test is superior to the Rapid U test and 
the SD Bioline Legionella urinary antigen tests for the diagnosis of infections caused 
by L. pneumophila serogroup 1. The performance of the SD Bioline test is below the 
acceptable level for any diagnostic assay. However, false positive test results occured 
in all three new tests, with poor positive predictive values as a result. Given the 
potential impact of misdiagnosis of LD, it would seem unwise to rely on these tests 
for the diagnosis of LD. Chapter 6. Another Urinary antigen test, the SAS Legionella 
Test (SA Scientific, San Antonio, Texas) showed a high degree of sensitivity (83%; 
95% CI, 72 to 90%) and specificity (99%; 95% CI, 94 to 100%). The sensitivity in-
creased significantly (97%; 95% CI, 90 to 100%) after a prolonged incubation time. 
Because prolongation does not affect specificity, we recommend to use an incubation 
time longer than what is currently recommended by the manufacturer.
A drawback of the studies described in chapter 4, 5 and 6 is that we evaluated a 
relatively small group of patients; this means that the calculated sensitivity and speci-
ficity figures for the assays are more uncertain. However, the studies provide relevant 
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data related to the clinical sensitivity and specificity levels of these new commercial 
kits for the detection of L. pneumophila serogroup 1 antigen in urine.
The diagnosis of pneumococcal infections in patients with community-acquired 
pneumonia (CAP) is relying heavily on culture of Streptococcus (S.) pneumoniae 
from blood or other normally sterile fluids, and is therefore limited by prior admin-
istration of antibiotics. Given the difficulty in identifying precise microbial etiologies 
in patients with pneumonia, there is a clear need for new diagnostic tests. An immu-
nochromatographic test, the NOW S. pneumoniae urinary antigen test (Binax, Inc., 
Portland, Maine), has been developed; the test is simple to perform, detects the C 
polysaccharide cell wall antigen common to all S. pneumoniae strains, and provides 
results within 15 min. Chapter 7 describes an evaluation of this test using uncon-
centrated urine samples from adults admitted to hospital with community-acquired 
respiratory tract infections. Antigen was detected in 40 of 58 cases overall, resulting 
in a test sensitivity of 69% (95% CI, 58 to 78%). Antigen detection was greater in 
patients with bacteremia (38 of 52 [73%]) than in those without bacteremia (2 of 6 
[34%]) (p = 0.07). Urinary antigen was also detected in 3 of 136 adult patients with 
community-acquired respiratory tract infections caused by other organisms, giving 
a test specificity of 98% (95% CI, 93 to 99%). There were no false-positive results 
among tested patients (n=98) with LD. Detection of urinary antigen could be a valu-
able, sensitive, and rapid test for the early diagnosis of pneumococcal infections in 
adult patients [16,17,18]. Further prospective studies are warranted. This research 
should focus on the utility of a positive test result for safe, targeted use of a small 
spectrum penicillin for immunocompetent individuals with severe CAP.
Isolation of Legionella from respiratory secretions is considered the gold standard to 
define a case (100% specificity), but its reported sensitivity varies from 10 to 80%, 
and a positive result is not available until at least 3 days of incubation. Another limi-
tation of sputum culture is that less than 50% of patients with LD actually produce 
sputum [3,19]. PCR techniques have the potential to provide a rapid diagnosis of LD 
on readily obtainable specimens such as serum or urine. The use is appealing, since it 
may provide an answer within a relatively short period of time. In accordance with 
our own findings, other investigators have tried to amplify Legionella spp. DNA in 
urine, but the test proved of low sensitivity (0-30%) [20,21,22]. In chapter 8 we 
describe two patients with LD diagnosed by both the urinary antigen test and PCR 
on serum samples. Quantification of L. pneumophila DNA using real-time PCR dur-
ing the course of illness was carried out. The results of real-time PCR mirrored both 
the clinical condition and the C-reactive protein values during the course of illness. 
The detection of Legionella DNA in serum probably reflects changes in the quantity 
of bacteria in the bloodstream over time, and may, in theory, allow assessment of 
the response of the patient to treatment. However, the clinical course is also closely 
reflected by the CRP course, which has already been shown to bear prognostic poten-
tial in patients with pneumonia [23]. Future investigations might help to determine 
associations between amount of bacteria in blood or serum samples and clinical signs 
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and symptoms. Due to the high cost and unproven (cost)-effectiveness, PCR is not 
recommended at the moment as a marker to monitor treatment response in patients 
with LD.
The application of PCR on serum samples is attractive, because this will circumvent 
the problem of patients who do not produce sputum and the inability of the urinary 
antigen test to reliably detect organisms other than L. pneumophila serogroup 1. 
In chapter 9.1 we assessed the performance of PCR as a rapid diagnostic method 
and compared the results of different PCR assays in serum samples from patients 
with LD. We performed a laboratory-based study, with stored serum samples from 
patients with proven LD and patients with respiratory tract infections other than 
Legionella. Laboratory validation of several PCR assays was carried out using a 
panel of human-pathogenic and environmental Legionella spp. Three assays were 
used, targeted at specific regions within the 5S rRNA gene, the 16S rRNA gene, 
and the mip gene. The analytical sensitivity of the 5S rRNA based PCR assay was 
highest with a lower detection limit of 10 fg of chromosomal DNA. In the mip gene 
based assay, the lower detection limit was 100 fg, and 1000 fg was found as lower 
detection limit for the 16S rRNA based PCR. In the clinical evaluation, we included 
68 patients with proven LD, with 151 serum samples taken in total. The key ques-
tion of this evaluation was to know what the clinical utility of serum PCR is in the 
early phase of disease. Among the patients with proven LD, 54% tested positive 
in 5S rRNA PCR, 53% in mip gene PCR, and 31% in 16S rRNA PCR in the first 
available serum sample. Discrepant results between 16S rRNA gene, 5S rRNA gene 
and mip gene based PCR occurred, most probably due to differences in analytical 
sensitivity and because some samples might contain amounts of bacterial DNA at the 
limit of detection. In contrast to the high sensitivity found by Lindsay et al. (80%), 
the sensitivity of PCR in our study was relatively low (31%-54%) [22]. In the PCR 
described by Lindsay [22], to confirm the specificity of PCR a Southern blot with a 
50 basepair long digoxigenin-labelled probe is required. Due to its large size, as well 
as overlap in homology with species other than Legionella, this PCR assay may not 
be very specific. In 60 serum samples of patients with respiratory tract infections due 
to other pathogens than Legionella, we found 15 false positive results, using the same 
conventional 5S rRNA based PCR. This lack of specificity might explain the higher 
sensitivity described by Lindsay et al.
Because of the retrospective nature of our observations we were not able to in-
vestigate the relation between test sensitivity and severity of disease. However, the 
association between Ct value in 5S rRNA PCR positive serum samples (n=49) and 
CRP-value was determined and showed a strong negative correlation (r = -0.63, 
Pearson correlation coefficient, p <.0001). The urinary antigen test is less reliable 
in milder cases of LD, and we think it is plausible that the same holds true for the 
detection of Legionella DNA in serum. In February 1999 an outbreak involving 188 
cases of LD occurred in Bovenkarspel, The Netherlands. In chapter 9.2 we investi-
gated the relationship between PCR test sensitivity and the severity of disease with 
a selection serum specimens from patients with outbreak-related LD. Severity of 
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pneumonia was scored according to the criteria for severity of CAP advised by the 
American Thoracic Society. Patients were classified as category 1 (mild pneumonia 
and moderately severe) and category 2 (severe pneumonia). In patients with severe 
pneumonia, 49% (19/39; 95% CI 34–64%) tested positive in the first available se-
rum sample compared to 37% (7/19; 95% CI 19–59%) in patients with mild and 
moderately severe pneumonia. An important limitation of this study is that we only 
tested a small number of patients in both groups and the fact that the serum samples 
were stored at -20°C and thawed repeatedly before the PCR assays were applied. The 
storage and thawing most probably influenced the stability of Legionella spp. DNA 
present in the samples.
Detection of L. pneumophila DNA in serum could be a valuable tool in addition 
to existing diagnostic tests for the rapid diagnosis of LD caused by any Legionella 
species and serogroup in the acute phase of disease. As our results show, the sensitiv-
ity of the detection of Legionella DNA in serum is relatively low (∼50-60%) in LD 
patients, but will most probably be higher (∼70-90%) in those patients with more 
severe disease. However, the ultimate proof for its presumed utility would lie in a 
prospective study to evaluate the value of Legionella-specific PCR on serum samples 
in patients with pneumonia.
In addition to L. pneumophila, 19 other Legionella spp. have been documented as 
human pathogens on the basis of their isolation from clinical material. Unfortunately, 
Legionella spp. infection does not present with a distinctive clinical syndrome; it can-
not be reliably differentiated from pneumonia due to other bacterial pathogens on 
the basis of signs, symptoms or laboratory findings. Patients with non-pneumophila 
Legionella infections are more likely to be immunocompromised than are patients 
with L. pneumophila infection [24]. Infection with non-pneumophila spp. in im-
munocompetent patients is considered to be extremely rare. Chapter 10 describes the 
case of a patient who developed a severe CAP with unknown etiology. A single spu-
tum culture and urinary antigen test tested negative for Legionella spp. The sputum 
sample was sent to our laboratory and tested positive for non-pneumophila Legion-
ella spp. Nucleotide sequence analysis of the 16S rRNA gene amplification product 
showed 100% match with L. longbeachae. In addition, an acute serum sample tested 
positive for non-pneumophila Legionella species, and showed an elevated IgM titer 
of 1:512 and an IgG titer of 1:64 for non-pneumophila Legionella spp. This case is 
highly suggestive for infection with a non-pneumophila Legionella species. A point 
of criticism could be the absence of a definite proof of L. longbeachae pneumonia; 
seroconversion or even better a positive culture. However, non-pneumophila strains 
are more easily missed in clinical specimens because the culture media that are used 
often are less sensitive for isolation of non-pneumophila species, especially if anti-
biotics are added. Instructive for the difficulty of culturing legionellae was a case 
of CAP due to L. pneumophila serogroup 3, reported by Herpers et al. [25]. In this 
case, urinary antigen testing and the first culture of a bronchoalveolar lavage fluid 
sample were negative for Legionella spp. L. pneumophila DNA was detected by 
PCR in the BAL washing sample. Eventually, after repeated culture, L. pneumophila 
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serogroup 3 was isolated from this specimen. Because of the shortcomings of avail-
able diagnostic tests, and because culture of sputum samples for Legionella spp. is 
not a standard practice in the evaluation of CAP, it is possible that cases of both 
community-acquired and nosocomial non-pneumophila Legionella spp. infection re-
main undiagnosed. In patients with severe pneumonia of unknown etiology, repeated 
culture on Legionella-selective media or PCR should therefore be considered.
The unique growth requirements of legionellae, the ability to switch to a viable 
but nonculturable state and the association of Legionella Like Amoebal Pathogens 
(LLAPs) with amoebae complicates the detection of Legionella in potable water us-
ing standard microbiological techniques. Chapter 11 describes an investigation on 
the occurrence and identity of Legionella spp. in Dutch tap water installations with 
culture, real-time PCR and sequence analysis. The PCR assays used were a 16S rRNA 
gene-based PCR, with both a Legionella species-specific probe and a L. pneumophila 
specific-probe, and a L. pneumophila-specific PCR based on the sequence of the 
mip-gene. A total of 357 water samples from 250 locations in The Netherlands were 
investigated. The detection rates of Legionella spp. were 2,2% (8 of 357) by culture, 
and 87,1% (311 of 357) by PCR. The majority of samples was found to contain 
Legionella species other than L. pneumophila. We conclude that Legionella spp. 
DNA is ubiquitous in Dutch tap water installations and uncultured Legionella spp. 
are part of the indigenous microbial community. We should be aware that Legionella 
is a very common colonizer of water distribution systems, similar to other poten-
tially pathogenic bacteria and fungi. Our observations are in concordance with other 
studies [26,27,28]: more positive samples by PCR than by conventional culture are 
found. Wellinghausen et al. [26], using 16S rRNA gene PCR to quantify the genus 
Legionella and mip-PCR to quantify L. pneumophila, found a weak correlation with 
conventional culture. This may reflect the fact that PCR methods detect all legionel-
lae, whereas culture only detects viable and culturable cells. Conventional culture 
may underestimate the number of viable legionellae, owing to the use of selective 
media and pretreatment by acid or heating [3,29].
However, the PCR results must be applied with caution. Many assume that the 
nucleic acids being copied are from viable cells, but PCR can detect both viable and 
nonviable cells by amplifying the target nucleic acids in the sample. This can explain 
why no correlation was observed between culture and PCR results. Another possibil-
ity for this poor correlation is low specificity of the 16S rRNA PCR used. We have 
made a comparison of sequences and concluded that the region that we used has a 
high homology with known Legionella spp. However, amplification and detection of 
non-Legionella DNA cannot be completely excluded, since alignment of the target 
sequence of the primers can never include all environmentally occurring, known 
and unknown, bacteria. Although multiple species may colonize water-distribution 
systems, only a few species will cause disease in patients exposed to the water. L. 
pneumophila is by far the most pathogenic, accounting for more than 90% percent 
of culture confirmed LD worldwide. Although 15 serogroups of L. pneumophila 
have been described, serogroup 1 accounts for almost 85% of the reported cases 
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of LD caused by L. pneumophila. Dutch guidelines mandate routine environmental 
surveillance for Legionella spp. in certain high risk buildings such as jails, hotels 
and nursing homes, regardless of the occurrence of cases. However, the necessity 
to sample water routinely is unclear or, at least, questionable. The linkage between 
specific levels of colonization and risk of LD remains controversial. When samples 
for culture are obtained routinely there is an obligation to try to eradicate Legionella 
if they are detected. The apparent infrequency of sporadic LD, the ubiquitous nature 
of the organism, the difficulty in eradicating the organism from water sources and 
the lack of data on preventing disease makes routine culturing questionable [7,30]. 
Using PCR to test water for Legionella may further overestimate the risk of infec-
tion. If disinfection is performed, it is likely that the water samples will contain 
nonviable Legionella cells which were killed by the disinfection measures. The re-
maining nucleic acids in the dead cells may still be recovered and amplified by PCR. 
Therefore, implementation of PCR assays for the detection Legionella in potable 
water samples will probably lead to more unnecessary and expensive “emergency” 
decontamination procedures.
Acute respiratory tract infections (ARI) are very common and responsible for con-
siderable morbidity in the general population. Most infections are caused by viruses, 
especially rhinovirus, influenza virus, and respiratory syncytial virus [31,32,33], 
although in 30-40% no etiological agent is found. In studies conducted in Israel, 
Legionella spp. were found to be important agents of ARI [34,35]. Lieberman et al. 
found evidence for Legionella spp. as an etiologic agent in 12% of cases both in gen-
eral practice and in patients admitted to a general hospital. The etiological diagnoses 
in this study were based exclusively on an in-house IFA, detecting 41 “serogroups” 
of Legionella spp.
Given the difficulty involved in obtaining and handling appropriate material for 
the isolation of the pathogen, the technical complexity of the isolation, and the fact 
that most other tests only reliably detect infections due to L. pneumophila serogroup 
1, a sensitive PCR test might enhance the ability to diagnose these infections in pa-
tients with ARI. Since 1970, the GPs from the Continuous Morbidity Registration of 
The Netherlands Institute of Primary Health Care have registered all patients who 
have consulted them about influenza-like illnesses (ILIs). An extension of the system 
with the registration of all patients consulting with other ARI (Acute Respiratoire 
Infecties in de Eerste Lijn, ARIEL studie) gave the unique possibility to estimate 
whether Legionella spp. play a role as etiologic agent in ARI. This study is described 
in chapter 12. The inclusion of control subjects made it feasible to investigate whether 
a causal relationship between detection of Legionella spp. and airway complaints ex-
ists. Nose and throat swab specimens were obtained from case patients and control 
subjects, and PCR tests were performed for the detection of Legionella spp. The 
primers and probes of the Legionella PCR assay were based on the 16S rRNA gene. 
In real-time PCR, Legionella spp. DNA was not detected in any of the samples of the 
patients with ARI nor in the control patients. Thus, in contrast to reports based on 
serological observations we demonstrated that Legionella spp. are not present in the 
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nose or oropharynx of patients with ARI in general practice. Observations made by 
direct fluorescent-antibody (FA) testing suggested that colonization with Legionella 
spp., although infrequently, does occur [36]. We found no evidence for asymptomatic 
carriage of Legionella spp. in the upper airways.
How to explain the results [34,35] found by Lieberman et al.? Although in theory 
local Legionella epidemiology may have influenced the results, we have serious doubts 
about the validity of serological testing using in-house IFA assays for a reliable diag-
nosis of Legionella spp. infection in patients with ARI. This may have lead to false-
positive results. Specificity has only been acceptably established for L. pneumophila 
serogroup 1 and cross-reactivity between L. pneumophila serogroup 1 and other 
serogroups and species has been reported in the literature [3]. In their outbreak-
related case-control study, Boshuizen et al. [37] observed that control seroconvertors 
did not show any statistically significant clinical difference when compared to non-
seroconverters. Although previous studies associated respiratory symptoms with the 
presence of Legionella antibodies [38,39], Boshuizen et al. conclude that as most 
studies have looked at multiple symptoms, some statistically significant results are to 
be expected based on pure chance. The same is true in case of a patient serum that 
is subjected to 41 different in-house IFA tests for the detection of Legionella spp.; 
the use of a less specific diagnostic method for a low prevalent disease, increases the 
likelihood of false-positive reactions dramatically.
Acute exacerbation of chronic obstructive pulmonary disease (AECOPD), is char-
acterized by an acute sustained worsening of the patient’s condition from a stable 
state, beyond normal day-to-day variations, which occurs one to three times a year 
and may warrant additional treatment. The aetiology of AECOPD is heterogeneous 
and still under discussion. In several studies serological evidence of C. pneumoniae, 
Legionella spp. and M. pneumoniae playing a role as a pathogen or copathogen 
in acute exacerbations has been reported [40-50]. We investigated the presence of 
atypical pathogens in sputum samples in patients with stable COPD and those with 
AECOPD using real-time PCR, described in chapter 13. A total of 248 sputum 
samples, 122 samples obtained during stable and 126 samples obtained during ex-
acerbations, from 104 patients were tested. All samples were negative for M. pneu-
moniae and C. pneumoniae DNA, whereas two samples (one stable state sputum 
and one exacerbation sputum) were positive for Legionella non-pneumophila DNA. 
In search for an association between the presence of atypical pathogens in patients 
with stable chronic obstructive pulmonary disease and in those patients with acute 
exacerbations of the disease, no indication was found of a role for Legionella spp., 
Chlamydia pneumoniae or Mycoplasma pneumoniae in stable, moderately severe 
chronic obstructive pulmonary disease and in its exacerbations. Our study results 
further indicate that nonstandardised serology might introduce a false association 
between atypical pathogens and acute exacerbations of chronic obstructive pulmo-
nary disease. In our view, the serological evidence of C. pneumoniae, Legionella spp. 
and M. pneumoniae playing a role as a pathogen or copathogen in AECOPD simply 
reflects the principal methodological problems of diagnosing such infections. The 
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use of a less specific diagnostic method for the detection of a pathogen, will, from a 
statistical point of view, increase the likelihood of false-positive reactions.
Chapter 14. Attempts to determine the relative roles of bacterial and viral pathogens 
as etiological agents of CAP have yielded widely divergent results. It is known that in 
studies on the etiology of CAP, in up to 50% of patients the etiologic agent cannot be 
identified. For many respiratory pathogens, PCR has been shown to be more sensitive 
than conventional microbiological methods. We conducted a study on oropharyngeal 
swabs obtained from a group of hospitalised patients with CAP to evaluate if the 
use of real-time PCR for detection of respiratory viruses and Legionella spp. would 
increase the diagnostic yield. Specimens from 242 adults admitted to hospital with 
CAP were tested. Overall, viral pathogens were identified by conventional techniques 
(serology) in 7 (2%) patients, and real-time PCR in 50 (21%) patients (p<0.0001). 
The diagnostic yield increased from 137 cases (57% of patients using conventional 
microbiological assays) to 158 cases (65% of patients using real-time PCR assays 
and conventional microbiological assays; p=0.06). This increase was mainly a result 
of the detection of respiratory viruses, especially influenza virus, parainfluenza virus 
and human coronaviruses, which were not detected by serology. L. pneumophila 
PCR was positive in 3 out of 11 cases (27%) of Legionnaires’ Disease (LD). This 
study demonstrates that real-time PCR can increase the number of microbiological 
detection of respiratory pathogens in patients with CAP from a little more than a half 
of the cases to nearly two thirds of patients. Although detection of Legionella spp. 
is possible, our results show that oropharyngeal swabs are not suitable as a reliable 
sample for Legionella PCR.
The promise of molecular diagnostics to revolutionize the diagnosis of LD is still 
unfulfilled [19]. Nucleic acid amplification tests (NAAT) have greatly expanded the 
capabilities of clinical microbiology laboratories and have created new paradigms for 
the diagnosis and management of illness in patients with many kinds of infectious 
diseases. Despite development over many years, none of the many published Legio-
nella PCR assays is commercially available and in widespread routine use, and few 
studies have addressed the practical value of PCR in routine clinical microbiology 
laboratories. At the Regional Public Health Laboratory, located at the St. Elisabeth 
Hospital, Tilburg, The Netherlands, we have used a repertoire of conventional diag-
nostic tests (serology, culture, urinary antigen testing) as well as Legionella specific 
PCR for several years. Chapter 15 describes a comparison between results obtained 
with PCR with those of conventional tests on samples sent to our laboratory from 
patients suspected of having LD. The two main objectives of our study were the fol-
lowing. First, to determine the performance of PCR compared to that of conventional 
diagnostic tests in terms of sensitivity and specificity. An estimated sensitivity and 
specificity of 83%, and 93%, respectively, was found for 16S rRNA based PCR, and 
88%, and 98%, respectively, was found for the mip-gene based PCR assay (p >.5). 
Eight potential false-positive results were obtained with the 16S rRNA-based PCR, 
and 2 with the mip gene-based PCR, respectively. Because sensitivity of conventional 
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testing is not 100%, we suspected that estimates of PCR specificity might be biased 
downward since a number of PCR-positive specimens from infected persons would 
be misclassified as uninfected if the conventional test failed to detect Legionella. A 
proportion of PCR-positive results were confirmed, and these results are considered 
true Legionella infections; two patients were positive for L. pneumophila, and one 
patient was diagnosed with a Legionella non-pneumophila spp. With the results of 
the discrepancy analysis, and assuming a prevalence of 5% of Legionella spp. in 
patients with pneumonia, the sensitivity, specificity, positive predictive value, and 
negative predictive value were recalculated and found to be 82%, 95%, 44% and 
99% for the 16S rRNA assay, and 86%, 100%, 100% and 99% for the mip-gene-
specific PCR, respectively.
Although it is clear that NAAT offer new opportunities to improve the diagno-
sis and management of illness in patients with infectious diseases, the introduction 
of new diagnostic tests does not always lead to an improved diagnostic yield. Our 
second and main objective was to evaluate the additional value of a Legionella-
specific PCR for the diagnosis of LD, compared to the urinary antigen test. With the 
urinary antigen test 35 patients were diagnosed as having LD, the same number as 
diagnosed with the 16S rRNA-based PCR. The main problem with 16S rRNA PCR, 
however, was a high proportion of false-positive results, making confirmation neces-
sary. Although the mip-gene PCR was able to detect more cases of LD, enhancing the 
etiologic diagnosis of LD patients with 4% in the acute stage of disease, this differ-
ence was not found to be statistically significant. However, with the combination of a 
urinary antigen test and mip-gene PCR LD was diagnosed in 40 patients, eg. in 14% 
(5/35) more compared to the use of the urinary antigen test alone (35/139 vs 40/139; 
p=0.58). We therefore conclude that the addition of a Legionella pneumophila spe-
cific mip-gene PCR is useful in patients with suspected LD who produce sputum, and 
might allow the early detection of a significant number of extra patients.
CONCLUSIONS
When systematically sought, Legionella species are consistently recognized as one 
of the more common causes of pneumonia. The failure to diagnose LD in routine 
clinical practice largely depends on 3 factors: the inability to clinically and radio-
graphically distinguish LD from other causes of pneumonia, the omission to order 
specific diagnostic tests for Legionella infection, and the shortcomings of available 
diagnostic tests. During an epidemic or in a setting with an unusual high prevalence, 
a specificity of 100% is not an essential prerequisite for a diagnostic test. However, 
when the prevalence of infection is low, even a modest loss of specificity will result 
in false-positive findings. As outlined in this thesis, this holds true especially for 
new (commercial) diagnostic methods for which clinical specificity is not yet well 
defined. The sensitivity of diagnostic tests for LD is usually in the 60-70% range, 
and does not exceed 90% for any test used. Therefore it appears that none of the 
individual diagnostic tests fulfils the needs of both clinicians and microbiologists, 
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and the examination of different specimen types with several tests in parallel is 
recommended.
The amount of microbiological work-up should be determined by the severity of 
the pneumonia. The incidence of LD is higher among patients with severe pneumonia, 
and all patients with pneumonia who are admitted to an intensive care unit should 
therefore be tested for this infection. Patients with pneumonia that does not respond 
to therapy with beta-lactam antibiotics or the combination with aminoglycosides, 
or patients with severe underlying disease, should also be tested for Legionella spp. 
Culture diagnosis remains the gold standard for diagnosis of LD and is the most 
specific diagnostic procedure, but its relatively low sensitivity and the reliance on 
the availability of a lower respiratory tract sample make it inadequate as a sole 
diagnostic test.
In The Netherlands, LD is a notifiable disease and a supplementary nationwide 
source identification program is operative (Bemonsterings Eenheid Legionella-
pneumonie; BEL project). In this survey, 172 culture-confirmed LD cases were 
identified between August 2002 and Oktober 2006. L. pneumophila constituted 
98.8% (170) of the isolates. Serogroup 1 was the predominant serogroup (86.6%), 
and serogroups 2 (2.3%), 3 (1.7%), 6 (2.3%), and 2-14 (5.2%) accounted for the 
remaining serogroups. The Legionella non-pneumophila species isolated were L. 
longbeachae (1.7%) and L. maeceachernii (0.6%) (E. Yzerman, J. Bruin, personal 
communication). In regions, as The Netherlands, where L. pneumophila serogroup 
1 are numerically the most important Legionella species causing disease, urinary 
antigen detection is recommended for patients with severe CAP and in patients where 
this infection is clinically or epidemiologically suspected. In case of a negative antigen 
test, Legionella-specific PCR should be considered in severe pneumonia of unknown 
etiology. In regions where legionellae other than L. pneumophila serogroup 1 are 
important pathogens, current urinary antigen tests are still useful but should never 
be used as the sole diagnostic tool.
The availability of a good diagnostic repertoire, suitable for accurately diagnosing 
LD, constitutes the basis for the early recognition and treatment of the individual 
patient as well as for effective measures for prevention and control.
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Het doel van een diagnostische test in de klinische microbiologie is het tijdig aantonen 
van een verwekker, zodat een gerichte (antibiotische) therapie kan worden gestart. De 
ideale test voor het aantonen van Legionella speciës bestaat echter niet. Hoewel de 
laboratoriumdiagnostiek sinds de eerste beschrijving van legionellose in 1976 sterk 
is verbeterd, is geen enkele test in staat ziekte veroorzaakt door alle legionellasoorten 
aan te tonen met een optimale mate van snelheid, sensitiviteit en specificiteit.
Serologisch onderzoek (het aantonen van antilichamen gericht tegen L. pneumop-
hila), was eens de meest gebruikte diagnostiek. Bij het doormaken van legionellose 
kan seroconversie echter zeer langzaam verlopen [1]. Dit heeft er mede voor gezorgd 
dat het gebruik ervan de laatste jaren is afgenomen [2]. Binnen 3 weken treedt in 
de meeste gevallen een significante titerstijging op, maar soms duurt het 3 maanden 
vooraleer een titerstijging wordt waargenomen [1,3]. Indirecte immunofluorescentie-
tests (IFA) en enzyme-linked immunosorbent assays (ELISA) zijn op dit moment de 
meest gebruikte technieken. Deze laatste lijkt gevoeliger dan de IFA [3,5,6,8]. Ook 
kan een ELISA makkelijker geautomatiseerd worden en is het aflezen van de uitslag 
minder subjectief dan bij een IFA. Deze tests, die commercieel verkrijgbaar zijn, wor-
den tegenwoordig veel gebruikt. Er zijn echter weinig studies verricht die de gevoelig-
heid en specificiteit van deze tests hebben bepaald. In hoofdstuk 2 beschrijven we 
de evaluatie van een aantal commercieel verkrijgbare IFA’s en ELISA’s (Vircell, S.L., 
Santa Fé, Granada, Spanje). Voor het bepalen van de sensitiviteit en specificiteit werd 
gebruik gemaakt van een groep van 65 patiënten met legionellose en 29 patiënten 
met respiratoire infecties anders dan legionellose. Gebruikmakend van de testresulta-
ten werden tevens de overeenkomst, sensitiviteit en specificiteit van de Vircell assays 
vergeleken ten opzichte van een andere test, een veelgebruikte ELISA (Serion clas-
sic ELISA). Monsters werden met IFA en ELISA getest op de aanwezigheid van L. 
pneumophila serogroep 1 IgM- en IgG-antilichamen en met een gecombineerde IgM-
plus-IgG ELISA op L. pneumophila serogroep 1 tot en met 6, volgens de instructies 
verstrekt door de fabrikant. De sensitiviteit en specificiteit bedroegen respectievelijk 
75% en 97% voor IFA IgM, 65% en 88% voor IFA IgG, 92% en 100% voor ELISA 
IgM, 43% en 97% voor ELISA IgG en 91% en 100% voor de gecombineerde IgM-
plus-IgG ELISA. Als de te evalueren tests, de Vircell assays, vergeleken worden met 
een toegewezen serologische standaard, de Serion ELISA, worden een overeenkomst, 
sensitiviteit en specificiteit gevonden van respectievelijk 79%, 66% en 89% voor IFA 
IgM, 75%, 59% en 84% voor IFA IgG, 90%, 97%, en 83% voor IgM ELISA, 82%, 
55% en 96% voor Vircell IgG ELISA, en 94%, 96% en 92% voor gecombineerde 
IgM-plus-IgG ELISA.
Het feit dat we een even hoge of zelfs hogere sensitiviteit vonden bij de ELISA’s 
ten opzichte van de IFA’s was niet echt verrassend; dit werd al in eerdere publicaties 
gemeld [3,5,6]. Een hoge gevoeligheid is natuurlijk belangrijk, aangezien je met een 
enkele test zoveel mogelijk patiënten met legionellose wilt diagnosticeren. De be-
langrijkste testeigenschap voor een relatief zeldzame ziekte is echter de specificiteit 
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[3,7]. Bij bijvoorbeeld een prevalentie van 5% en een gevoeligheid en specificiteit 
van 97% zijn nog ongeveer vier op tien positieve tests fout-positief. Het gevaar voor 
fout-positieve uitslagen is daarom waarschijnlijk te hoog bij beide (IgM en IgG) 
immuunfluorescentietests. De Vircell IgM ELISA en IgM-plus-IgG ELISA lijken wel 
bruikbaar, gezien de hoge gevoeligheid en specificiteit.
Een welomschreven populatie met en zonder legionellose werd onderzocht, waar-
van de overgrote meerderheid een infectie met L. pneumophila serogroep 1 had, 
waardoor de waarde van de tests voor infecties met andere speciës en serogroepen 
onbekend is. Een ander nadeel is het gebruik van een relatief kleine controlegroep 
met luchtweginfecties anders dan legionellose. Deze studie benadrukt echter het be-
lang van een onafhankelijke evaluatie voor nieuwe diagnostische tests.
Hoewel vele beschikbare serologische tests een hoge gevoeligheid en specificiteit 
hebben, vormt de trage antistofrespons een ernstige belemmering voor een snelle 
diagnose [1,3,8,9]. Hierdoor is het belang ervan voor de patiëntenzorg in de acute 
fase bijzonder gering.
In hoofdstuk 3 wordt een patiënt beschreven die waarschijnlijk een infectie met L. 
pneumophila had, maar bij wie de diagnose werd bemoeilijkt door de aanwezigheid 
van kruisreagerende antistoffen tegen Coxiella burnetii, de verwekker van Q-koorts. 
In het acute stadium van de ziekte was de serologie voor legionellose weliswaar nega-
tief in ELISA, maar de gevonden IgM-waarde was hoger dan men zou verwachten op 
basis van gegevens uit een normale, gezonde populatie [10], en seroconversie volgde. 
Dus gelijktijdige seroconversie voor Q-koorts en legionellose. Omdat legionellose en 
Q-koorts een vergelijkbaar klinisch beeld kunnen hebben, is het belangrijk een cor-
recte diagnose te stellen. De behandeling van beide beelden is namelijk verschillend.
Vanaf het begin van de jaren 80 van de vorige eeuw zijn verschillende tests be-
schikbaar voor het aantonen van L. pneumophila serogroep 1-antigeen in de urine 
[11,12,13]. De sensitiviteit van de test ligt rond de 80% (hoe ernstiger de ziekte, des 
te sensitiever de test), de specificiteit is 99-100%. Met deze test, die in Nederland 
thans tot de routinediagnostiek behoort, is het mogelijk om vroeg in de ziekte de 
diagnose te stellen en dus snel adequate antibiotische therapie te starten, in tegenstel-
ling tot bijvoorbeeld met serologie en kweek. De urineantigeentest is nu de meest 
gebruikte test in Nederland en Europa [2,14]. In deel 2 wordt de evaluatie van een 
aantal nieuwe, commerciële immunochromatografische urineantigeentests beschre-
ven. Voor het bepalen van de sensitiviteit en specificiteit werd gebruik gemaakt van 
ingevroren, ongeconcentreerde urine, afgenomen van een groep patiënten met legi-
onellose en een groep patiënten met respiratoire infecties anders dan legionellose. 
De sensitiviteit en specificiteit bedroegen respectievelijk 71% en 97% voor de Rapid 
U-test (Diamondial, Sees, Frankrijk); 32% en 99% voor de SD Bioline-test (Standard 
Diagnostics, Inc., Kyonggi-do, Korea); en 92% en 100% voor de Binax NOW-test 
(hoofdstuk 4). De gevoeligheid nam toe na verlenging van de incubatietijd naar een 
uur: 81% (59/73) (p = 0,25) en 95% (69/73) (p = 0,75), voor respectievelijk de Rapid 
U-test en de Binax NOW-test. Het verlengen van de incubatietijd had geen invloed op 
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de specificiteit van zowel de Rapid U- als de Binax NOW-test. De fabrikant paste de 
Rapid U-urineantigeentest aan, en wij hebben deze aangepaste test geëvalueerd (Ra-
pid U Plus-test), beschreven in hoofdstuk 5. De sensitiviteit en specificiteit bedroegen 
respectievelijk 92% en 96%. De gevoeligheid nam toe naar 93% na verlenging van 
de incubatietijd naar een uur, maar de specificiteit daalde naar 80%. Het verlengen 
van de incubatietijd had opnieuw geen invloed op de specificiteit van de Binax NOW-
test. Het blind accepteren van getallen die in de bijsluiter staan kan tot verkeerde 
conclusies en keuzes leiden bij diegene die de test wil gaan gebruiken. Hoewel de 
SD Bioline- test de slechtste resultaten liet zien, werden vals-positieve resultaten 
bij alle (Rapid U en SD Bioline) nieuwe urineantigeentests gezien, met lage positief 
voorspellende waarden als gevolg. Gezien het belang van een juiste diagnose van 
deze (aangifteplichtige) ziekte lijkt het onverstandig om op deze tests te vertrouwen. 
De Binax NOW-test presteerde optimaal en kan dus wel gebruikt worden voor een 
betrouwbare sneldiagnostiek.
De sensitiviteit en specificiteit van een andere nieuwe test, de SAS Legionella Test 
(SA Scientific, San Antonio, Texas, VS), bedroegen respectievelijk 83% en 99%, en 
de gevoeligheid nam significant toe naar 97% na het verlengen van de incubatietijd 
(hoofdstuk 6). Omdat het verlengen van de incubatietijd geen invloed heeft op de 
specificiteit van de SAS Legionella Test, raden wij aan een langere incubatietijd te 
gebruiken dan de 10 minuten die nu door de fabrikant wordt aanbevolen.
De diagnose pneumokokkenpneumonie bij een patiënt met een community-acquired 
pneumonie (CAP) wordt bevestigd door isolatie van het organisme in het bloed of 
sputum. Sputum is echter frequent niet te verkrijgen (patiënt hoest niet op), of het on-
derzoek is minder betrouwbaar door voorafgaand antibioticagebruik. Bloedkweken 
hebben een zeer hoge specificiteit, maar hebben een zeer lage (<30%) sensitiviteit. 
Er is duidelijk behoefte aan nieuwe, snelle tests voor de diagnose pneumokokken-
pneumonie. De pneumokokkenantigeentest (Binax, Inc., Portland, Maine, VS) is een 
immunochromatografische membraantest die het C-polysaccharide celwandantigeen 
van de pneumokok in urine kan detecteren. De test kan eenvoudig en snel (<15 
minuten) worden uitgevoerd. In hoofdstuk 7 wordt de evaluatie van deze test be-
schreven. Voor het bepalen van de sensitiviteit en specificiteit werd gebruik gemaakt 
van ingevroren, ongeconcentreerde urine, afgenomen van een groep patiënten met 
pneumokkenpneumonie (n=58), en patiënten met respiratoire infecties anders dan 
pneumokokken (n=136), met name patiënten met legionellose (n=98). De sensitivi-
teit en specificiteit bedroegen respectievelijk 69% (95% betrouwbaarheidsinterval 
[95% BI] 58 tot 78%) en 98% (95% BI 93 tot 99%). Opvallend was dat in de groep 
patiënten met een legionellose geen enkel vals-positief resultaat werd gevonden. Bij 
een legionellose lijkt een vals-positieve pneumokokkenantigeentest dus niet voor te 
komen. Het antigeen werd vaker aangetoond bij patiënten met een bacteriëmie (38/52 
[73%]) dan zonder bacteriëmie (2/6 [70%]) (p = 0,07). Het verrichten van een pneu-
mokokkenantigeentest kan bijdragen tot snellere determinatie van de oorzakelijke 
verwekker en mogelijk dus tot vroegtijdige stroomlijning van de initiële therapie. 
Het is een veelbelovende test, maar waarschijnlijk nog onvoldoende gevalideerd om 
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het gebruik als besliscriterium voor te stellen bij patiënten met een ernstige CAP. 
Toekomstig onderzoek zou zich hierop moeten richten.
De gouden standaard voor het stellen van de diagnose legionellose is de kweek van 
het micro-organisme uit patiëntenmateriaal. Dit lukt echter niet altijd, aangezien 
minder dan de helft van de patiënten sputum opgeeft. De gevoeligheid varieert (sen-
sitiviteit van 10% tot 80%), en een positief resultaat is op zijn vroegst na drie dagen 
beschikbaar [3,19]. PCR heeft als voordeel dat alle serogroepen van L. pneumophila 
en andere Legionella spp. relatief snel kunnen worden aangetoond. Zoals ook geldt 
voor kweek is het echter een nadeel dat het materiaal dat voor de PCR noodzakelijk 
is (bronchoalveolaire lavage, sputum of pleuravocht) niet altijd wordt verkregen. 
Het gebruik van PCR op makkelijker verkrijgbaar patiëntenmateriaal, zoals urine 
of bloed, zou een groot voordeel kunnen opleveren bij legionellosepatiënten. In 
hoofdstuk 8 worden twee patiënten met legionellose beschreven, bij wie de diagnose 
mede werd gesteld door de aanwezigheid van L. pneumophila-DNA in serum met 
behulp van real-time PCR. De patiënten werden kwantitatief vervolgd in de tijd. De 
gevonden resultaten correleerden met de klinische bevindingen en de gevonden CRP-
waarden. De kwantitatieve aanwezigheid van L. pneumophila-DNA in serum is een 
weerspiegeling van de hoeveelheid DNA in het bloed, en het is wellicht mogelijk om 
hiermee de klinische respons op antibiotische therapie van een individuele patiënt te 
vervolgen. Gezien de hoge kosten van PCR, het gebrek aan validatie en de aanwezig-
heid van een simpel alternatief (CRP [23]), raden wij deze techniek vooralsnog niet 
aan als marker voor de klinische respons bij patiënten met legionellose.
PCR biedt theoretisch de mogelijkheid om snel en betrouwbaar alle Legionella spp. 
te diagnosticeren in een patiëntenmonster dat makkelijk verkrijgbaar is. Het doel 
van de studie beschreven in hoofdstuk 9 was om de sensitiviteit en specificiteit te 
testen van detectie van Legionella-specifiek DNA in serum. Voor het aantonen van 
Legionella werden drie verschillende assays gebruikt met targets op genen coderend 
voor het 5S en 16S rRNA-gen, en het mip-gen. In totaal werden 68 patiënten met 
bewezen legionellose (151 monsters) geïncludeerd: bij 54% van de patiënten was de 
test positief in 5S rRNA PCR, bij 53% in mip-gen PCR, en bij 31% in 16S rRNA 
PCR in het eerst beschikbare serum. Er werd een significant verband aangetoond 
tussen de hoogte van de Ct-waarde (gemeten in 5S rRNA PCR, n=49) en de CRP 
(r = -0,63, Pearson correlation coefficiënt, p <0,0001). Met andere woorden, hoe ho-
ger het CRP, hoe lager de Ct-waarde en hoe hoger dus de hoeveelheid DNA gemeten 
in het bloed.
De urineantigeentest is minder gevoelig bij patiënten met een mild ziektebeeld dan 
bij patiënten die ernstig ziek zijn, en wij denken dat hetzelfde zou kunnen gelden 
voor de detectie van Legionella-DNA in serum. Begin 1999 trad onder bezoekers 
en deelnemers aan de tuinbouwtentoonstelling in Bovenkarspel een omvangrijke 
legionellose-epidemie op. In hoofdstuk 9.2 werd de relatie tussen de gevoeligheid 
van 5S rRNA PCR en de ernst van ziekte onderzocht met sera afkomstig van deze Bo-
venkarspelepidemie. Patiënten werden in twee groepen verdeeld: categorie 1 (milde 
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en matig ernstige pneumonie) en categorie 2 (ernstige pneumonie). De sensitiviteit 
bedroeg 49% (19/39; 95% BI 34-64 %) en 37 % (7/19; 95% BI 19-59 %) voor 
patiënten uit respectievelijk categorie 1 en 2, in het eerst beschikbare serummonster. 
Een groot nadeel van deze studie is dat de sera herhaaldelijk ontdooid zijn. Aange-
zien DNA chemisch instabiel is en relatief snel vervalt, zal dit de resultaten negatief 
beïnvloed hebben.
Onze bevindingen laten zien dat detectie van Legionella-specifiek DNA een waar-
devolle aanvulling zou kunnen zijn voor de diagnostiek van legionellose, maar dit 
zou in een prospectieve onderzoeksopzet moeten worden bevestigd.
Tot heden zijn 50 verschillende Legionella spp. beschreven, waarvan ongeveer de 
helft is geduid als pathogeen voor de mens. Infectie door Legionella non-pneumophila 
spp. in een immuuncompetente gastheer is in Nederland zeer zeldzaam. In hoofdstuk 
10 beschrijven wij een patiënt met een ernstige CAP, met een negatieve uitslag van 
de antigeentest en Legionella-kweek, die geïnfecteerd was met L. longbeachae. De 
diagnose werd uiteindelijk gesteld op basis van PCR-onderzoek en sequentieanalyse. 
Hoewel in Nederland L. pneumophila serogroep 1 in meer dan 95% van de gevallen 
de verwekker van legionellose is, toont deze casus dat deze diagnose niet zomaar 
verworpen mag worden op basis van een negatieve urineantigeentest en kweek. Maar 
al te vaak zal het diagnostisch proces stoppen bij een negatieve uitslag van de uri-
neantigeentest. Bij patiënten met een ernstige pneumonie met onbekende verwekker, 
alsmede bij patiënten met klinische aanwijzingen voor een Legionella-pneumonie 
en een negatieve uitkomst van de urineantigeentest, moet de diagnostiek uitgebreid 
worden met kweek en Legionella-PCR op respiratoir materiaal.
Klassiek worden kweekmethoden gebruikt om Legionella spp. aan te tonen in water, 
in Nederland volgens de zogenaamde NEN-norm 6265. De sensitiviteit van deze 
methode is echter niet optimaal en lijkt minder geschikt te zijn voor Legionella 
non-pneumophila spp. Het doel van de studie beschreven in hoofdstuk 11 was om 
een inventarisatie te maken van het voorkomen van Legionella spp. in Nederlands 
drinkwater. Watermonsters werden afgenomen op diverse locaties in Nederland en 
onderzocht op de aanwezigheid van Legionella spp. met behulp van kweek, PCR 
en sequentieanalyse. In totaal werden 357 drinkwatermonsters onderzocht. De 
kweek was slechts 8 maal positief (2%); twee maal voor L. pneumophila en zes 
maal voor Legionella non-pneumophila spp. Het water was 311 maal positief (87%) 
met behulp van PCR, met name speciës anders dan L. pneumophila. Identificatie 
van Legionella non-pneumophila spp. werd gedaan door sequentieanalyse van het 
geamplificeerde fragment coderend voor het 16S rRNA. De PCR-fragmenten van 
vrijwel alle Legionella non-pneumophila PCR-positieve monsters vertoonden 94-
100% homologie met het genus Legionella. We kunnen concluderen dat bijna 90% 
van het onderzochte (niet-geremde) drinkwater besmet was met voornamelijk Legi-
onella non-pneumophila spp. DNA. Blijkbaar is of raakt iedere leidingwaterinstal-
latie van enige complexiteit onvermijdelijk gekoloniseerd met Legionella spp. Het is 
nog onduidelijk wat hiervan de betekenis is voor de volksgezondheid. Hoewel in de 
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familie Legionellaceae meer dan 50 soorten bekend zijn, is Legionella pneumophila 
verantwoordelijk voor meer dan 95% van de infecties. Beheersmaatregelen van een 
waterleidingnet hebben tot doel in te grijpen in het traject van amplificatie, dissemi-
natie en transmissie. De nieuwe Waterleidingwet is gericht op het waarborgen van 
veilig drinkwater, waarbij minder dan 100 kolonievormende eenheden Legionella 
spp. per liter als norm wordt gehanteerd. Wie zich niet aan die norm houdt, kan 
bestuursrechtelijk worden vervolgd. In de praktijk betekent dit echter dat in vrijwel 
alle gevallen waarin Legionella spp. worden gekweekt, deze grenswaarde zal wor-
den overschreden. Dit impliceert dat in Nederland Legionella spp. niet gedetecteerd 
mogen worden zonder dat daarop direct maatregelen volgen. Door het gebruik van 
PCR-technieken zouden watermonsters waarschijnlijk nog vaker als besmet worden 
beschouwd. In de praktijk is echter de associatie tussen het aantonen van Legio-
nella spp. in watermonsters en het optreden van ziekte bij blootgestelde personen 
volstrekt onduidelijk. Een uniforme benadering waarbij eigenaren van collectieve 
waterleidinginstallaties aan de meest strenge eisen moeten voldoen, mag daarom ter 
discussie worden gesteld: de eisen bieden geen garantie voor volstrekte veiligheid en 
zijn bovendien buitengewoon kostbaar en ingrijpend.
Acute respiratoire infecties (ARI), variërend van met name milde klachten van de 
bovenste luchtwegen tot soms ook ernstiger beelden zoals pneumonie, komen vaak 
voor. De meeste infecties worden veroorzaakt door virussen, met name rhinovirus, 
influenzavirus en het respiratoir syncytieel virus [31,32,33]. Bij 30 tot 40% van de 
gevallen wordt echter geen verwekker gevonden. Lieberman et al. vonden in een twee-
tal prospectieve studies bij volwassenen met ARI (eerste- en tweedelijnspatiënten) bij 
12% van de gevallen serologische aanwijzingen voor een infectie met Legionella spp. 
[34,35]. De diagnose werd gesteld met behulp van een in-house IFA.
In Nederland registreren de huisartsen van het NIVEL-peilstationnetwerk alle pa-
tiënten die hen consulteren voor onder andere influenza-achtige ziektebeelden (IAZ). 
Omdat op basis van klinische symptomen niet duidelijk is welk pathogeen de ziekte 
veroorzaakt, werd de ARIEL-studie (acute respiratoire infecties eerste lijn) verricht: 
een case-controlestudie naar ARI bij huisartspatiënten, een samenwerking tussen het 
RIVM, NIVEL en het Streeklaboratorium voor de Volksgezondheid Tilburg. Een 
ARI-ziektebeeld is gedefinieerd als een acute infectieuze aandoening betreffende de 
bovenste en/of onderste luchtwegen, waarbij ten minste 1 van de volgende sympto-
men aanwezig is: hoesten, neusverkouden, keelpijn. Acuut is daarbij gedefinieerd als 
een prodromaal stadium van maximaal 4 dagen. Peilstationartsen namen een neus/
keelwat af bij een aselect deel van hun patiënten met een IAZ of een ziektebeeld van 
een andere ARI. Voor Legionella spp. is niet goed bekend hoe vaak ze voorkomen bij 
patiënten met ARI in Nederland. Wij wilden graag weten of en hoe vaak Legionella 
spp. voorkomen bij patiënten met ARI, vergeleken met patiënten zonder luchtweg-
klachten (hoofdstuk 12). Aangezien Legionella-PCR gevoeliger lijkt dan de kweek, 
kan daarmee naar ons idee het best een schatting worden gemaakt van de aanwezig-
heid van deze bacterie bij zowel symptomatische als asymptomatische patiënten. De 
primers en probes die gebruikt werden, grijpen aan op een fragment van het gen 
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dat codeert voor het 16S rRNA-eiwit. In totaal werden 430 monsters, afkomstig 
van 230 cases en 200 controles, onderzocht. Legionella-DNA werd in geen enkel 
patiëntenmonster aangetoond. Onze bevindingen laten zien dat Legionella spp. zeer 
waarschijnlijk geen rol van betekenis spelen in de etiologie van ARI in de eerste lijn. 
Tevens hebben we laten zien dat asymptomatisch dragerschap zeer waarschijnlijk 
niet voorkomt [36]. De discrepantie van onze resultaten met die van Lieberman et al. 
kan natuurlijk berusten op geografische verschillen in het voorkomen van Legionella 
spp.-infecties, seizoensinvloeden, alsmede op verschillen in patiëntkarakteristieken. 
Naar ons idee berust het gevonden verschil echter op de verschillen in gebruikte diag-
nostiek om infectie met Legionella spp. aan te tonen. Zoals eerder aangegeven is de 
specificiteit een belangrijke testeigenschap voor een relatief zeldzame ziekte. Bij een 
theoretische Legionella spp.-prevalentie van 2% bij patiënten met ARI, en een gevoe-
ligheid en specificiteit van een IFA van 99%, zijn nog ongeveer drie op tien positieve 
tests fout-positief. Het gevaar voor fout-positieve resultaten is nog veel hoger als je 
een enkel serum 41 keer test middels IFA met glaasjes gecoat met de verschillende 
serogroepen van L. pneumophila en verschillende Legionella spp. [34,35].
Chronisch obstructieve longziekte (Chronic Obstructive Pulmonary Disease, COPD) 
is een chronische vernauwing van de luchtwegen die de ademhaling beperkt, en wordt 
gekenmerkt door klachten van kortademigheid, hoesten en/of het opgeven van slijm. 
Een COPD-exacerbatie (AECOPD) wordt gekenmerkt door een forse toename van 
klachten en gaat vaak samen met een (virale) luchtweginfectie. Op basis van verschil-
lende serologische studies wordt gesuggereerd dat atypische luchtwegpathogenen 
(Chlamydophila pneumoniae, Legionella spp. en Mycoplasma pneumoniae geas-
socieerd zijn met AECOPD [40-50]. In hoofdstuk 13 beschrijven wij een onderzoek 
onder COPD-patiënten bij wie de aanwezigheid van deze atypische luchtwegpatho-
genen werd onderzocht. De aanwezigheid van DNA in sputa werd met real-time 
PCR onderzocht. In totaal werden 248 sputa onderzocht, 122 van patiënten die 
klinisch stabiel waren, en 126 afkomstig van patiënten met een acute exacerbatie. 
C. pneumoniae en M. pneumoniae werden in geen enkel monster aangetoond. Le-
gionella spp. werd tweemaal gedetecteerd: eenmaal uit een monster afkomstig van 
een stabiele patiënt, en eenmaal uit een monster van een patiënt met een exacerbatie. 
De bevindingen tonen geen associatie tussen atypische verwekkers en AECOPD. 
Methodologische factoren kunnen de resultaten van sero-epidemiologisch onderzoek 
beïnvloeden, en als gevolg daarvan kan in andere studies een associatie gevonden zijn 
die er in werkelijkheid waarschijnlijk niet is.
In studies naar de prevalentie van verwekkers van CAP is Streptococcus pneumoniae 
de meest voorkomende. Haemophilus influenzae, M. pneumoniae en Legionella spp. 
bezetten vaak de tweede plaats. Bij een belangrijk deel (30-50%) van de patiënten 
kan echter, ondanks uitgebreide microbiologische diagnostiek, geen verwekker wor-
den gevonden. In hoofdstuk 14 beschrijven wij een onderzoek onder 242 gehospitali-
seerde CAP-patiënten bij wie de aanwezigheid van respiratoire virussen en Legionella 
spp. in keelswabs met behulp van real-time PCR werd onderzocht. Virale respiratoire 
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pathogenen werden met behulp van serologie bij 7 (2%) patiënten aangetoond, en 
bij 50 (21%) patiënten met PCR (p < 0,0001). In totaal werden met conventionele 
diagnostiek bij 137 (57%) patiënten één of meerdere verwekkers gevonden, en dit 
aantal nam toe naar 158 (65%) na het toepassen van de verschillende PCR-assays 
(p = 0,06). Deze toename was voornamelijk het gevolg van het aantonen van een 
groot aantal respiratoire virussen, met name influenzavirus, para-influenzavirus en 
humaan coronavirus. De L. pneumophila-PCR was positief bij 3 van de 11 beves-
tigde legionellosepatiënten (29%).
Deze studie laat zien dat het aantal verwekkers dat men vindt bij patiënten met 
een CAP, toeneemt van ongeveer de helft naar ongeveer twee derde van de patiënten. 
Hoewel de detectie van Legionella in keelswabs mogelijk is, laten onze resultaten 
zien dat dit materiaal niet betrouwbaar is voor de detectie van Legionella met behulp 
van PCR.
De moleculaire diagnostiek is een belangrijk onderdeel geworden van de dagelijkse 
praktijk in de microbiologische ziekenhuislaboratoria. Met name de ontwikkelingen 
op het gebied van de real-time PCR-technologie hebben nieuwe toepassingen van 
zowel kwalitatieve en kwantitatieve tests makkelijker en toegankelijker gemaakt. 
Ondanks dat er vele publicaties voorhanden zijn die de (veelal in-vitro) evaluatie van 
nieuwe PCR-assays voor de detectie van Legionella spp. beschrijven, weten we echter 
nog niet precies wat nu de waarde (of meerwaarde) is van deze techniek voor een 
routinelaboratorium. Met andere woorden: zijn deze PCR-tests daadwerkelijk een 
verbetering c.q. aanvulling ten opzichte van de klassieke technieken? In het Streekla-
boratorium voor de Volksgezondheid in Tilburg wordt al jaren een combinatie van 
klassieke technieken (kweek, urineantigeentest en serologie) en PCR voor de detectie 
van Legionella spp. uitgevoerd. Hoofdstuk 15 beschrijft een vergelijking tussen de 
resultaten verkregen met klassieke technieken en PCR. Voor het aantonen van Le-
gionella werden gedurende de onderzochte periode twee assays gebruikt met targets 
op genen coderend voor het 16S rRNA-gen en het mip-gen. We wilden twee vragen 
beantwoorden.
Ten eerste, hoe is de gevoeligheid en specificiteit van PCR in vergelijking met de 
conventionele diagnostiek? De sensitiviteit en specificiteit werden geschat op respec-
tievelijk 83% en 93% voor de 16S rRNA PCR, en 88% en 98% voor de mip-gen 
PCR. Acht potentieel fout-positieve resultaten werden gevonden in 16S rRNA PCR, 
en 2 potentieel fout-positieve resultaten in de mip-gen PCR. Omdat de gevoeligheid 
van de conventionele diagnostiek nooit 100% is, vermoeden we dat een deel van de 
fout-positieve resultaten in werkelijkheid waar-positief zijn, vanwege de (wellicht) 
hogere gevoeligheid van PCR. Dit zou betekenen dat de specificiteit in werkelijkheid 
hoger is dan nu gevonden. Daarom werd een discrepantieanalyse verricht waarbij 
discrepante resultaten (PCR positief, conventioneel negatief) bevestigd werden met 
PCR (herhaling, andere assays) of sequentieanalyse (waar-positief) of juist niet (fout-
positief). Van de negen patienten met discrepante resultaten werd bij twee patiënten 
een infectie met L. pneumophila, en bij één patiënt een Legionella non-pneumophila 
spp.-infectie bevestigd. De overige 6 positieve resultaten werden beschouwd als 
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fout-positief. Met deze gecorrigeerde resultaten, en uitgaand van een prevalentie van 
Legionella spp. bij patiënten met CAP van 5%, werden een sensitiviteit, specificiteit, 
positief voorspellende en negatief voorspellende waarde van 82%, 95%, 44% en 
99% voor 16S rRNA PCR, en 86%, 100%, 100% en 99%, voor de mip-gen PCR 
gevonden.
Het tweede doel van de studie was om na te gaan of Legionella-specifieke PCR een 
meerwaarde heeft voor de diagnose legionellose ten opzichte van de urineantigeentest. 
Met andere woorden, leidt de introductie van een nieuwe extra test tot een toename 
van het aantal diagnoses? 139 patiënten waren zowel met PCR als met de urineanti-
geentest onderzocht. Met de urineantigeentest werden 35 patiënten gediagnosticeerd, 
evenveel als met 16S rRNA PCR (na discrepantieanalyse). De specificiteit van 16S 
rRNA PCR is echter te laag (95%). Een positief resultaat zou daarom altijd eerst 
bevestigd moeten worden met een andere PCR-assay of een geheel andere techniek 
alvorens een betrouwbare uitslag mag worden afgegeven. Een echt snelle diagnose 
lijkt daarom met deze assay moeilijk haalbaar. Hoewel de mip-gen PCR meer legio-
nellosepatiënten detecteerde (37 versus 35 patiënten), was dit verschil niet statistisch 
significant. De combinatie van een urineantigeentest en een mip-gen PCR detecteerde 
echter in totaal 40 patiënten. Hoewel dit verschil niet significant is, denken wij dat 
de mip-gen PCR kan zorgen voor een relevante toename van het aantal diagnoses van 
patiënten met legionellose. Dit zou echter idealiter in een prospectief vergelijkende 
studie moeten worden bevestigd.
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Het feit dat slechts een auteursnaam op dit proefschrift vermeld staat, doet geen recht 
aan de bijdrage die velen hebben geleverd aan de totstandkoming ervan. Omdat ik 
niet iedereen genoemd heb, wil ik hierbij eenieder die een bijdrage heeft geleverd aan 
dit proefschrift daarvoor hartelijk bedanken. Enkele mensen wil ik in het bijzonder 
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Mijn copromotor en A-opleider, dr. Marcel Peeters, wil ik allereerst bedanken voor 
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persoonlijkheid maakt je voor mij de ideale opleider. Je werklust is in ieder geval niet 
te overtreffen: ik heb nog nooit iemand gezien die zoveel verschillende “bijbaantjes” 
bekleedde, zonder dat je werk daaronder te lijden had. In mijn ogen is voor de vor-
ming tot medisch specialist een ouderwetse leermeester-gezelrelatie onontbeerlijk. Jij 
bent een echte leermeester: een krachtige, kleurrijke persoonlijkheid die een blijvende 
bijdrage levert binnen een medisch-specialistische opleiding. Zonder mensen zoals jij 
wordt een opleiding een levenloos, vreugdeloos en kleurloos traject.
Mijn promotor en B-opleider, prof. dr. Jan Kluytmans, stelde mij tijdens mijn sol-
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Mijn antwoord was “nee, liever niet”, en daarom werd hartelijk gelachen. Dat moest 
ik bij mijn eventuele volgende sollicitatiegesprek (lees: bij een academisch centrum) 
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om een bijzondere prestatie te leveren. Een echte teamspeler, die makkelijk bij tien 
projecten tegelijkertijd betrokken is. Het is daarom ook niet verwonderlijk dat je 
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andere die daarop volgden. (Het verbaast me overigens nog steeds dat je mobiele 
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met bellen. Pas op voor een bloemkooloor!). Als ik jou een artikel of hoofdstuk gaf 
ter correctie was het altijd zeer snel terug met bruikbaar commentaar, een eigenschap 
die ik erg kan waarderen. Ook jij bent voor mij een heel belangrijke leermeester 
geweest.
Mijn promotor, prof. dr. Christina Vandenbroucke-Grauls. Beste Christina, de uitein-
delijke samenwerking met jou heeft de voltooiing van dit proefschrift mede mogelijk 
gemaakt. Veel dank voor je heldere kritiek in de laatste fase van dit proefschrift.
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Dr. Anneke van der Zee, beste Anneke. Een ding hadden wij al direct gemeen: zonder 
koffie in de ochtend zijn wij beiden niets waard (de sigaret heb ik echter niet nodig). 
Jij hebt mij enigszins wegwijs gemaakt in de soms donkere gangen van de moleculaire 
microbiologie. Zonder jou was een groot deel van dit proefschrift niet mogelijk ge-
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virologielaboratorium kwam opstormen kreeg jij vaak een lichte hartverzakking. Ik 
ben je veel dank verschuldigd. Een groot deel van het moleculair onderzoek is door 
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onderzoek is onmisbaar geweest.
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geldonk-Lafeber, Ron Hendrix, Paul Valk, Ton van Zwet, Menno van der Eerden, 
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De auteur van dit proefschrift werd geboren op 12 oktober 1974, te Hoensbroek, 
Zuid-Limburg. In 1994 werd het eindexamen Voorbereidend Wetenschappelijk On-
derwijs behaald aan de R.K. Scholengemeenschap te Brunssum. De numerus fixus 
deed hem ertoe besluiten zijn studie in het buitenland te volgen: in hetzelfde jaar 
startte hij met de studie geneeskunde aan de Katholieke Universiteit Leuven, te Leu-
ven, België. In september 1997 werd de eerste cyclus (3 kandidaatsjaren) behaald 
en met de tweede cyclus (4 doctoraaljaren) begonnen. In september 1999 stapte hij 
over naar de Universiteit Leiden alwaar een korte wetenschappelijke stage werd ge-
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2002 werd meegewerkt aan een onderzoeksproject in Ghana, met als voornaamste 
doel het verstoren van de levenscyclus bij de endemisch voorkomende parasiet Oe-
sophagostomum bifurcum (afdeling parasitologie LUMC, o.l.v. dr. A.M. Polderman, 
parasitoloog). Het artsexamen werd op 18 januari 2002 behaald (cum laude). In fe-
bruari 2002 werd met de opleiding tot arts-microbioloog begonnen (opleider dr. M.F. 
Peeters, Streeklaboratorium voor de Volksgezondheid, Laboratorium voor Medische 
Microbiologie en Immunologie, gevestigd in het St. Elisabeth Ziekenhuis, te Tilburg). 
Het onderzoek zoals beschreven in dit proefschrift werd uitgevoerd gedurende de 
opleiding tot arts-microbioloog. Op 1 februari 2007 werd hij ingeschreven in het 
Medisch Specialisten Register. In april 2007 trad hij toe tot de Maatschap Medische 
Microbiologie Kennemerland verbonden aan de Stichting Streeklaboratorium voor 
de Volksgezondheid Kennemerland te Haarlem.
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